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0 ABSTRACT 
 
Understanding the relevance of T cells in limiting influenza illness severity will 
facilitate the rational design and evaluation of T cell-based universal influenza 
vaccines. The aim of this thesis was to characterise pre-existing T cell responses to 
influenza and follow the kinetics of these T cell responses to infection by exploiting 
the 2009 H1N1 pandemic (pH1N1). Peripheral blood mononuclear cells (PBMCs) 
were collected from healthy adults naïve to pH1N1 who were longitudinally followed 
over 2 influenza seasons from 2009 – 2011. Ex vivo pH1N1-specific memory CD4+ 
and CD8+ T cell responses were characterised by IFN- /IL-2 fluorescence-
immunospot and 14-colour flow cytometry.  In pH1N1 seronegative adults in a 
community setting, pre-existing influenza-specific T cells cross-reacting with pH1N1 
were prevalent, pre-dominantly of a single-cytokine positive (IFN- +, IL-2+ or TNF-
+) and effector memory (CD45RA-CCR7-) or late effector (CD45RA+CCR7-) 
phenotype and expressed lung homing receptor (CCR5+) and cytotoxic 
degranulation marker (CD107ab+). Pre-existing CD8+IFN- +IL-2- Temra 
(CD45RA+CCR7-) cells limited disease severity following incident pH1N1 infection in 
the absence of protective strain-specific antibodies. Furthermore, we show that this 
protection-associated T cell subset is durably maintained in the absence of re-
infection up to 1.5 years post-infection. The identification of a protection-associated 
immune correlate, the frequencies of which were increased and durably maintained 
by natural infection, is highly relevant for the development of a universal influenza 
vaccine inducing long-lasting, protective T cells.          
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1 INTRODUCTION 
1.1 General introduction to the problem of influenza 
1.1.1 Influenza virology and epidemiology 
Influenza remains a huge health burden globally with an estimated 250,000 – 
500,000 deaths and 3 – 5 million cases of severe influenza worldwide every year 
(WHO, 2014b). There are 3 types of influenza virus: A, B and C that vary according 
to their genome organisation, host range, and pathogenicity. Influenza types B and C 
are mainly isolated from humans whereas influenza A virus (IAV) infects a wide 
range of species including humans, birds, pigs and horses. Of the 3 types, IAV is the 
most virulent and prevalent in humans (Knipe et al., 2006).  
 
The virus was first isolated in 1933 and is an enveloped, single-stranded, negative-
sense RNA virus belonging to the Orthomyxoviridae family (Knipe et al., 2006). The 
eight-piece segmented genome encodes at least 11 viral proteins. There are two 
main surface glycoproteins that are involved in infection of host cells. 
Haemagglutinin (HA) is a trimeric lectin that attaches to sialic acid residues on the 
surface of target cells. Neuraminidase (NA) is an enzyme that cleaves sugar bonds 
to enable viral entry into the host cell and release of progeny virus particles from 
infected cells. Another surface protein expressed at a lower abundance in the virion 
than HA and NA, is matrix protein 2 (M2) that forms tetrameric ion-channels. The 
remaining eight proteins are: polymerase basic proteins 1, 1-F2 and 2 (PB1, PB1-F2 
and PB2); polymerase acid (PA); matrix protein 1 (M1); non-structural proteins 1 and 
2 (NS1 and NS2) and nucleoprotein (NP) (Knipe et al., 2006). 
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Although each IAV strain displays only one subtype of HA and NA molecule, there 
are 18 different subtypes of HA and 11 different subtypes of NA characterised to 
date giving rise to a number of possible IAV subtype combinations (Knipe et al., 
2006, Kapoor & Dhama, 2014). The HA subtypes are further characterised into 
group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and H18) and group 2 
(H3, H4, H7, H10, H14, and H15) phylogenetic groups (Kapoor & Dhama, 2014). 
Viral strain nomenclature is according to the virus type, place of initial isolation, strain 
number, and year of isolation. H3N2 and H1N1 are subtypes currently in circulation 
as ‘seasonal’ strains (sH3N2 and pH1N1 derivatives) in the human population. IAV 
has a high mutation rate, especially in the surface proteins HA and NA resulting in 
IAV antigenic ‘drift’ variants responsible for seasonal influenza epidemics. Larger 
changes and reassortment of genetic material between 2 or more different influenza 
strains infecting the same host cell can result in antigenic ‘shift’ variants, leading to 
the generation of new potentially ‘pandemic’ strains (Knipe et al., 2006). In 1918, the 
‘Spanish Flu’ pandemic was caused by H1N1 introduced into the human population. 
In 1957, H2N2 viruses replaced the H1N1 subtype and caused the ‘Asian Flu’ 
pandemic. In 1968, H3N2 viruses replacing the previously circulating H2N2 subtype 
caused the ‘Hong Kong’ pandemic. A swine-origin H1N1 IAV (pH1N1) emerged in 
April 2009 and caused the first pandemic of the 21st century declared on 11th June 
2009 (WHO, 2010). This pH1N1 contained components from Classical Swine (HA, 
NP, NS), Eurasian swine (NA, M) and North American Swine (PA, PB1, PB2) lineage 
reassortants (Garten et al., 2009). 
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Although the H1 subtype has previously been encountered through a human 
pandemic (1918 H1N1) and the derivatives that became sH1N1 viruses in circulation 
prior to 2009, pH1N1 was still able to cause a pandemic in 2009. There was 
significant divergence (20 – 24%) in the protein sequence of the HA of pH1N1 
compared to the HA of seasonal H1 subtypes, whereas it was more closely related 
to North American swine influenza strains (only 1 – 9% divergence) (Gatherer, 
2009). The majority of the world’s population had little or no immunity to this 
antigenically shifted virus, hence potentiating pandemic spread of the virus. 
 
1.1.2 Epidemiology of pH1N1 
In the United Kingdom (UK) there were 3 waves of pH1N1 infection: the first wave 
occurred in April to August 2009, the second wave occurred in September 2009 – 
April 2010, and the third wave occurred in August 2010 – April 2011 (WHO, 2014a). 
The WHO announced the beginning of the post-pandemic phase on 10 August 2010. 
A systematic review of serological studies from various countries (Australia, Canada, 
England, Hong Kong, India, New Zealand, Norway and Singapore) estimating the 
cumulative incidence of pH1N1 infection prior to the initiation of pH1N1 vaccination 
calculated a population cumulative incidence of 11% – 21% (Kelly et al., 2011). This 
study also revealed differences in susceptibility among different age groups, with the 
highest estimated cumulative incidence among children (16% – 28% in pre-school 
aged and 34% – 43% in school-aged) compared to 12% – 15% in young adults and 
the lowest incidence (2 – 3%) in adults over 60 years old (Kelly et al., 2011). 
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A wide clinical spectrum of illness was observed during the pH1N1 pandemic, 
including self-limited illness presenting most commonly with fever, cough and sore 
throat, and sometimes diarrhea and vomiting. Infection outcome also included more 
severe disease with respiratory failure associated with viral or bacterial pneumonia 
and death (Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, 2009). 
Although the WHO had originally estimated that 18,500 laboratory confirmed pH1N1-
related deaths had occurred worldwide, a later study suggested a much higher 
global mortality for pH1N1 (Dawood et al., 2012).   
      
1.1.3 Natural history of influenza infection  
Influenza virus causes an acute respiratory tract infection and seasonal influenza 
virus infections are usually mild with self-limiting symptoms in otherwise healthy 
individuals. The annual attack rates are 5 – 10% in adults and 20 – 30% in children 
(WHO, 2014b) with individuals repeatedly infected during their lifetime. A cohort 
study of the prevalence of serum antibodies specific to seasonal influenza in children 
aged 1 month to 7 years old in the Netherlands found that the first influenza 
infections occur at least 6 months after birth and all children are seroconverted to at 
least one influenza strain by age 6 years (Bodewes et al., 2011a). Asymptomatic 
infection can occur in up to a third of infected individuals (Carrat et al., 2008). The 
wide clinical spectrum of influenza disease can be determined by virus intrinsic 
factors such as virulence of the strain, and/or host intrinsic factors such as host 
genetics (Everitt et al., 2012) and co-morbidities. After an incubation period of about 
2 days, infected individuals experience rapid onset of influenza-like-illness (ILI) 
symptoms including fever (≥38°C), cough, sore throat, headache and myalgia 
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(Monto et al., 2000). The typical duration of systemic symptoms in humans is 3 – 5 
days (Carrat et al., 2008), but respiratory symptoms such as a cough may persist for 
1 – 2 weeks. There are significant age-dependent differences in the immune 
response to influenza and in the severity of disease. An estimated 90% of the 
mortality associated with seasonal influenza in the United States occurs among the 
65 years and older age group (Thompson et al., 2010); hence these high-risk groups 
are the primary target of annual influenza vaccination programmes.  
 
1.1.4 Pathogenesis of influenza in humans 
Influenza disease pathogenesis is determined by the interaction of virus intrinsic 
virulence factors, host intrinsic factors, as well as the host immune response to 
influenza infection (Kuiken et al., 2012). Influenza virus enters the human respiratory 
tract via virus-containing respiratory droplets, and infection proceeds viral attachment 
(via influenza HA) to sialic acid receptors on ciliated epithelial cells in the upper 
respiratory tract (URT) (van Riel et al., 2010). Following attachment to the host cell 
membrane, the influenza virus is endocytosed and acidification in late endocytic 
vesicles induces a conformational change in viral HA to generate a fusogenic protein 
that enables viral and endosomal membrane fusion. The viral M2 ion channel 
imports H+ ions into the virion from the acidified late endosome, disrupting the low 
pH-sensitive interaction between M1 and viral RNA. This releases viral RNA into the 
cell cytoplasm for import into the nucleus to be transcribed, followed by translation 
and synthesis of viral structural and envelope proteins. New virions capable of 
infecting neighbouring epithelial cells are released by budding from the apical 
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membrane of infected epithelial cells, via the cleavage action of viral NA (Knipe et 
al., 2006) (Figure (Fig.) 1.1, middle panel).     
 
Influenza viral tissue tropism is an important determinant of disease phenotype, with 
seasonal influenza viruses showing strong tropism for the human URT and lower 
respiratory tract (LRT) (van Riel et al., 2007). Furthermore, influenza viral attachment 
is preferentially through sialic acid receptors of epithelial cells terminating in 
galactose α-(2,6)-linkages in humans (Rogers & Paulson, 1983). Viral infectivity is 
determined by the cleavage and activation of influenza HA by specific host 
proteases, hence replication permissive influenza infection appears mainly restricted 
to the epithelial cells of URT and LRT (Zambon, 2001). Local URT disease 
symptoms including rhinitis, sinusitis, pharyngitis, laryngitis and tracheobronchitis fit 
with this pattern of virus attachment and tissue restriction for replication (Kuiken et 
al., 2012, Zambon, 2001). Systemic symptoms (including muscle aches, fatigue, 
headache and fever) with influenza infection and viral replication have been 
associated with levels of nasal wash IFN-α and IL-6 and IL-6 in the circulation in 
human volunteer challenge studies (Hayden et al., 1998, Skoner et al., 1999). This 
suggests that induction of such proinflammatory cytokines may explain the 
expression of systemic symptoms from a localised infection (Van Reeth, 2000). 
Importantly, a recent study identified mucosal inflammatory mediators including 
nasal lavage monocyte chemotactic protein-3, IFN-α2, as well as plasma IL-10 levels 
in an innate immune profile that predicted severe influenza disease outcome, 
independent of age and viral load (Oshansky et al., 2014). This suggests that 
regulation of innate immune responses can have a significant impact on disease 
outcome.   
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1.1.5 Antiviral drugs against influenza 
The two main classes of antivirals in use specifically target and inhibit the influenza 
proteins NA (oseltamivir, zanamivir, peramivir and laninamivir) and M2 
(adamantanes including amantadine and rimantadine) (Cox et al., 2004). These 
drugs may reduce severe complications and deaths associated with influenza, 
however they are most effective when administered early post infection (within 48 
hours post onset of symptoms). Furthermore, the development of resistance can limit 
the effectiveness of antivirals, and as such the currently circulating influenza viruses 
are resistant to adamantanes (WHO, 2014b). While antivirals may be useful 
therapeutic adjuncts, influenza vaccination remains the main form of prophylaxis 
against influenza.  
 
1.1.6 Licensed influenza vaccines 
Currently available seasonal influenza vaccines are the trivalent inactivated virus 
(TIV), the live attenuated influenza virus (LAIV) vaccine, or the recently approved 
baculovirus-expressed recombinant HA protein subunit vaccine (Jin & Chen, 2014). 
All are trivalent composed of two seasonal IAV strains (variants of sH3N2 and 
sH1N1) and one influenza B virus strain (Nichol & Treanor, 2006), although a 
quadrivalent LAIV containing two IAVs and two B strains (Victoria-like and 
Yamagata-like) was first available in 2013 – 2014 influenza season in the US (Jin & 
Chen, 2014). TIV and recombinant HA subunit vaccines are administered 
intramuscularly whereas LAIV vaccines are administered intranasally (Jin & Chen, 
2014).  
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Inactivated influenza vaccines are traditionally produced by reassortment in eggs, 
whereby embryonated eggs are co-infected with the circulating influenza strain and a 
well-characterised, high yield egg adapted influenza virus (commonly the A/Puerto 
Rico/8/1934 strain). The resulting combinations are then screened to select the 
reassortant strain containing the appropriate HA and NA genes along with the 
remaining genes from the egg adapted strain (Knipe et al., 2006). LAIV vaccines can 
also be produced by reverse genetics whereby cultured cells are co-transfected with 
plasmids encoding the HA and NA gene segments of the circulating strain along with 
plasmids encoding the remaining 6 internal gene segments from donor viruses 
(commonly the A/Ann Arbor/6/1960 and B/Ann Arbor/1/1966 strains). The donor 
viruses contain genetic loci conferring cold adapted (efficiently replicate at 25 C, 
which is otherwise restrictive for replication of wild type strains), temperature- 
sensitive (replication restricted at 37 C or 39 C) and attenuated (reduced replication 
in the LRT) phenotypes  (Jin & Chen, 2014). TIV is chemically inactivated whole 
virion, detergent mediated split virus, or subunit vaccine containing purified HA and 
NA and variable amounts of internal viral proteins (Co et al., 2009). In contrast, LAIV 
vaccine comprises an attenuated, replication-competent virus and therefore all 
influenza viral proteins can be expressed.  
 
The monovalent 2009 pandemic vaccine was available in the UK from 21 October 
2009 as an inactivated split virus (Pandemrix®, GSK) containing 
A/California/07/09(H1N1)-virus like strain, or inactivated whole virus vaccine 
(Celvapan®, Baxter) containing wild-type A/California/07/09(H1N1) (Department of 
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Heath, 2009). Vaccines used in subsequent influenza seasons post pandemic 2009 
in the Northern hemisphere have been trivalent vaccines containing a 
A/California/07/09(H1N1)-virus like strain, a H3N2 strain (A/Perth/16/2009 (H3N2)-
like virus or A/Victoria/361/2011 (H3N2)-like virus) and a B strain 
(B/Brisbane/60/2008-like virus or B/Wisconsin/1/2010-like virus) (Public Health 
England, 2012). In the UK in the 2013 – 2014 influenza season, an LAIV (Fluenz, 
Astra Zeneca) was available for the first time, as was a quadrivalent vaccine 
containing B/Brisbane/3/2007 (Yamagata lineage strain) in addition to the trivalent 
strain recommendations (WHO, 2013). 
 
Current influenza vaccines induce protective neutralising antibody responses to 
surface proteins HA and NA which is effective against infection with matched 
homologous influenza strains, but poor at protecting against infection with un-
matched heterologous (different strains within a given subtype) or heterosubtypic 
(different subtype) influenza strains (Ellebedy & Webby, 2009). Constant virus 
mutation generates antibody-escape variants that evade host humoral immunity. 
This necessitates yearly reformulation, production and deployment of influenza 
vaccines with little preparation for the infrequent but unpredictable event of a novel 
strain of pandemic potential. A recent meta-analysis reported an average vaccine 
efficacy of 59% (95% confidence interval (CI), 51 – 67%) for inactivated influenza 
vaccines in adults aged 18 – 65 years, and 83% (95% CI, 69 – 91%) for LAIV in 
children aged 6 months – 7 years (Osterholm et al., 2012). At best, vaccine efficacy 
of inactivated influenza vaccine against antigenically matched influenza strains was 
65% (95% CI, 54% to 73%) while vaccine efficacy against un-matched strains was 
52% reported in another meta-analysis (Tricco et al., 2013).  
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During the recent 2009 H1N1 pandemic, the first wave of the pandemic had already 
occurred before a matched vaccine was available, further highlighting the need for 
better vaccine preparedness (Abelin et al., 2011). A universal influenza vaccine 
capable of inducing durable protective immunity against infection or illness severity 
with all strains of IAV, including novel reassortant strains could alleviate the constant 
threat of a severe influenza pandemic. 
 
1.1.7 Experimental universal influenza vaccine development  
Much research effort has been directed toward the development of influenza 
vaccines affording broad protection, particularly against IAVs. The strategies 
employed target conserved influenza antigens including the HA stalk domain, the M2 
protein ectodomain and internal viral proteins including M1, NP, PB1 and PB2. 
These antigenic targets are naturally weakly immunogenic, hence novel vaccine 
designs focus on vaccine delivery systems for optimal antigen presentation to 
improve immunogenicity (Zhang et al., 2014, Lee et al., 2014). 
 
The amino terminal of the ectodomain of influenza M2 (M2e) is highly conserved 
among human IAVs, and several experimental influenza vaccines have been 
targeted to induce M2e-specific antibodies to this domain. Candidates completing 
phase I clinical trials include an adjuvanted intranasal virus-like particle (VLP) M2e 
conjugated to Hepatitis B core protein (M2e-HBc, ACAM-FLU-ATM) (De Filette et al., 
2006), and a fusion protein of M2e with Salmonella typhimurium flagellin (M2e-
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flagellin, VAX102) given intramuscularly (Turley et al., 2011). These have 
demonstrated safety and immunogenicity in humans, and reduced morbidity in 
animal models. Multiple mechanisms have been proposed that may be involved in 
M2e vaccine-mediated protection including antibody dependent cellular cytotoxicity 
(ADCC), antibody dependent NK cytotoxicity, complement-mediated lysis, and 
activation of M2e-specific CD4+ and CD8+ T cells (Zhang et al., 2014, Lee et al., 
2014). However, virus neutralising protection is not provided by M2e-based vaccines 
and hence these may be useful adjuncts to other TIV or LAIV that induce neutralising 
antibodies (Zhang et al., 2014). 
 
The long α-helix domain of influenza HA stalk (HA2 subunit) is another highly 
conserved epitope region of IAVs (Wang et al., 2010), and low levels of stalk-
reactive antibodies are elicited during seasonal influenza infection (Pica et al., 2012). 
Monoclonal antibodies targeting the HA stalk are broadly reactive against many IAV 
subtypes encompassing the 2 phylogenetic groups, group 1 (including H1 subtypes) 
and group 2 (including H3 subtypes). Passive transfer of such monoclonal stalk-
reactive antibodies has demonstrated effective protection in animal models (Zhang 
et al., 2014, Lee et al., 2014). Furthermore, gene delivery using Adenovirus of a 
monoclonal stalk-reactive antibody (F16) provided broad protection in mice and 
ferrets (Limberis et al., 2013). Several experimental approaches have been pursued 
to enhance the exposure of the stalk domain, including ‘headless’ stalk domain that 
require stabilisation (Bommakanti et al., 2010); short stalk peptides fused with carrier 
proteins (Wang et al., 2010); sequential vaccination with chimeric HA containing the 
same stalk but different head domains (Krammer et al., 2013), and glycosylation 
modified head domains to redirect immunogenicity to the stalk domain (Eggink et al., 
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2014). These approaches can induce neutralising and non-neutralising anti-stalk 
antibodies. Hence in addition to virus neutralisation, stalk reactive antibodies inhibit 
viral fusion and HA maturation, as well as mediating ADCC (Zhang et al., 2014). 
Some stalk-reactive non-neutralising antibodies have demonstrated enhanced 
disease, highlighting the need for careful evaluation in the development of such 
stalk-reactive non-neutralising antibodies (Zhang et al., 2014). 
 
The highly conserved internal influenza proteins including NP, M1, PB1 and PB2 are 
targets of T cell-based universal influenza vaccines. One such candidate is 
Multimeric-001, containing conserved linear epitopes from the NP, and M1 and also 
HA proteins of IAVs and type B strains (Atsmon et al., 2012). In phase I and II clinical 
trials in healthy elderly adults, intramuscular administration of Multimeric-001 has 
been shown to be safe and immunogenic, inducing Multimeric-001 protein-specific 
serum immunoglobulin G (IgG) and demonstrating sera-mediated lysis of target cells 
infected with H1N1, H3N2 and influenza B strains. Furthermore, in the presence of 
vaccine, PBMC proliferation and increase in cytokines IFN-γ and IL-2 were observed 
(Atsmon et al., 2012). Another candidate currently in phase I clinical trials to assess 
safety and immunogenicity is modified vaccinia Ankara (MVA) viral vector encoding 
NP and M1 (ClinicalTrials.gov, 2014). In an earlier smaller Phase I study, MVA-
NP+M1 vaccination (intradermal and intramuscular) induced significant NP- and M1- 
specific CD8+IFN-γ+ T cells post-vaccination (Berthoud et al., 2011). In a phase IIa 
MVA-NP+M1 vaccination and intranasal challenge (H3N2, A/Wisconsin/67/2005) 
study, clinical efficacy was demonstrated with a moderate but statistically significant 
reduction in days of viral shedding post-challenge in vaccinees compared to controls 
(Lillie et al., 2012). Although frequencies of M1 immunodominant epitope tetramer-
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specific CD8+ T cells up to day 7 post challenge were similar between vaccinees 
and controls, there were differences in the quality of antigen-specific T cells, since T 
cells in vaccinees showed higher levels of expression of cytotoxicity markers 
including granzyme A and perforin (Powell et al., 2013).       
 
Considering the recent introduction of LAIV vaccination in the UK, it is important to 
highlight some LAIV based universal influenza vaccine candidates that are in pre-
clinical research phases of development. A pseudotyped influenza virus made 
replication deficient through disruption of the HA open reading frame (S-FLU) has 
been produced (Powell et al., 2012). The A/PR/8/34 (H1N1) strain on which S-FLU is 
based is otherwise highly virulent in mice, but S-FLU preparation completely lacked 
virulence and induced protection against homologous H1N1 and also heterologous 
H3N2 IAVs. Robust NP- and HA- specific CTL responses were induced in the lung 
and were associated with protection including reduced lung virus replication and 
prevention of weight loss following challenge (Powell et al., 2012).        
    
1.2 The immune response to influenza  
1.2.1 The innate immune response to influenza 
Influenza primarily infects ciliated mucosal epithelial cells in the human respiratory 
tract (Matrosovich et al., 2004, Hers, 1966) and initiates innate and adaptive immune 
responses ultimately resulting in inhibition of viral replication (Kreijtz et al., 2011) 
(summarised in Fig. 1.2.1). Before reaching these target cells, inhaled influenza virus 
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encounters a number of host defence mechanisms in the respiratory tract (Nicholls, 
2013).  
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Figure 1.2.1 Immune responses to influenza infection and replication in the human respiratory tract.  
Figure adapted from images in (Trifonov et al., 2009, Racaniello, 2009, Behrens & Stoll, 2006, Lambert & Fauci, 2010). 
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Mucins are secreted or epithelial cell-associated glycoproteins that bind cells, cell 
debris and polypeptides constituting mucus in the airways. These glycoproteins are 
highly sialylated, hence mucins can bind influenza virus and the viscous gel-like 
nature of mucus also act as a physical barrier to infection (Nicholls, 2013, Cohen et 
al., 2013). However, influenza NA activity enables the virus to cleave sialic acid 
residues in mucin and penetrate (Cohen et al., 2013). Influenza viruses penetrating 
to the lung alveoli encounter lectins, proteins that bind carbohydrates and of which 
there are various types (Ng et al., 2012). The C-type lectins surfactant protein A (SP-
A) and surfactant protein D (SP-D) are produced by Type II pneumocytes of the 
alveoli and are the two main anti-influenza lectins in the lungs. SP-A contains sialic 
acid and acts as a decoy receptor to bind free influenza virus, and SP-D binds 
mannose type oligosaccharides on glycosylated HA and NA thereby aggregating 
virus particles (Nicholls, 2013) resulting in viral opsonisation.  
 
Various cell populations in the respiratory mucosa and lungs are involved in the 
innate immune response to influenza. Neutrophils are not abundant cell types in the 
lungs, however, during influenza infection neutrophils can be recruited as an early 
responder population and a protective role in influenza infection has been 
demonstrated in mouse models (Tate et al., 2011). These phagocytic cells can bind 
lectin opsonised influenza and eliminate virus through neutrophil respiratory burst 
responses (Hartshorn et al., 1996). Other important phagocytic cells are resident 
alveolar macrophages that express mannose receptor and galactose-type lectin 
receptor to bind glycosylated influenza virus for phagocytosis. Resident alveolar 
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macrophages are also permissive to influenza viral infection and replication (Yu et 
al., 2011).  
 
Intracellularly, influenza RNA is recognised by pathogen recognition receptors Toll-
like receptor 7 (TLR7), NOD-like receptor 3 (NLRP3) and retinoic acid inducible gene 
I (RIG-I). These are expressed in target cells and influenza infection activates signal 
transduction and initiates an immediate inflammatory response that includes 
expression of pro-inflammatory cytokines IL-12 and IL-6, and type I interferons 
(IFNs) (McGill et al., 2009). Type I IFNs inhibit viral replication by inducing interferon 
stimulated genes and inhibiting protein synthesis in infected host cells (Hsu et al., 
2012). However, influenza viruses have evolved strategies to evade this antiviral 
immunity, for example through the IFN antagonising effect of the NS-1 protein (Hsu 
et al., 2012).  Hence other arms of the host immune system are induced.  
 
The inflammatory milieu activates resident leukocytes and recruits other immune 
cells such as CCR2+ CD11b+ monocytes that can modulate inflammation and 
mediate killing of virally infected cells (Valkenburg et al., 2011). In vitro infection of 
primary human alveolar macrophages induces pro-inflammatory cytokines including 
TNF-  and chemokines such as CXCL-10 (also known as Inteferon gamma-induced 
protein, IP-10) that activate and attract other immune cells to the site of infection (Yu 
et al., 2011). Natural killer (NK) cells can be directly activated via type I IFN signaling 
following influenza virus infection to mount target cell lysis and cytokine production, 
including IFN-  (Hwang et al., 2012). Furthermore, NK cell-derived IFN-  production 
has been shown to require IL-2 from influenza-specific T cells in human PBMC (He 
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et al., 2004), highlighting the interactions between the innate and adaptive immune 
response to influenza. 
 
The involvement of other innate cell populations in the immune response to influenza 
has also been reported. The innate-like lymphocytes invariant natural killer T (iNKT) 
cells have been shown to be important in regulating the early innate immune 
response to influenza infection (Ho et al., 2008, Kok et al., 2012). iNKT cells also 
influenced the adaptive immune response by maintaining lung-homing dendritic cells 
(DCs) that enhance influenza-specific CD8+ T cell response in draining lymph nodes 
and lungs of mice (Paget et al., 2011). Another innate-like lymphocyte population, 
gamma-delta T (  T) cells have been proposed in the regulation and resolution of 
inflammation in the lungs of influenza-infected mice (Carding et al., 1990). Ex vivo  
T cells from human PBMC infected with influenza virus were found to rapidly 
upregulate activation markers and secrete antiviral IFN-  (Jameson et al., 2010). The 
recently identified Group 2 innate lymphoid cells (ILC2s) or nuocytes producing type 
2 cytokines such as IL-5, found as lung resident populations in mice and humans, 
were shown to be important in maintaining lung epithelial integrity in the resolution 
phase of influenza infection in mice (Monticelli et al., 2011). The relevance and 
importance of these other innate cell populations in human influenza infection 
remains to be determined.      
 
DCs are the main professional antigen presenting cells (APCs) of the immune 
system and include two main subsets: conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs) (GeurtsvanKessel & Lambrecht, 2008). Lung DCs are pivotal in the 
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initiation of influenza-specific CD8+ T cell responses for rapid viral clearance in mice 
(McGill et al., 2008). Two populations of resident lung DCs with distinct anatomical 
localisation can be distinguished based on the expression of the alpha-E and alpha-
M integrins CD103 and CD11b respectively (Sung et al., 2006). CD103+CD11b- 
migratory lung DCs that localise to the airway mucosa have been shown to transport 
influenza antigen from the lungs via the afferent lymphatics to mediastinal draining 
lymph nodes as soon as 20 hours post-infection, and process and present antigen 
via Major Histocompatibility Complex class I (MHC-I) to naive CD8+ T cells (Ho et 
al., 2011).  CD103-CD11b+ DCs that are localised to the submucosa and lung 
parenchyma, efficiently take up influenza antigen post-infection and produce pro-
inflammatory cytokines such as TNF- , but this subset migrates poorly (Ho et al., 
2011). pDCs that are recruited from the circulation have also been shown to activate 
influenza-specific CD4+ and CD8+ T cells, in addition to their antiviral role in 
producing type I IFN in response to influenza (Fonteneau et al., 2003). However, 
pDCs were not required for influenza clearance from the lungs of infected mice 
(GeurtsvanKessel et al., 2008). 
 
1.2.2 The adaptive immune response to influenza 
Naïve CD4+ and CD8+ T cells in the lung draining lymph nodes are presented with 
antigen by migratory cDCs. Naïve B cells in the mediastinal lymph nodes also 
encounter antigen transported by antigen-carrying DCs (Sealy et al., 2003). In 
humans, both CD4+ and CD8+ T cells from PBMC induced by seasonal H3N2 and 
H1N1 IAVs through prior exposure are directed toward the relatively conserved core 
proteins M1 and NP, and also PB1, PB2 and PA (Lee et al., 2008). However, only 
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CD4+ T cells recognised epitopes from the influenza surface glycoproteins HA and 
NA presented by Major Histocompatibility Complex class II (MHC-II), whereas CD8+ 
T cells recognised epitopes from the core antigens, particularly NP, M1 and PA 
presented by MHC-I (Lee et al., 2008).   
 
Intra- (helper T cell-dependent) and extra- follicular (helper T cell-independent) B cell 
responses are initiated following recognition of viral antigens (Sealy et al., 2003), 
particularly directed to HA and NA antigens (Potter & Oxford, 1979). Cognate 
antigen recognition as well as co-stimulation signals and polarising cytokines from 
APCs results in clonal expansion of influenza-specific T cells and B cells (Kreijtz et 
al., 2011, Valkenburg et al., 2011).  
 
Activated effector CD4+ T helper 2 (Th2) cells produce IL-4 and IL-13 and promote 
intra-follicular B cell responses, whereas IFN-γ and IL-2 producing CD4+ T helper 1 
(Th1) cells promote cellular responses including induction of CD8+ cytotoxic T 
lymphocytes (CTL) (Kreijtz et al., 2011). Activated effector CD8+ T cells traffic out of 
the mediastinal lymph node via the efferent lymphatics and are recruited to the site 
of infection where they carry out FAS/perforin- (Topham et al., 1997) and TRAIL- 
(Brincks et al., 2008) mediated lysis of infected cells. Influenza-specific CD8+ T cells 
also sequentially secrete IFN-γ, TNF-  and IL-2 upon recognition of antigen (La 
Gruta et al., 2004). Other subsets of CD4+ T cells, including regulatory T cell (Tregs) 
and T helper 17 (Th17) cells are activated upon influenza infection in mice. Tregs 
regulate effector CD4+ and CD8+ T cells (Betts et al., 2012), and have also been 
reported to regulate CD8+ T cell memory development  (Brincks et al., 2013) in 
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influenza infected mice. Th17 cells were shown to play an important role in 
protecting naïve mice against lethal influenza challenge infection (Hamada et al., 
2009). Interestingly, IL-10 from influenza-specific CD8+ T cells in the lungs of 
influenza infected mice has also been shown to limit immunopathology (Sun et al., 
2009).  
 
Following LAIV (sH1N1 or sH3N2 strain) primary challenge infection in children aged 
1.5 – 4.5 years old, anti-HA immunoglobulin classes G, (IgG), IgM, and the less 
prevalent IgA antibodies were all detectable in serum within 2 weeks of infection. IgM 
and IgA antibodies reached a peak and declined whereas IgG antibodies peaked at 
4 – 7 weeks post LAIV infection (Murphy et al., 1982) (Fig. 1.3.1). Waning of mean 
titres of serum anti-HA antibodies after infection or vaccination with IAV and B 
viruses occurred over the first 6 months post-peak response, and then levels were 
maintained for 2 – 3 years in the absence of further antigen re-exposure (Cate et al., 
1977, Couch & Kasel, 1983). Anti-HA IgG antibodies from the serum or secreted at 
the airway mucosal surfaces mainly bind to the trimeric globular head of the HA, 
thereby inhibiting virus attachment and entry into host cells and effectively 
neutralising the virus to give sterilising immunity (Potter & Oxford, 1979, Couch & 
Kasel, 1983). Anti-NA antibodies bind and inhibit the enzymatic activity of NA, 
thereby preventing the cleavage of sialic acid residues on the infected cell surface 
that facilitates the release and spread of progeny virions (Couch & Kasel, 1983, 
Gerhard, 2001). Antibodies against the less abundant viral membrane protein M2 
have been reported in mice (Zebedee & Lamb, 1988), but are rare following natural 
infection in humans (Couch & Kasel, 1983). Anti-NP IgG antibodies have also been 
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reported to mediate viral clearance in mice (Lamere et al., 2011) but anti-M2 or anti-
NP antibodies cannot protect against infection in humans (Couch & Kasel, 1983).   
 
Mouse studies suggest antigen is cleared within 10 to 14 days of primary influenza 
infection (Flynn et al., 1999) although prolonged antigen presentation to CD4+ T 
cells for up to 3 to 4 weeks has been reported (Jelley-Gibbs et al., 2005). A meta-
analysis of human volunteer influenza challenge studies (with H1N1, H3N2 or 
Influenza B virus) found that influenza virus shedding increased during day 1 after 
intra-nasal inoculation, peaked on day 2 and lasted less than 5 days, with virus 
clearance by day 8 (Carrat et al., 2008) (Fig. 1.3.1). 
 
1.2.3 Mucosal immune responses to influenza  
Influenza enters and initiates replication at the human respiratory mucosa hence 
mucosal immunity can provide a critical first line of defence. Mucosal immune 
effector mechanisms include mucosal antibodies (IgA, IgM and IgG isotypes) that 
neutralise viruses; evoke cytotoxic effects on infected cells via eosinophilic and 
neutralphilic granulocytes and NK cells; and opsonise pathogens for phagocytes to 
process and present antigens to activate mucosal effector T cells. The mucosa-
associated lymphoid tissue (MALT) encompasses nasopharynx-associated lymphoid 
tissue (NALT) and gut-associated lymphoid tissue (GALT). In humans, NALT 
comprises of the nasopharyngeal adenoids, paired tubal tonsils, and the paired 
palatine and lingual tonsils (Rose et al., 2012). Similar to the systemic lymphoid 
tissues, the MALT is anatomically and functionally organized, with activation sites at 
follicles where B and T cells are activated, clonally expand and differentiate into 
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effector cells. Effector cells migrate from the NALT via the cervical lymph nodes and 
thoracic duct into the general circulation, to reach effector sites in the lamina propria 
underneath the mucosal epithelium covering the internal surface of the whole body. 
Hence effector functions of CTLs and antibody secreting cell (ASC) -secreted 
mucosal IgA and IgM induced at one site can act across this common mucosal 
immune system (Rose et al., 2012, Tamura & Kurata, 2004). 
 
Secretory IgA (S-IgA) are dimeric IgA antibodies produced by ASCs and are the 
main antibody isotype found in mucosal secretions (Rose et al., 2012). A high 
prevalence of influenza-specific ASCs were found in nasal mucosa of individuals 
with no reported influenza in the preceding year (Brokstad et al., 2001). Furthermore, 
in the absence of serum antibodies, nasal wash S-IgA was a major determinant of 
resistance to infection and illness in volunteer challenge studies (Clements et al., 
1986). Hence mucosal S-IgA appears to play a significant role in anti-influenza 
immunity. However, mucosal protection mediated by S-IgA can be substituted, since 
mice deficient in IgA (IgA-/-) have similar lung viral titres and morbidity as wild type 
mice (IgA+/+) upon influenza infection (Mbawuike et al., 1999).    
 
Respiratory mucosal immunity against influenza can also be mediated by cellular 
components including mucosal NK cells, T cells, ILCs (as discussed in the above 
section on the innate immune response to influenza) and mucosal T cells (as 
discussed below on memory T cell subsets and memory T cell response to influenza 
infection).  
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1.3 Immunological memory to influenza  
1.3.1 Humoral memory response to influenza infection 
Following natural pH1N1 infection in humans, there is a rise in neutralising serum 
anti-HA IgG antibody response that was shown to peak at 1 month post-infection 
followed by waning in the antibody response within 11 months post-infection (Liu et 
al., 2012). However, in one pH1N1-infected individual followed longitudinally, strain-
specific serum antibodies were detectable up to 700 days post-infection (Wagar et 
al., 2011). Strain-specific serum antibodies to influenza have been detected in 
individuals surviving infection with 1918 H1N1 up to 90 years later (Yu et al., 2008). 
Furthermore, epidemiological evidence suggests that protective immunity to H1N1 
can last as long as 20 years (Couch & Kasel, 1983). In a mouse model of influenza 
infection, it has been suggested that the long-term maintenance of the humoral 
response and serum antibodies to influenza is from the continual conversion of 
influenza-specific splenic memory B cells to long-lived antibody-secreting plasma 
cells that reside in the bone marrow (Ng et al., 2014). 
 
pH1N1-specific neutralising antibody responses to pH1N1 inactivated vaccine in 
vaccinated individuals followed similar kinetics to natural pH1N1 infection (Liu et al., 
2012). Although the post-vaccination haemagglutination inhibition (HAI) titre was 
higher at 2 months post-vaccination compared to infected individuals, the antibody 
response was more durable over the 14 month study period in naturally infected 
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individuals compared to vaccinated individuals (Liu et al., 2012). Whilst strain-
specific serum antibodies may be long-lived against homologous virus, the antigenic 
targets (HA and NA) have high mutation rates due to host immune pressure. Hence 
humoral immunity is evaded by heterologous influenza strains, enabling multiple 
infections of the same individuals over their lifetime.  
 
1.3.2 Memory T cell subsets   
Human peripheral blood CD4+ and CD8+ T cells subdivided based on the 
expression of the lymph node homing receptor CCR7 in combination with the cell 
activation marker CD45RA (differentially expressed on human naïve and memory T 
cells) led to the identification of distinct subsets of circulating memory T cells and the 
coining of central memory (Tcm) and effector memory (Tem) T cells (Sallusto et al., 
1999). The two subsets therefore possess differential migratory capacity, with 
CCR7+ Tcm representing an antigen-experienced, clonally expanded circulating 
population that can enter lymphoid organs and mount secondary proliferative 
responses. CCR7- Tem showed enhanced responsiveness to activation, 
representing an antigen-experienced, peripherally circulating population that can 
enter inflammatory tissues and readily mediate inflammatory or cytotoxic effector 
functions. Both subsets were shown to proliferate in response to recall tetanus toxoid 
antigen in PBMC from individuals up to 10 years post-vaccination, demonstrating in 
vivo maintenance. Furthermore, progressive shortening of telomere length in CD4+ 
naïve compared to Tcm and Tem cells suggested progressively increasing number 
of cell divisions among the subsets. In vitro stimulation revealed a stepwise 
differentiation program of naïve to Tcm to Tem (Sallusto et al., 1999). CD45RA is 
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also re-expressed on a population of CD8+ T cells termed terminal late effectors 
(Temra) (Hamann et al., 1997, Champagne et al., 2001). 
  
Subsequently, studies in mice have identified these subsets, addressed the lineage 
relationships, and compared the persistence and protective capacities of Tem versus 
Tcm in vivo. The initial study had proposed division of labour among phenotypically 
and functionally distinct memory T cell subsets located in anatomically different sites 
(Sallusto et al., 1999). In support of this, other studies in mice have found that 
memory CD8+ T cells in non-lymphoid organs had more robust cytotoxic activity than 
memory CD8+ T cells in lymphoid organs following systemic vesicular stomatitis 
virus or oral Listeria monocytogenes (LM) infection (Masopust et al., 2001). 
Similarly, CD4+ T cells in non-lymphoid organs produced higher levels of IFN-  
relative to IL-2 compared to memory CD4+ T cells in lymphoid organs following 
vaccination with ovalubumin peptide and lipopolysaccharide (Reinhardt et al., 2001).  
 
Due to their enhanced proliferative capacity, adoptively transferred antigen-specific 
CD8+ Tcm cells were more effective than antigen-specific CD8+ Tem cells in 
controlling Lymphocytic choriomeningitis virus (LCMV) or vaccinia viral replication in 
models of infection, irrespective of the routes or sites of infection (Wherry et al., 
2003). Similarly, in a melanoma tumour mouse model, adoptive transfer of in vitro 
generated tumour-reactive CD8+ Tcm cells was more effective than Tem cells in 
tumour eradication (Klebanoff et al., 2005). However, other studies have suggested 
the converse with respect to the memory subset correlating with protection. Antigen-
specific CD8+ Tem cells were more efficient than Tcm cells in secondary recall 
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response to intranasal parainfluenza virus infection in mice (Roberts & Woodland, 
2004). CD8+ Tem and effector T cells also mediated protection against peripheral 
vaccinia virus infection (Bachmann et al., 2005, Olson et al., 2013) and LM infection 
(Olson et al., 2013), whereas protection against systemic LCMV infection was 
mediated by Tcm (Bachmann et al., 2005) in mice.        
 
In contrast to the results dissecting lineage relationships of Tem and Tcm from in 
vitro studies on human PBMC (Sallusto et al., 1999), a linear differentiation of naïve 
to effector to Tem to Tcm cells was observed in mice in vivo (Wherry et al., 2003). 
Further, the self-renewing Tcm cells exhibited long-term persistence in vivo, whereas 
Tem cells represented an intermediate state in the effector-to-memory transition 
(Wherry et al., 2003). 
 
The original seminal work (Sallusto et al., 1999) provided a conceptual model for the 
organisation of various circulating memory T cell subsets. But subsequent 
contrasting results on the protective capacities of Tem and Tcm cautions at the 
simplicity of the model, although differences in the experimental conditions including 
the route of infection, pathogen dose, or pathogen tropism could account for this 
(Kaech, 2014). Distinct from circulating Tem and Tcm cells, tissue-resident memory 
T cells (Trm) have been identified at mucosal sites that provide defense at portals of 
pathogen entry (Schenkel et al., 2013, Wu et al., 2014). Therefore, optimal protection 
against pathogens may require diverse populations of memory T cells (Kaech, 
2014).  
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1.3.3 Memory T cells to influenza infection 
Influenza is an acute infection with rapid antigen clearance; with a shift from effector 
T cells to memory T cells following resolution of infection and antigen clearance 
(Pantaleo & Harari, 2006). In human peripheral blood, a decrease in influenza 
tetramer-specific CD8+ effector and Temra but an increase in Tcm following natural 
infection has been reported (Hillaire et al., 2011b). Mouse studies have also 
highlighted the importance of long-lived, influenza-specific Trm cells in the lungs to 
provide rapid effector function and T cell dependent influenza immunity at the site of 
infection (Masopust & Picker, 2012, Hogan et al., 2001). 
 
There are limited reports on the kinetics (Fig. 1.3.1) of influenza-specific T cell 
responses following natural infection in humans. One study prospectively following a 
single infected individual showed robust pH1N1-specific CD4+IFN- + and CD8+IFN-
+ T cell responses in the peripheral blood that peaked at 3 weeks post-infection, 
and then declined reaching baseline levels by day 700 post-infection (Wagar et al., 
2011). Another study suggested that there is a rapid recall CD8+ T cell response 
peaking within a week post-infection with pH1N1 that contracted within 3 weeks 
post-infection at group level, but there were also inter-individual differences in the 
kinetics (Hillaire et al., 2011b). H1N1-specific CTL activity measured at 2 weeks 
post-infection showed an increase compared to 2 weeks pre-infection in one 
individual infected with H1N1 in 1978 (McMichael et al., 1983a). In the same study, 
during a 6-year period between 1977 and 1982, there was a decline in CTL 
responses in healthy individuals with an estimated CTL half-life of 2 – 3 years within 
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the cohort, coinciding with reduced influenza activity in the community during the 
same period (McMichael et al., 1983a). 
 
While some influenza-specific T cell responses are thought to be protective, they 
have also been implicated in influenza illness exacerbation. Frequencies of NP- and 
M1- specific CD4+IFN- + T cells were higher in PBMC during the early phase of 
disease from hospitalised patients subsequently developing more severe pH1N1 
illness, compared to mild infections and PBMC responses from healthy controls 
(Zhao et al., 2012). In 2 individuals where paired lung and peripheral blood sampling 
was performed, a significantly higher number of tetramer-specific CD8+ T cells were 
observed in bronchoalveolar lavage samples compared to PBMC, implying homing 
of influenza-specific CD8+ T cells to the site of disease. In this study (Zhao et al., 
2012), sampling was within 48 hours of hospital admission without longitudinal 
follow-up of T cell responses, hence the kinetics of the pH1N1-specific CD4+ T cell 
response over the course of infection was not reported. Thus it is unclear how the 
influenza-specific CD4+ T cells, which are associated with severity of illness 
(demonstrated at an early time-point post-infection), develop with resolving infection.   
 
Polyfunctional T cells are important in T cell memory and vaccine clinical trials 
(Seder et al., 2008). These are defined as cells capable of producing 2 or more 
cytokines and with or without proliferation capability, and have been shown to be 
functionally superior to monofunctional (single cytokine producing) T cells in viral 
(Harari et al., 2004, Betts et al., 2006), bacterial (Wilkinson & Wilkinson, 2010) and 
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parasitic (Darrah et al., 2007) infections. However, the prevalence and role of 
polyfunctional T cells in response to influenza infection in humans is not known.      
 
1.3.4 Memory T cells to influenza vaccination 
In humans the duration of inactivated vaccine-induced boost in CTL responses has 
been reported to last less than 12 months (McMichael et al., 1981, Ennis et al., 
1981), whereas boosting following natural infection appears to last longer 
(McMichael et al., 1983a). Many studies have demonstrated enhanced ex vivo IFN-γ 
production from human PBMC detected from 7 to 10 days (He et al., 2006, He et al., 
2008); 4 weeks (Avetisyan et al., 2005); 1 month (Tu et al., 2010) and from 2 weeks 
to 1 month or 2 months (Co et al., 2008, Terajima et al., 2008) post-vaccination with 
TIV compared to pre-vaccination. Similarly, ex vivo IFN-γ production from human 
PBMC was enhanced following LAIV vaccination compared to pre-vaccination (He et 
al., 2006, He et al., 2008, Forrest et al., 2008).  
 
Enhanced influenza-specific T cell proliferation following TIV vaccination (Co et al., 
2008, Guthrie et al., 2004, Murasko et al., 2002) and recombinant HA vaccination 
(Powers et al., 1997) has been observed, suggesting vaccine-induced clonal 
expansion of antigen-specific cells. In vitro CTL cytotoxicity following LAIV 
vaccination (Gorse & Belshe, 1990, McMichael et al., 1983b) has also been 
reported. Together these studies demonstrate that influenza vaccination can 
enhance influenza-specific T cell responses in humans. 
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Importantly a few studies have also correlated influenza vaccine-induced T cell 
responses with protection against clinical influenza disease (Forrest et al., 2008, 
Murasko et al., 2002, McElhaney et al., 2006). In a large placebo-controlled efficacy 
trial of LAIV in young children aged 3 – 36 months, vaccine-induced IFN- + PBMC 
responses correlated with protection against community-acquired, culture confirmed 
influenza. The majority of individuals with vaccine-specific cells greater than 100 
IFN- + SFC per million PBMC (on 7 – 10 days post-vaccination) were protected, 
proposing a possible level of cellular response to target in influenza vaccine 
development and evaluation (Forrest et al., 2008). In a prospective study of elderly 
(older than 60 years) individuals, ex vivo influenza virus-specific PBMC responses, 
including the mean IFN-γ:IL-10 ratio and granzyme B levels in PBMC lysate were 
significantly lower pre- and post- TIV vaccination in individuals subsequently 
developing laboratory diagnosed influenza illness compared to those who did not. In 
contrast however, pre- or post-vaccination serum antibody titres did not distinguish 
between these individuals (McElhaney et al., 2006). In another study of the elderly 
who were vaccinated every year over the four years of the study period, the risk of 
developing influenza disease was the highest in individuals without vaccine-induced 
serum antibody or T cell proliferative responses. However, the risk of developing 
influenza disease subsequent to vaccination was the same in individuals with a cell-
mediated response alone, an antibody response alone, or both cell-mediated and 
antibody responses (Murasko et al., 2002). Thus the importance of cell-mediated 
immune responses in vaccine-induced protection from influenza disease has been 
demonstrated in at least a subset of the population, including the very young and the 
elderly.  
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Influenza vaccine adjuvants, the route of vaccination and the type of vaccine used 
(inactivated or LAIV), have all been shown to affect the quantity and/or the quality of 
human T cell responses. The frequency of proliferation marker Ki-67-expressing 
influenza-specific CD4+ T cells in PBMC that produce IFN-γ, IL-2 and/or TNF-α in 
vitro showed a sharp but transient rise at 4 - 6 days after vaccination with non-
adjuvanted inactivated pH1N1 vaccine (Li et al., 2012). The frequency of Ki-67+ 
CD4+ T cells then declined rapidly, and at 10 days after vaccination, both Ki-67+ and 
overall influenza-specific CD4+ T cell numbers returned to pre-vaccination levels (Li 
et al., 2012).   In healthy adults, single and multi-cytokine CD4+ T cells positive for 
combinations of IFN- , TNF-  and IL-2 were significantly increased at 7, 14 and 21 
days post-vaccination with GSK Pandemrix monovalent split virus vaccine 
adjuvanted with oil-in-water adjuvant AS03, compared to pre-vaccination (Pathirana 
et al., 2012). Using the same adjuvanted vaccine, a higher increase in frequency of 
activation marker (CD40L) or cytokine (IFN- , IL-2 or TNF- ) positive CD4+ T cell 
responses was observed over 42 days following vaccination with adjuvanted 
compared to non-adjuvanted inactivated pH1N1 vaccine in healthy adults (Roman et 
al., 2011). Thus adjuvanted pH1N1 vaccine appears to induce a higher magnitude 
and longer duration of activated influenza-specific CD4+ T cell responses compared 
to non-adjuvanted vaccine.  
 
Regarding the route of administration, intramuscular seasonal TIV vaccination of 
healthy adults induced only CD4+ T cell responses to influenza vaccine at 14 and 28 
days post influenza vaccination, whereas transcutaneous TIV vaccination induced 
both CD4+IFN- + and CD8+IFN- + T cells to influenza vaccine (Vogt et al., 2008). 
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Regarding the functional profile of natural influenza infection or inactivated vaccine –
induced T cell responses, one study suggests a greater proportion of antigen-
specific CD4+IFN-γ+IL-2+ dual cytokine positive cells following pH1N1 vaccination of 
healthy adults compared to a predominant CD4+IFN-γ+IL-2- T cell signature 
following natural pH1N1 infection (Schmidt et al., 2012).    
 
Currently available inactivated influenza vaccines are designed and selected to 
preferentially induce neutralising antibody responses, hence it is expected that some 
CD4+ helper T cell responses will be induced to provide B cell help for antibody 
production. Indeed, recent reports have correlated the circulating counterpart of 
follicular helper T (Tfh) cells induced post-vaccination (with inactivated vaccine) that 
predict neutralising antibody titre rise (Spensieri et al., 2013). In children aged 6 – 35 
months vaccinated with combinations of TIV vaccine and LAIV prime-boost, only 
regimens containing LAIV showed enhanced IFN-  positive and proliferating CD4+ 
and CD8+ T cells and  T cells at 1 month and 60 days post-vaccination (Hoft et al., 
2011). Enhanced frequencies of CD4+IFN- + and CD8+IFN- + T cell responses 
were reported following LAIV vaccination compared to TIV vaccination in 5 to 9 year 
old children, although this was not the same for healthy adults (He et al., 2006). 
However, increased CTL activity measured 1 month post-vaccination in healthy 
adults was more frequent in inactivated whole virus vaccines (detected in 6/8 
individuals) compared to inactivated subunit vaccines (detected in 3/9 individuals) 
(McMichael et al., 1983b). Together these studies demonstrate that LAIV may be 
superior to TIV in inducing T cell (including CD8+ T cells) responses, especially in 
young children. Furthermore, different types of inactivated vaccines may differ in 
their ability to induce cell-mediated immunity in healthy adults. 
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The existing literature reports on memory T cells to influenza infection (section 1.3.3) 
or influenza vaccination demonstrate induction of antigen-experienced influenza-
specific T cells following infection or vaccination, and notably, some have 
demonstrated a significant role of cell-mediated immunity in vaccine-induced 
protection against influenza disease. Outstanding knowledge gaps include the 
longevity of these influenza-specific responses, particularly in the context of natural 
influenza infection. This can be addressed through the careful, prospective study of 
T cell responses and a comprehensive assessment of their phenotype in healthy 
individuals naturally exposed to influenza.   
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Figure 1.3.1 Course of viral shedding and adaptive immune responses to influenza measured in 
peripheral blood of humans naturally infected or following primary infection with LAIV.  
Figure constructed with data from (Carrat et al., 2008, Murphy et al., 1982, Cate et al., 1977, 
Wagar et al., 2011, Hillaire et al., 2011b).  
  
1.4 Heterosubtypic immunity (HSI) to influenza  
1.4.1 The immunological basis for HSI  
Cross-reactive immune responses to conserved regions of one influenza subtype 
generated through prior exposure to a different influenza subtype may provide some 
protection against disease, and this HSI was first described in 1965 (Schulman & 
Kilbourne, 1965). Priming with an H1N1 virus 4 weeks prior to lethal challenge 
infection with a H2N2 virus resulted in reduced lung viral titres (as early as 24 – 28 
hours post-challenge), less extensive lung lesions and decreased mortality in mice 
(Schulman & Kilbourne, 1965). Subsequently, many studies have corroborated and 
extended knowledge of HSI in different species including mice (Table 1.4.1), 
chickens (Table 1.4.1), ferrets (Table 1.4.1), nonhuman primates (Table 1.4.1), pigs 
(Table 1.4.1), cotton rats (Straight et al., 2006), ducks (Fereidouni et al., 2009) and 
guinea pigs (Steel et al., 2010).  
 
Both B cell and T cell components of the adaptive immune system can mediate HSI 
(Grebe et al., 2008). Early work showed that a large proportion of CTLs induced after 
influenza infection in humans (McMichael et al., 1983b, Gotch et al., 1987, 
McMichael et al., 1986) or mice (Yewdell et al., 1985, Townsend & Skehel, 1984) 
were directed against the conserved NP and M1 proteins of influenza, and target cell 
lysis by mouse CTLs was cross-reactive between different influenza subtypes 
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(Zweerink et al., 1977a, Zweerink et al., 1977b). More recent immunoinformatic 
analysis of all the known influenza-specific B cell and T cell epitopes listed in the 
Immune Epitope Database (www.immuneepitope.org) has shown that conservation 
of T cell epitopes (51%) between recently circulating H1N1 strains and the novel 
pH1N1 is much greater than conservation of B cell epitopes  (31%), reflecting the 
conservation or variability in respective antigens from which the epitopes are derived 
(Greenbaum et al., 2009). Furthermore, CD8+ T cell epitopes had a higher level of 
sequence similarity (69%) compared to epitopes targeting CD4+ T cells (41%) 
(Greenbaum et al., 2009). IFN-γ producing memory T cell PBMC responses cross-
reactive between seasonal (sH3N2) and avian (H5N1) IAVs detected in healthy 
individuals showed the highest prevalence of responses directed to the conserved 
core proteins M1, NP and PB1 (Lee et al., 2008). Cross-reactivity of circulating 
memory CD4+ (Ge et al., 2010, Richards et al., 2010) and CD8+ (Tu et al., 2010, 
Gras et al., 2010, Scheible et al., 2011) T cells with pH1N1 in PBMC obtained from 
healthy individuals before the 2009 pandemic has also been reported. Targeting 
such conserved influenza proteins to induce immune responses that are therefore 
cross-reactive between influenza subtypes forms the basis of HSI to influenza. 
 
1.4.2 B cell-mediated heterosubtypic anti-influenza immunity  
Pre-existing, broadly cross-reactive virus neutralising antibodies directed towards 
conserved regions of H3, H5 and H7 subtypes have been detected at very low levels 
(0.001% of total IgG) in human serum (Sui et al., 2011). IgM+ memory B cells 
recovered from recent seasonal influenza vaccinees enabled identification of H5N1 
and H1N1 cross-reactive antibodies directed towards an epitope on the conserved 
stem region of HA (Throsby et al., 2008). Furthermore, this monoclonal antibody 
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given prophylactically to mice enhanced survival against lethal challenge 24 hours 
later with H5N1 or H1N1 (Throsby et al., 2008). Similarly, HA stem-reactive 
monoclonal antibodies were isolated from immortalised IgG+ B cells of individuals 
previously vaccinated with seasonal influenza vaccines (Corti et al., 2010). These 
monoclonal antibodies could neutralise many influenza HA subtypes in vitro 
including the pH1N1 strain, and showed in vivo protection in mice (Corti et al., 2010). 
Furthermore, broadly neutralising antibodies targeting the HA stem region have been 
detected in individuals naturally infected with pH1N1 (Wrammert et al., 2011).  
 
While the identification of influenza-specific, broadly neutralising antibodies has 
revealed conserved potential antibody target sites, experimental vaccine efforts to 
date have not yet been able to generate effective, fully cross-reactive neutralising 
antibody responses (Li et al., 2013, Laursen & Wilson, 2013). 
 
 
1.4.3 T cell-mediated heterosubtypic anti-influenza immunity in animal models 
T cell-mediated heterosubtypic immunity against influenza is well documented in 
many animal models (Table 1.4.1). Using various adoptive transfer or depletion of T 
cell subset experiments, it has been shown that heterosubtypic immunity is primarily 
mediated by cross-reactive cytotoxic CD8+ T cells, and epitope mapping revealed 
specificity of protective cross-reactive T cells directed to NP, PB2 and PA influenza 
antigens (Table 1.4.1). Rather than preventing infection of a host, cross-reactive 
CTLs mediate protection from morbidity and mortality demonstrated by reduced viral 
replication, accelerated viral clearance, enhanced recovery from disease and 
enhanced survival following lethal challenge (Table 1.4.1). Thereby, cross-reactive T 
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cell responses reduce disease severity in animal models. Studies defining the 
induction of cross-reactive CTLs have demonstrated the importance of priming via 
the mucosal route that induces long-lived, protective mucosa-associated CTLs 
(Christensen et al., 2000). Low dose priming was also able to induce protective HSI 
(Powell et al., 2007). Although the exact mechanism of HSI has not been elucidated, 
most studies suggest it is via CTL activity and/or antiviral cytokines. HSI was directly 
related to the frequency of responding cross-reactive CD8+ T cells in a mouse model 
(Christensen et al., 2000). Also in a mouse model, CTL mediated cross-protective 
immunity with reduced lung viral titre was demonstrable up to 1 year after an initial 
priming infection (Liang et al., 1994). Interestingly, in a ferret model of HSI, a longer 
duration of protection of up to 18 months post-priming was observed (although this 
study did not identify the immune mediator of protection) (Yetter et al., 1980). Whilst 
T cell-mediated HSI has been detected in many different animal models of influenza 
infection (Table 1.4.1), some studies have observed HSI independent of CD8+ CTLs 
under some circumstances (Epstein et al., 1997, Nguyen et al., 2001). Variable HSI 
observed between these studies highlights the effect of dissimilar experimental 
designs, but is also suggestive of the redundancy of the immune system, where 
more than one mechanism can mediate heterosubtypic immunity in animal models. 
 
1.4.4 T cell heterosubtypic anti-influenza immunity in humans  
There is paucity of data assessing the role of HSI in natural human influenza 
infection. Epidemiological studies provide some indirect evidence of T cell-mediated 
HSI in humans when a pandemic virus entered a naïve population previously 
exposed to a different virus subtype. Adults who experienced H1N1 infection 2 – 3 
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months (Slepushkin, 1959) or up to 4 – 6 years (Epstein, 2006) prior to 1957, were 
less likely to develop symptomatic illness with influenza infection during the 1957 
H2N2 pandemic. Experimental challenge studies have also demonstrated T cell-
mediated HSI in humans without detectable pre-challenge antibodies. Pre-challenge 
CTL responses were associated with decreased viral shedding following 
experimental challenge with a live H1N1 virus (McMichael et al., 1983b). Pre-
challenge CD4+ T cells have also been inversely associated with viral shedding and 
illness severity following challenge with live influenza vaccine strain sH3N2 and 
sH1N1 viruses (Wilkinson et al., 2012). These few studies, together with the 
extensive data from animal models, support the importance of T cell-mediated 
immune responses in limiting influenza illness, and suggest that T cell-mediated HSI 
may lessen influenza disease severity during a pandemic.      
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Species The immune 
mediator/correlate 
of protection (and 
anatomical location 
if applicable) 
Experiment Priming 
strain 
Challenge 
strain 
Protection 
measure(s) 
Timing/ 
duration of 
protection if 
applicable 
Comments 
(notable 
findings) 
Reference 
Mouse MHC-I restricted (but 
not MHC-II restricted) 
CTLs 
Adoptive 
transfer (H2-
haplotype 
matched/mis-
matched cells 
or anti-
Ly1.1/anti-
Ly2.1 serum 
treated cells) 
H1N1 H1N1 Reduction of 
lung virus titre 
and prevented 
death from 
lethal dose 
challenge 
Peak CTL 
activity and 
protection 
around 6 days 
post-infection 
1
st
 
demonstration 
of specific T 
cell subset to 
have a 
protective 
effect in host 
with a 
respiratory 
viral infection 
(Yap et al., 
1978, Yap & 
Ada, 1978) 
Mouse (Nude) CTLs Adoptive 
transfer of 
radiolabelled 
spleen cells  
H3N2 H3N2 More rapid 
clearance of 
virus from 
lungs 
Lung viral 
titres reduced 
by day 7 post 
infection 
(compared to 
mice without 
adoptive 
transfer) 
 (Wells et al., 
1981) 
Human CTLs in peripheral 
blood (in the absence of 
antibodies) 
Experimental 
challenge of 
subjects with 
LAIV  
(Donors 
born pre- 
(prior 
H1N1 
exposure) 
or post- 
(no prior 
H1N1) 
1950) 
H1N1 Decreased 
nasal viral 
shedding 
 1
st
 evidence of 
CTL mediated 
HSI in humans 
(McMichael 
et al., 1983b) 
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Mouse CTL clones Adoptive 
transfer 
H2N2 H1N1 Reduction of 
lung virus titre 
and prevented 
death from 
lethal dose 
challenge 
 Cross-reactive 
and subtype-
specific CTLs 
reduced lung 
viral titres but 
only cross-
reactive CTLs 
could promote 
recovery from 
lethal 
heterosubtypic 
infection 
(Lukacher et 
al., 1984) 
Mouse NP-specific CTL clones Adoptive 
transfer 
H3N2 H1N1, H3N2, 
H2N2 
Reduction of 
lung virus titre 
and prevented 
death from 
lethal dose 
challenge 
 Protective 
effect of an 
antigenically 
mapped cross-
reactive CTL 
clone 
(Taylor & 
Askonas, 
1986) 
Mouse Cross-reactive NP-
specific CTLs 
Purified NP 
protein priming 
NP from 
H3N2 
H1N1 Enhanced 
recovery from 
disease and 
protected 
against death 
from lethal 
dose 
challenge 
Protective 
effect with 
lethal 
challenge 
infection at 1 
month post 
priming 
 (Wraith et al., 
1987) 
Mouse Cross-reactive NP-
specific CTLs and Th 
clones 
Adoptive 
transfer 
H3N2 H3N2 Reduction of 
lung virus titre  
 Cloned CTLs 
are more 
effective at 
clearing virus 
in lungs of 
challenged 
mice than 
cloned Th 
(protective 
effect of Th is 
more variable) 
(Askonas et 
al., 1988) 
 43 
Mouse CD4+ and CD8+ T cells 
in nose and CD8+ 
CTLs in lungs 
Depletion of T 
cells 
H1N1 H3N2 Reduction of 
virus titre in 
respiratory 
tract 
Protective 
effect 
demonstrable 
with challenge 
infection up to 
1 year post 
priming 
Contribution of 
different T cell 
subsets to 
heterosubtypic 
immunity can 
differ between 
upper and 
lower 
respiratory 
tract  
(Liang et al., 
1994) 
Mouse CTLs induced in MALT 
(mediastinal lymph 
nodes) 
Mucosal 
versus 
systemic 
routes of 
priming  
H3N2 H1N1 Enhanced 
recovery from 
disease and 
protected 
against death 
from lethal 
dose 
challenge 
Protective 
effect with 
lethal 
challenge 
infection at 10 
months post 
priming 
Mucosal 
immunization 
(compared to 
systemic 
immunization) 
induces 
longer-lived 
CTL 
responses in 
mucosa-
associated 
lymphoid 
organs that 
correlated with 
protective 
heterosubtypic 
immunity  
(Nguyen et 
al., 1999) 
Mouse Sequential double 
priming with 
heterosubtypic 
influenza strains to 
increase NP-specific 
cross-reactive CD8+ 
memory T cells 
Depletion of 
CD8+ T cells 
H1N1 
followed 
by H3N2 
H7N7 Reduction of 
lung (and 
brain) viral 
titres of lethal 
H7N7 
challenge 
Lung viral 
titres reduced 
by day 3 post 
challenge in 
doubly primed 
mice 
(compared to 
single primed 
or naïve mice) 
Heterosubtypic 
protection 
directly related 
to the 
frequency of 
responding 
CD8+ T cells  
(Christensen 
et al., 2000) 
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Mouse KO for 
IFN-
CTLs induced in MALT 
(mediastinal lymph 
nodes) 
Depletion of 
CD8+ T cells 
H3N2 H1N1 Reduction of 
lung virus 
titres, 
enhanced 
recovery from 
disease and 
protected 
against death 
from lethal 
dose 
challenge 
 IFN-  is not 
required for 
CTL mediated 
HSI 
(Nguyen et 
al., 2000) 
Mouse KO for 
MT 
NP or PB2-specific 
CTLs 
Prime-
challenge 
H9N2 H5N1 Enhanced 
recovery from 
disease and 
reduced 
mortality 
following lethal 
challenge 
 In B cell 
deficient mice, 
HSI correlated 
with CTL 
responses to 
NP or PB2 
(O'Neill et al., 
2000) 
Mouse KO for 
Ig, CD1 or γδ  
CD4+ and CD8+ T cells Depletion of 
CD4+ and 
CD8+ T cells 
H1N1 H3N2, H2N2 Reduction of 
lung and upper 
respiratory 
tract virus 
titres and 
protected 
against death 
from lethal 
dose 
challenge 
 Ig, NKT cells 
or γδT cells 
are not 
required for 
HSI 
(Benton et 
al., 2001) 
Pigs CD8+ T cells Prime-
challenge 
H1N1 H3N2 Reduced virus 
shedding and 
no fever 
associated 
with illness  
  (Heinen et 
al., 2001) 
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Chickens CD8+ CTLs Adoptive 
transfer  
H9N2 H5N1 Reduced 
mortality 
following lethal 
challenge 
Protective 
effect with 
lethal 
challenge 
infection at 3 
to 70 days 
post priming 
 (Seo & 
Webster, 
2001) 
Chickens CD8+IFN-γ+ T cells in 
lungs 
Depletion of T 
cells 
H9N2 H5N1 Reduced 
mortality 
following lethal 
challenge 
Declining 
protective 
immunity over 
time (20 – 100 
days) lasting 
100 days after 
priming 
correlated with 
declining 
CD8+IFN-γ+ T 
cells in the 
lungs 
Vβ1 αβTCR+ 
T cells but not 
Vβ2 αβTCR+ 
or γδTCR+ T 
cell subset 
required for 
protection  
(Seo et al., 
2002) 
Mouse CD8+VLA-1+ T cells in 
lungs 
Blocking of 
VLA-1 
(integrinα4β1) 
on T cells 
H3N2 H1N1 Reduced 
mortality 
following lethal 
challenge 
 VLA-1 retains 
CD8+ T cells 
in the lungs 
that mediate 
HSI 
(Ray et al., 
2004) 
Mouse NP366–374-specific CTLs Prime-
challenge 
H3N2 H1N1 Reduction of 
lung virus 
titres, 
enhanced 
recovery from 
disease and 
reduced 
mortality 
following lethal 
challenge 
  (Kreijtz et al., 
2007) 
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Mouse NP –specific CTLs T cell 
depletion 
H3N2 
cold-
adapted 
virus  
H1N1 Enhanced lung 
viral 
clearance, 
enhanced 
recovery fom 
disease and 
reduced 
mortality 
following lethal 
challenge 
T cell-
mediated HSI 
effective within 
5-6 days post 
lethal 
challenge and 
persists for > 
70 days 
Low dose 
priming with 
cold-adapted 
virus can 
achieve T cell-
mediated HSI 
against high 
dose lethal 
challenge 
(Powell et al., 
2007) 
Mouse NP- and PA-specific 
CTLs 
Prime-
challenge 
H3N2 H5N1 Reduction of 
lung virus 
titres, 
enhanced 
recovery from 
disease and 
reduced 
mortality 
following lethal 
challenge 
  (Kreijtz et al., 
2009) 
Ferrets CTLs Prime-
challenge 
H3N2 H5N1 Reduction of 
lung virus 
titres, reduces 
virus 
associated 
histopathologic
-al changes in 
the brain, 
enhanced 
recovery from 
disease and 
reduced 
mortality 
following lethal 
challenge 
 HSI in ferret 
model that 
more closely 
resembles 
human 
influenza             
HSI hampered 
by prior 
vaccination  
(Bodewes et 
al., 2011b) 
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Mouse CD4+ and CD8+ T cells Depletion of 
CD4+ and 
CD8+T cells 
H3N2 pH1N1 Reduction of 
lung virus 
titres, 
enhanced 
recovery from 
disease and 
reduced 
mortality 
following lethal 
challenge 
 1
st
 in vivo 
evidence of 
HSI against 
pH1N1 
(Guo et al., 
2011) 
Mouse CD4+ and CD8+ T cells Adoptive 
transfer of 
CD4+ and 
CD8+ T cells 
H3N2 pH1N1 Enhanced lung 
viral clearance 
and enhanced 
recovery from 
disease 
  (Hillaire et al., 
2011a) 
Nonhuman 
primate 
CD4+ and CD8+ T cells Prime-
challenge 
H1N1 pH1N1 Enhanced 
lower and 
upper 
respiratory 
tract viral 
clearance 
 More 
physiological 
and 
immunological 
relevant model 
of influenza in 
humans 
(compared to 
mice or ferrets) 
(Weinfurter et 
al., 2011) 
Humans NP- and M- specific 
CD4+ T cells (but not 
CD8+ T cells) in 
peripheral blood (in the 
absence of antibodies 
to challenge strains) 
Experimental 
challenge of 
subjects with 
TIV 
(Donors 
without 
antibodies 
to 
challenge 
strains) 
H1N1, H3N2 Decreased 
nasal viral 
shedding, 
reduced 
severity of 
illness  
  (Wilkinson et 
al., 2012) 
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Mouse 
(including KO 
for MT)  
Lung resident CD8+ T 
cells (and antibodies) 
Adoptive 
transfer 
H1N1 H3N2 Reduction of 
lung virus 
titres, 
enhanced 
recovery from 
disease and 
protected 
against death 
following lethal 
challenge 
Lung Trm 
numbers 
decreased 
over time and 
correlated with 
reduced HSI 
by 7 months 
post-priming  
Pulmonary 
priming 
required for 
optimal HSI, 
circulating T 
cells (including 
effector T 
cells) recruited 
to lungs during 
viral clearance 
not required 
for HSI 
Importance of 
lung Trm cells 
in HSI 
(Wu et al., 
2014) 
 
Table 1.4.1 Evidence of T cell-mediated HSI.  
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1.4.5 Heterosubtypic T cell responses to influenza vaccination  
By definition, strain-specific neutralising antibodies induced by influenza vaccination 
would not be expected to provide sterilising immunity against heterosubtypic 
influenza infection. This is particularly the case for inactivated influenza vaccines, 
however LAIV may provide broader immunity (Cox et al., 2004). Interestingly, 
following seasonal TIV vaccination in healthy adults, H5N1 cross-reactive CD4+ T 
cells producing IFN-  and IL-2 were detectable from in vitro expanded PBMC 
obtained 30 days post-vaccination (Gioia et al., 2008), suggesting that seasonal 
influenza vaccination may boost H5N1 cross-reactive cellular immune responses. 
LAIV induced a broader range of anti-influenza cytotoxicity against homosubtypic 
and heterosubtypic strains than TIV vaccination at 14 or 28 days post-vaccination in 
chronically ill older adults (Gorse & Belshe, 1990). In mice, LAIV induces 
heterosubtypic immunity that reduces lung virus titres, prevents weight loss and 
reduces inflammatory cytokines in the lungs following challenge infection 3 weeks 
later (Lanthier et al., 2011). This LAIV-induced heterosubtypic immunity was 
associated with enhanced expression of chemokines involved in T cell recruitment to 
the lungs of mice. Furthermore, similar memory T cell response characterised by 
IFN-  and chemokines involved in T cell and DC recruitment were induced in 
supernatants of LAIV-stimulated PBMC from healthy adults vaccinated with LAIV 
(Lanthier et al., 2011).  
 
A meta-analysis showed a moderate level of cross-protection (34 – 38%) of seasonal 
TIV vaccination against laboratory confirmed pH1N1 illness and hospitalization 
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across studies in all age groups, but mainly in healthy adults (Yin et al., 2012). It has 
been postulated that the observed cross-protection may be due to heterosubtypic 
humoral and/or cellular immune responses activated by seasonal influenza vaccines 
(Johns et al., 2010).   
 
1.5 Immune correlates of protection against influenza 
1.5.1 B cell-mediated immune correlates of protection against influenza  
Seminal work in 1972 identified levels of HAI assay (described in Materials and 
methods section 2.13) titre required to provide 50% protection against influenza 
infection in adult challenge experiments (Hobson et al., 1972). This evidence is the 
historical basis for the currently used surrogate of influenza vaccine-induced 
protection of HAI titre ≥ 1:40 (Katz et al., 2009). Whilst this is a well-characterised 
and routinely used correlate of protection, compared to young adults, higher HAI 
titres are required to achieve the same or higher protection rates in children (Black et 
al., 2011). Furthermore, this surrogate for sterilising humoral immunity cannot 
evaluate potential universal influenza vaccines that include components to reduce 
viral shedding and transmission or disease severity.   
 
Anti-NA serum antibodies have been shown to be protective against influenza illness 
in humans (Couch et al., 1974, Couch et al., 2013). Other humoral responses 
(mucosal IgG, IgM and IgA anti-HA antibodies, HA stalk-reactive serum IgG 
antibodies, anti-M2 serum IgG antibodies) that may contribute to protection against 
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influenza require other assays lacking standardisation and the minimal requirements 
for protection are yet unknown (Kreijtz et al., 2011). 
   
1.5.2 T cell-mediated immune correlates against influenza  
Cellular responses to influenza are becoming increasingly used measures in the 
evaluation of vaccine-induced immunity. In elderly individuals, cellular responses 
provide a better correlate of influenza TIV vaccine-induced protection than antibody 
responses (McElhaney et al., 2006, McElhaney, 2008, Shahid et al., 2010). 
Furthermore, serum antibodies have not been proven to be predictive of efficacy for 
LAIV (Forrest et al., 2008), which induce immune responses that may differ from 
those induced by inactivated influenza vaccines (Hoft et al., 2011). Thus there is a 
concensus among the literature that there is a need for incorporation of ex vivo 
measures of cell-mediated immunity into the evaluation of existing influenza 
vaccines. Influenza-specific serum antibody responses as the sole measure of 
vaccine efficacy may have limited value, particularly in the older adult population and 
also in young children vaccinated with LAIV. Furthermore, measures of cell-mediated 
immunity are required in the development of new influenza vaccines, especially for 
some T cell-based universal influenza vaccines.       
 
The high conservation among different influenza subtypes in the antigenic targets of 
influenza specific CD4+ and CD8+ T cells makes them attractive candidates for 
universal influenza vaccine design (Atsmon et al., 2012, Berthoud et al., 2011). 
Since T cell responses significantly correlated with decreased viral shedding and 
illness severity to experimental challenge in humans (McMichael et al., 1983b, 
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Wilkinson et al., 2012), testing this in natural influenza infection in humans and 
defining the frequency and phenotype of such a protection-associated T cell 
correlate is a logical step towards establishing a relevant minimal requirement for 
protection. 
    
1.5.3 Measuring antigen-specific T cells 
Assessment of influenza-specific cross-reactive T cell responses is complicated 
given the low frequency of circulating antigen-specific memory T cells in humans. 
Quantification of the memory T cell response usually involves the measurement of 
IFN-γ producing cells using a sensitive T cell Enzyme-linked Immunosorbent Spot-
forming (ELISpot) assay. Further analysis in strong responders uses multi-parameter 
flow cytometry and intracellular cytokine staining (ICS). ELISpot has higher 
sensitivity than flow-cytometry which is ideal for detecting low frequency influenza-
specific memory T cell responses (Lee et al., 2008). Memory T cells can be 
characterised based on expression of cell surface markers (Harari et al., 2006). The 
phenotypic characterisation based on the expression of the lymph node homing 
receptor CCR7 in combination with the cell activation marker CD45RA also 
correlates with IFN-  and IL-2 cytokine secretion patterns, allowing categorisation of 
functional subsets: IFN- -IL-2+ secreting Tcm, IFN- +IL-2+ dual secreting Tem, and 
IFN-γ+IL-2- secreting effector T cells (Teff) (Sallusto et al., 1999). However, this 
correlation is not absolute and there is functional heterogeneity in memory T cell 
populations within CD4+ and CD8+ T cell subsets depending on the cell-surface 
phenotypic markers used (Harari et al., 2006, Seder & Ahmed, 2003, Mahnke et al., 
2013).  
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The novel fluorescence-immunospot assay (Casey et al., 2010) can be used to 
detect cytokine secretion patterns at the single-cell level with sensitivity equivalent to 
ELISpot (Gazagne et al., 2003) and enables the assessment of antigen-specific 
single IFN- + or IL-2+, and co-localised IFN- +IL-2+ dual cytokine secretion patterns 
as surrogates of the main memory T cell subsets. The utility of fluorescence-
immunospot to identify clinically relevant immune responses and protective immune 
correlates in the context of infection, cancer and vaccination has been demonstrated 
by a few recent studies. Casey et al. used fluorescence-immunospot to identify T-cell 
cytokine signatures of pathogen burden in distinct clinical stages of tuberculosis 
infection (Casey et al., 2010). Chemotherapy-induced immunosupression of multiple-
cytokine-secreting T cell responses in patients with haematological malignancies has 
been determined using fluorescence-immunospot (Ohrmalm et al., 2013). Chauvat et 
al. report that the combination of IL-2 and IFN-  responses facilitated enumeration of 
more frequent influenza vaccine-specific responses than that determined by 
detection of either cytokine alone (Chauvat et al., 2013). However, the experimental 
conditions required for reliability and reproducibility of the fluorescence-immunospot 
assay have not been extensively demonstrated in existing reports.   
 
1.6 Hypotheses, aims and outline of thesis 
Conclusively defining the role of T cell-mediated HSI in humans requires a natural 
experiment involving the spread of an antigenically shifted influenza virus through a 
population lacking protective antibodies. A novel IAV entering a human population 
naïve to this virus allows the assessment of the level of pre-existing cross-reactive T 
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cells in the population, and the degree of protection if any, afforded by such HSI from 
influenza cross-reactive T cell responses in the absence of strain-specific antibodies. 
The 2009 H1N1 pandemic was exactly such a natural experiment and was exploited 
to characterise pH1N1 cross-reactive T cells, assess their association with influenza 
infection outcomes, and longitudinally follow pH1N1-specific responses in infected 
individuals. Using the study population, this thesis postulated the following 
hypotheses:   
1. Pre-existing pH1N1 cross-reactive T cells established following prior influenza 
infection or vaccination (experienced > 6 months previously) are prevalent in 
healthy individuals naïve to pH1N1, and are predominantly of an IL-2 
secreting functional Tcm memory subset. 
2. Pre-existing pH1N1 cross-reactive T cells protect against symptomatic 
influenza disease following natural pH1N1 influenza infection. 
3. Natural pH1N1 infection increases the frequency of pH1N1-specific T cells. 
The frequency of pre-existing pH1N1 cross-reactive IL-2+ functional memory 
T cell response predicts the magnitude of the IFN-γ+ effector T cell response 
following natural pH1N1 infection.  
 
To address the above hypotheses, the aims of this thesis are to:  
1. Optimise experimental conditions of a sensitive assay to measure frequencies 
of antigen-specific functional T cells (Results section 3.1).  
2. Characterise the pre-existing influenza-specific cross-reactive memory T cell 
responses (Results sections 3.2 and 3.4). 
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3. Identify a cellular correlate of protection against symptomatic influenza 
infection (Results section 3.3).  
4. Characterise the kinetics and longitudinal development of influenza-specific 
cross-reactive, polyfunctional cellular memory responses in the context of 
natural influenza infection and vaccination (Results section 3.5). 
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2 MATERIALS AND METHODS 
2.1 Blood samples and PBMC processing 
 
Blood samples for Results section 3.1 (optimisation of fluorescence-immunospot 
conditions): peripheral blood was obtained from healthy volunteers within the Section 
of Respiratory Infections, National Heart and Lung Institute, St Mary’s Hospital 
campus, Imperial College London. 
Blood samples for Results sections 3.2 – 3.5: Healthy adult (>18 years) staff and 
students of Imperial College London were invited to participate in the ‘ImmunoFlu’ 
study. The study outline and samples selected for analysis in respective results 
sections is shown in Fig. 2.1.1. Individuals already vaccinated for influenza or likely 
to be offered pandemic vaccination (as per the UK government guidelines in 
September 2009) were ineligible.  Written informed consent was obtained following 
study approval by the North West London Research Ethics Committee (REC 
reference: 09/H0724/27). 
20 – 30 mL whole blood was collected into heparinised tubes from participants. 
PBMCs were isolated by Ficoll-PaquePLUS (GE Healthcare, Amersham, UK) density 
centrifugation. Blood was diluted with RPMI 1640 (Sigma-Aldrich, UK) at 1:1, layered 
over Ficoll-PaquePLUS without mixing and centrifuged at 2000 rounds per minute 
(rpm) without brake for 20 minutes at 23 C. PBMC were taken from the 
gradient/plasma interface and washed twice in RPMI 1640 supplemented with 10% 
heat-inactivated foetal bovine serum (FBS), (Invitrogen, UK), (R10) by centrifugation 
(1600 rpm with brake for 5 minutes at 23 C). PBMC pellet was re-suspended in R10 
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medium and 10 L of cell suspension was removed and added to 0.4% trypan blue 
stain (Invitrogen, UK) at 1:1 to count viable cells using the Countess automated cell 
counter (Invitrogen, UK). PBMC were used immediately or cryopreserved in FBS 
supplemented with 10% dimethyl sufoxide (DMSO, Sigma-Aldrich, UK) for storage in 
liquid Nitrogen. Cryoperserved PBMC were rapidly thawed in 37 C water bath for 1 -
2 minutes, washed and re-suspended in warm R10, and rested (for up to 1 hour) at 
37 C prior to use.   
 
Figure 2.1.1 Study outline and samples selected for analysis.  
Study outline and timeline of the 2009–2010 and 2010–2011 pandemic waves in the UK. 
Shown is the outline of the study (top) in the context of the timeline of the evolving pH1N1 
pandemic (bottom). The bar chart shows UK influenza virological surveillance data from the 
World Health Organisation’s FluNet (WHO, 2014a) highlighting the study recruitment and 
follow-up time points for seasons 1 and 2 in relation to influenza activity in the UK during 
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2009 – 2011. Red bars indicate influenza A, and blue bars indicate the number of cases of 
pH1N1 detected by virological national surveillance. Week number was measured from the 
start of each year. Healthy adults recruited just after the first wave of the pandemic had 
passed in the UK were followed over two influenza seasons (T0–T3), with PBMC and serum 
samples collected before and at the end of each winter influenza season. During each 
influenza season, symptom questionnaires were emailed to participants every 3 weeks with 
automated weekly reminders. Nasal swabs were collected by participants if they were 
symptomatic and were returned to the laboratory. Infection was defined by detection of 
pH1N1 virus in the returned nasal swabs or a four-fold rise in pH1N1 HAI titre in paired 
serum samples. Nasal swab reverse transcriptase polymerase chain reaction (RT-PCR) and 
serum HAI assay were performed by Public Health England (PHE), (formerly known as the 
Health Protection Agency (HPA)). Arrows between the boxes denote the longitudinal 
progression of individuals during the study; coloured boxes represent the various infection or 
vaccination outcomes of the samples used in respective results sections. *9/18 individuals 
were re-vaccinated in season 2. 
 
 
2.2 Sample size estimation 
The primary hypothesis was to identify whether individuals developing mild or 
asymptomatic illness had higher frequencies of pre-existing cross-reactive CD8+ T 
cells. 100 infected individuals with a prevalence of 60% asymptomatic infection 
(Monto et al., 1985) would allow for the detection of a moderate effect size (odds 
ratio, OR of 4) between symptomatic and asymptomatic infection for each tenfold 
increase in cross-reactive T cell frequency (prevalence of 60%) (Lee et al., 2008) 
with 80% power at p = 0.05 (two-tailed) significance. Based on 30% incidence of 
 59 
infection during the first wave of the UK pandemic (Miller et al., 2010), a sample size 
of 350 participants was estimated to attain 100 infected individuals (calculations and 
recruitment conducted by Dr Saranya Sridhar). 
 
2.3 Culturing Madin Darby Canine Kidney cells  
Madin Darby Canine Kidney (MDCK) cells (kindly gifted from Professor Wendy 
Barclay) were stored cryopreserved in liquid Nitrogen in 5% DMSO with DMEM 
essential media (DMEM medium with high glucose, L-Glutamine and Sodium 
pyruvate (Sigma-Aldrich, UK), supplemented with 10% FBS, 2% non-essential amino 
acid 100X solution (Sigma-Aldrich, UK), 100 U penicillin (Invitrogen, UK) and 100 
µg/mL streptomycin (Invitrogen, UK)). Cryopreserved MDCKs were rapidly thawed in 
37 C water bath for 1 – 2 minutes, washed and re-suspended in DMEM essential 
media prior to use. Thawed MDCK cells were seeded and cultured at 37 C, 5% CO2 
in T75 tissue culture flasks with DMEM essential media and checked daily 
microscopically (VWR optical microscope) for confluence. Confluent MDCK cell 
cultures (attained on day 2 - 3 post seeding) were washed once with sterile 
phosphate buffered saline (PBS) treated for 5 - 10 minutes at 37 C, 5% CO2 with 
trypsin/ Ethylenediaminetetraacetic acid (EDTA) solution 1X (Sigma-Aldrich, UK) 
diluted 1 in 5 with PBS to dissociate adherence. Dissociated MDCK cell suspension 
was washed with DMEM essential media and cell pellet was either cryopreserved (in 
5% DMSO and DMEM essential media) for storage in liquid Nitrogen, or MDCK cells 
were seeded for growing or quantifying influenza stocks (see below sections 2.4 – 
2.6).    
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2.4 Titrating influenza trypsin 
MDCK cells were plated in 12-well plates in 1 mL/well serum-free DMEM essential 
media and dilutions (range: 0.1 – 2 L/mL) of TPCK treated influenza-trypsin 
(Worthington Biochemical Corporation, New Jersey, USA). Seeded plates were 
incubated for 2 - 3 days at 37 C, 5% CO2 to achieve confluence (checked daily 
microscopically). The concentration of influenza-trypsin at which confluence occurred 
without significant MDCK cell detachment or cell death was used in growing 
recombinant influenza (1 L/mL).   
 
2.5 Growing recombinant influenza  
Cryopreserved MDCKs were thawed, seeded and cultured (for 2 – 3 days) at 37 C, 
5% CO2 in T75 tissue culture flasks with DMEM essential media until 80 – 90% 
confluent (checked daily using microscope). Media was removed from confluent cells 
and cells were washed twice with 10 mL PBS. A recombinant A/England/195/09 
strain virus (kindly gifted from Professor Wendy Barclay) was diluted in serum-free 
DMEM essential media to infect MDCKs at multiplicity of infection (MOI) = 0.0001. 
Infected cells were incubated for 1 hour at 37 C, 5% CO2 with gentle rocking every 
10 – 20 minutes. Virus inoculum was removed from MDCK monolayer and serum-
free DMEM essential media with 1 L/mL titrated influenza-trypsin was added to the 
MDCK monolayer for incubation at 37 C, 5% CO2. Infected MDCKs were checked 
daily and virus was harvested when cell adherence was < 20% (around days 2 – 3 
post-infection). Virus-containing media was removed into falcon tubes and 
centrifuged at 2000 rpm for 10 minutes at 4 C to separate dead cell pellet from virus-
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containing supernatant. 1 mL virus aliquots were stored at -80 C and used each time 
without multiple freeze-thawing. 
 
2.6 Influenza plaque assay  
MDCKs were thawed (as described above), seeded in 12-well plates and incubated 
at 37 C, 5% CO2 overnight to form a confluent monolayer. The following day MDCK 
cell monolayers were washed with PBS and infected in duplicate with 100 L of 10-
fold dilutions of influenza A/England/195/09 stock virus and incubated for 1 hour at 
37 C, 5% CO2. 2% agarose (Oxoid LTD, UK) added to overlay medium warmed to 
37 C (distilled water with 10X MEM (Invitrogen, UK), 7.5% bovine serum albumin 
(BSA) fraction V (Invitrogen, UK), 200 mM L-Glutamine (Invitrogen, UK), 7.5% 
Sodium bicarbonate solution (Invitrogen, UK), 1 M HEPES (Invitrogen, UK), 1% 
dextran (Sigma-Aldrich, UK), 10,000 U/mL penicillin, 10,000 g/mL streptomycin) 
with 1 L/mL influenza trypsin (Worthington Biochemical Corporation, New Jersey, 
USA, TPCK treated Code: TRTPCK) was added to each well containing washed 
MDCK cell monolayer. Plates were incubated at 37 C for 3 days to enable plaques 
to form. After 3 days, visible plaques were marked on plates before removing 
agarose disks and plaques were stained for counting by adding 1 mL/well crystal 
violet stain (40 mL 1% crystal violet (Sigma-Aldrich, UK) in 80 mL methanol and 300 
mL distilled water). Virus concentration was calculated in plaque-forming units (pfu) 
per mL using the following formula:  
Virus titre (pfu/mL) = ((average number of plaques in well X dilution of virus in well)/ 
volume of virus in well ( L)) x 1000   
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2.7 Antigens and influenza vaccine strains used in fluorescence-
immunospot 
 
Live pH1N1 virus was obtained by growing a recombinant A/England/195/09 strain in 
MDCK cells as described above and used at MOI = 1 in IFN-γ and IL-2 fluorescence-
immunospot assays and MOI = 5 in flow cytometry. Inactivated vaccine strain viruses 
used were reassortant pandemic H1N1 (A/California/07/09, NYMCX-179A, 5 μg /mL, 
National Institute for Biological Standards and Control (NIBSC), UK), seasonal H1N1 
(A/Brisbane/59/2007, IVR-148, 5 μg/mL, NIBSC, UK) and seasonal H3N2 
(A/Uruguay/716/2007, NYMC X-175C, 5 μg/mL, NIBSC, UK). Peptide pools used 
were 9-mer peptides representing highly conserved reported HLA class I restricted 
epitopes in influenza A virus from PB1, M1 and NP proteins (Appendix Table 6.1) 
(NR-2667, 5 μg/mL per peptide) (NIH Biodefense and Emerging Infections Research 
Resources Repository, NIAID, USA); and peptide pool of 15-mer peptides 
overlapping by 10-mer covering the entire sequence of influenza (A/California/07/09) 
M1, NP and PB1 proteins (5 μg /mL per peptide) (ThinkPeptide, UK)  (Appendix 
Tables 6.2, 6.3, 6.4). Cell culture lysates from cells infected with Cytomegalovirus 
(CMV) and Epstein Bar Virus- (EBV) (East Coast Biologicals Inc., USA, 10 μg /mL), 
purified protein derivative (PPD, Statens Serum Institut, Denmark, 16.67 μg /mL) and 
6kDa early secreted antigenic target from Mycobacterium tuberculosis (ESAT-6 
antigen, Pepceuticals Limited, UK, 10 μg/mL) were also used. Phytohaemagglutinin 
(at 4 g/mL unless otherwise stated in figure legends) (PHA, MP Biomedicals, UK) 
was used as positive control and R10 medium alone as negative control. 
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2.8 Ex vivo IFN-  and IL-2 fluorescence-immunospot assays 
 
Freshly isolated or cryopreserved and thawed PBMC were counted using the 
Countess automated cell counter (as described above in section 2.1). Viability index 
was calculated as the ratio of the average viability of frozen-thawed PBMC to the 
average viability of fresh PBMC (viability data obtained from countess cell count 
readings). Fluorescence-immunospot pre-coated low fluorescence polyvinylidene 
fluoride (PVDF) plates (coated with mAb 1D1K/IL2 
0I/249, FluoroSpot, Mabtech, UK) were directly blocked with 10% FBS in PBS for 30 
minutes at room temperature. PBMC pre-stimulated in most experiments (except 
where indicated) with 0.5 g/mL (or indicated concentrations in anti-CD28 titration 
experiment) monoclonal anti-CD28 IgG antibody (Mabtech, UK) were plated at 2.5 x 
105 cells/well (or otherwise indicated cell input numbers in cell titration experiment) 
with R10 or antigens and incubated for 18 hours at 37°C, 5% CO2. After 18 hours 
incubation, supernatant was discarded and plates were washed with PBS and 
incubated with 2 g/mL biotinylated anti-IL-2 (IL2-II-biotin, Mabtech, UK) and 
monoclonal FITC-conjugated anti-IFN-γ (7-B6-1-FS-FITC, Mabtech, UK) at 100 
L/well for 2 hours in the dark at room temperature (Mabtech, antibodies were 
diluted in PBS supplemented with 0.1% BSA). Plates were washed with PBS and 
incubated with 1 µg/mL secondary detection antibodies anti-FITC-PF 488P and 
streptavidin-PF555 (Mabtech, 100 L/well) for 1 hour in the dark at room 
temperature. Plates were washed with PBS, incubated with 50 L fluorescence 
enhancer (Mabtech, UK) for 15 minutes before discarding and drying plates in the 
dark. Spot forming cells (SFC) were counted using a fluorescence spot reader 
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(iSpot, AutoimmunDiagnostika GmbH, Germany) fitted with colour filters for FITC 
and Cy3 detecting PF488 and PF555 respectively. Threshold size and intensity 
settings for spot enumeration were optimised for fluorescence-immunospot 
methodology presented in results section 3.1 (Appendix Table 6.5) and ImmunoFlu 
study sample experiments presented in results sections 3.2 and 3.3 (Appendix Table 
6.6). 
 
2.9 Sorting cells by magnetic bead isolation for fluorescence-immunospot 
PBMC were depleted of CD4+ or CD8+ T cells with magnetic activated cell sorting 
(MACS) by labelling with CD4 or CD8 microbead kits respectively and passing 
through LD columns (Miltenyi Biotec, Germany) according to manufacturer’s 
protocol. Freshly isolated or cryopreserved and thawed PBMC were counted using 
the Countess automated cell counter (as described above in section 2.1). 
Undepleted PBMCs were stored at 37°C, 5% CO2 incubator until required. 
Remaining PBMC were washed by centrifugation (at 4000 rpm, 10 mins, brake on) 
and the cell pellet was re-suspended in 80 L MACS buffer (PBS with 0.5% BSA and 
2 mM EDTA) and 20 L CD8 or CD4 microbeads. Cell suspension and microbeads 
were mixed well and incubated at 4ºC for 22 minutes. LD column was pre-wet by 
placing on a magnetic column holder and washing with 2 mL MACS buffer. Cell 
suspension and microbeads were applied to the top of the column and effluent was 
collected as the negative fraction (CD8 or CD4 depleted). LD column was washed 
out 3 times with 0.5 mL MACS buffer. A 20 L aliquot of effluent was taken into 
FACS tubes for staining (only for CD3, CD4 and CD8 antibody conjugates from 
Table 2.11.1). The purity of the depletion of CD4 or CD8 populations was assessed 
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by flow cytometry staining and was > 94% on all occasions (representative plots 
shown in Fig. 2.9.1).  Collected MACS column effluent was washed by centrifugation 
(at 4000 rpm, 10 minutes, brake on) and cell pellet was re-suspended in R-10 and 
plated in fluorescence-immunospot plated at 2.5 x 105 cells per well. Undepleted 
PBMC were also plated at 2.5 x 105 cells per well for comparison.  
 
 
Figure 2.9.1 Representative flow cytometry staining and purity check for CD4+ and CD8+ T cell 
depletion by MACS.  
Populations are gated on live single cells with low forward and side scatter for lymphocyte 
population. 
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2.10  Optimising 14-colour flow-cytometry staining panel 
Antibody conjugates were selected based on availability of cell markers, 
fluorochrome conjugations and compatibility of fluorochrome combinations for the 
BD Fortessa using the BD spectrum viewer online tool 
(http://www.bdbiosciences.com/research/multicolor/spectrum_viewer/). Each 
antibody was titrated independently on PBMC to determine optimal staining 
(Appendix Fig. 6.1 and Appendix Tables 6.7 - 6.18). IL-2-PE and TNF-α-APC were 
used at concentrations previously optimised in the laboratory (for the same antibody 
clone). Antibodies were combined into one panel (Table 2.11.1) following 
ascertainment of optimal concentrations giving appropriate compensation values and 
staining of distinct populations was achieved. A time-course experiment was 
conducted to determine the time for stimulation to detect all cytokines using live 
influenza. MOI was also varied to determine the optimal MOI to detect all influenza-
specific cytokines and degranulation marker. There was a trend in higher IFN-γ, IL-2 
and TNF-α responses with increasing stimulation time and higher responses in 
influenza MOI = 5 compared to MOI = 1 (Fig. 2.10.1), although there were no 
statistically significant differences between time-points in each cytokine or marker 
measured for each stimulation, or any significant differences due to co-stimulation 
(0.1 g/mL anti-CD28 and 0.1 g/mL anti-CD49d, BD Biosciences, UK). For 
consistency between fluorescence-immunospot and flow cytometry assays, we 
selected 18 hours stimulation time. An MOI of 5 was selected to increase the 
sensitivity for detection of influenza-specific cytokine positive T cell responses by 
flow cytometry. Peptide pool-specific responses were undetectable or very low 
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frequency, even in the presence of co-stimulation, hence only live virus stimulation 
was used in flow cytometry staining experiments.  
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Figure 2.10.1 Time-course of stimulation and influenza multiplicity of infection for intracellular cytokine staining by flow cytometry. 
Bars show mean and SD (n = 3 – 4). One-way ANOVA followed by Dunn’s multiple comparison correction, not significant.  
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2.11 PBMC stimulation and staining for flow-cytometry 
Staining of PBMC was undertaken following 18 hours stimulation of PBMC (3 x 
106 per condition) in 24-well plates with R10 media (negative control), phorbol 
myristate acetate (PMA, 5 ng/mL) (Sigma-Aldrich, UK) and Ionomycin (500 
ng/mL) (Sigma-Aldrich, UK) (PMA/I, positive control), live pH1N1 
(A/England/09/195) virus (MOI = 5) or CMV lysate (10 g/mL, antigen control). 
2 mM Monesin A in sodium hydroxide (Sigma-Aldrich, UK) was added 2 hours 
after addition of stimulus. Staining with CD107a (clone H4A3, Becton Dickinson 
and company (BD) Biosciences, UK) and CD107b (clone H4B4, BD 
Biosciences, UK) was undertaken at the time of stimulation. Following overnight 
stimulation, PBMC were harvested into 4 mL polystyrene conical base tubes 
and washed in FACS buffer (PBS with 0.5% BSA) by centrifugation (1600 rpm 
with brake = 5 for 5 minutes at 4 C). Supernatant was discarded and cell pellet 
was re-suspended in 1 mL FACS buffer to stain with amine-reactive viability 
dye Live/dead Blue (Invitrogen, UK) as a live/dead marker (20 minutes in the 
dark at 4 C). Live/dead Blue stained cells were washed in FACS buffer by 
centrifugation (1600 rpm with brake = 5 for 5 minutes at 4 C), supernatant was 
discarded and cell pellet was blocked (20 minutes in the dark at 4 C) with 10 % 
human AB serum (Sigma-Aldrich, UK) to prevent non-specific antibody binding 
prior to staining with surface staining fluorochrome-labelled markers (Table 
2.11.1). CD14-Biotin, CD19-Biotin and CD56-Biotin staining mix was prepared 
and added directly to the cell pellet in FC block (100 L/tube). Following 
incubation for 20 minutes in the dark at 4 C, cells were washed in FACS buffer 
by centrifugation (1600 rpm with brake = 5 for 5 minutes at 4 C), supernatant 
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was discarded and cell pellet was stained with a master-mix containing the 
remaining surface staining fluorochrome-labeled markers (25 L/tube, Table 
2.11.1) for 20 minutes in the dark at 4 C. Intracellular cytokine staining (ICS) 
was performed with BD Cytofix/Cytoperm Plus kit (BD Biosciences, UK) 
according to the manufacturer’s instructions. Surface stained cells were washed 
in FACS buffer by centrifugation (1600 rpm with brake = 5 for 5 minutes at 4 C), 
supernatant was discarded and cell pellet was fixed and permeabilised with 200 
L Cytofix/Cytoperm solution (BD Cytofix/Cytoperm Plus kit) for 15 minutes at 
4 C. Fixed and permeablised cells were washed by centrifugation (1600 rpm 
with brake = 5 for 5 minutes at 4 C) in 10X Perm/Wash buffer (BD 
Cytofix/Cytoperm Plus kit) diluted 1 in 10 with distilled water. Supernatant was 
discarded and cell pellet was stained with IFN-γ (cloneB27, BD Biosciences), 
IL-2 (clone MQ1-17H12, BD Biosciences) and TNF-α (clone MAb11, BD 
Biosciences) antibodies (50 L/tube, Table 2.11.1) for 30 minutes in the dark at 
4 C. Fully stained cells were washed once in Perm/Wash buffer followed by 
another wash with FACS buffer by centrifugation (1600 rpm with brake = 5 for 5 
minutes at 4 C), supernatant was discarded and cell pellet was re-suspended in 
FACS buffer for acquisition on BD LSR Fortessa (BD Biosciences, UK). 
Fluorescence minus one controls were PBMC stimulated with live pH1N1 virus 
that were used for identifying positive populations on all fluorochrome-labeled 
markers in the first experiment validating the panel, and then only on CCR7, 
CD107AB, CCR5 and CD45RA in all experiments (to minimise sample 
expenditure). Compensation controls for all fluorochrome-labeled antibodies 
were prepared using anti-mouse or anti-rat Ig  Compbead kits (BD 
Biosciences, UK) as per manufacturer’s instructions. In all samples, 500,000 – 
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1 million live events were collected and analysed. Antigen-specific cytokine 
responses were calculated only if the responses were > 0.001% of the parent 
population.  Flow cytometric analyses were performed using a Fortessa (BD 
Biosciences, UK) and data were analyzed with Flow Jo, version 9.7.5 software 
(Tree Star, USA) and SPICE, version 5 software (NIH, USA). 
Fluorochrome 
or biotin Conjugate Clone 
 
Dilution 
(by 
volume) 
 
LSR Fortessa 
Laser 
configurations  
 
Bandpass 
filter 
Live/Dead Blue 
N/A 
N/A 
1:1000 
 
355 
 
 
450/50 
PE-CF594 CD3 UCHT1 1:10 561 620/10 
AF700 CD8 RPA-T8 1:5 640 720/40 
QDot605 CD4 S3.5 1:80 405 605/12 
Qdot655 CD45RA MEM56 1:100 405 655/8 
PE-Cy7 CCR7 3D12  1:10 561 780/60 
PerCP-Cy5.5 CD69 FN50 1:10 488 710/50 
APC-Cy7 CCR5 2D7/CCR5 1:10 640 780/60 
BV570 CD57 HCD57 1:100 405 585/15 
V450 IFN-  B27 1:20 405 450/50 
PE IL-2 
MQ1-
17H12 
1:50 
561 582/15 
FITC CD107A H4A3 1:25  
488 
 
 
530/30 
FITC CD107B H4B4 1:25 
APC TNF-  MAb11 1:10 640 670/14 
Biotin CD14  HCD14 1;250  
N/A 
 
N/A Biotin CD19 HIB19 1:4000 
Biotin CD56  HCD56 1:4000 
PE-Cy5 Streptavidin N/A 1:320 488 675/20 
 
Table 2.11.1 Flow cytometry staining panel. 
 
 
2.12  RT-PCR for pH1N1 virus 
PHE laboratories performed this assay. The influenza A(H1)v specific assay 
of PHE contains primers and a dual-labelled TaqMan MGB probe (Applied 
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Biosystems, USA) targeting conserved sequences in the HA gene of A(H1N1) 
variant viruses, and the positive control swine A(H1N1) virus 
A/Aragon/3218/2009, in a 1-step TaqMan PCR assay as previously described 
in detail (Ellis et al., 2009). Data was analysed by Dr Saranya Sridhar. 
 
2.13  HAI assay 
PHE laboratories performed this assay. Antibody responses to the virus strain 
A/England/195/2009, circulating in the UK during our study, were detected by 
use of HAI assay according to standard methods at the Centre for Infections, 
PHE (London, UK) (Miller et al., 2010). Briefly, human sera were treated with 
receptor-destroying enzyme (RDE) II, (Denka Seiken, Japan) for 18 hours 
followed by heat inactivation for 1 hour at 56°C. Sera were screened in a 
limiting dilution range using the NIBRG122 virus (a reverse-genetic virus 
containing hemagglutinin and neuraminidase from the influenza 
A/England/195/2009 strain) and incubated with the HA antigen suspension for 
1 hour followed by addition of 0.5% turkey red blood cell suspension. The 
reaction is left for 1 hour at room temperature before reading. Each sample is 
titrated in duplicate and individual titres reported did not differ by more than a 
two-fold serial dilution. The serum titre is equal to the highest reciprocal 
dilution, which induces a complete inhibition of haemagglutination. Suitable 
control serum samples were included in all analyses, with post-infection ferret 
serum samples raised against the pH1N1 virus strain as positive controls; 
human pooled serum samples from individuals with either high antibody titres 
to the circulating influenza H1, H3, and B strains or from individuals with no 
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antibody titres to these seasonal strains were used as negative controls. Data 
was analysed by Dr Saranya Sridhar.  
 
2.14  Symptom score 
A summed symptom score was designed by totaling the weight for each of the 
canonical influenza symptoms used in clinical studies (Monto et al., 2000) and 
reported by returned symptom surveys, with a weight of 0 for none, 1 to mild 
symptoms and 4 for severe symptoms attributed to each symptom (Table 
2.14.1). Mild symptoms were of a severity that did not interfere with normal 
daily activities while severe symptoms were those that affected normal daily 
activity or required medical attention. Symptom survey data was analysed by 
Dr Saranya Sridhar.  
Symptom Weight for 
no 
symptoms 
Weight for 
mild 
symptoms 
Weight for 
severe 
symptoms 
Fever 0 1 4 
Cough 0 1 4 
Sore throat 0 1 4 
Headache 0 1 4 
Myalgia 0 1 4 
 
Table 2.14.1 Symptom scores. 
 
2.15  Statistical analysis 
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GraphPad Prism 5 software (California, USA) and SPSS version 21 (IBM, UK) 
were used to construct graphs and perform statistical analyses. P values were 
estimated by Mann-Whitney nonparametric test for un-paired comparisons 
and Wilcoxon-signed rank nonparametric test for paired data comparions. 
Spearman rank correlation coefficient was used to test association between 
variables and linear regression was used to assess linearity of data. Specific 
statistical tests and significance values are indicated in figures and figure 
legends.  
 
Antigen-specific responses in fluorescence-immunospot were calculated only 
in samples with a positive control response (indicating viable cells). 
Responses per well were normalised to per million PBMC. The median 
background frequencies of the IFN-γ and IL-2 responses were 4 SFCs per 
million (range = 0 – 56) and 12 SFCs per million (range = 0 – 156) PBMC, 
respectively. A threshold for calculating antigen-specific responses was 
derived using background data such that responses were calculated if they 
were two standard deviations above mean background (IL-2 = 68 and IFN-γ  
= 25). The frequencies of antigen-specific cells (total IFN-γ+, total IL-2+ and 
IFN-γ+IL-2+ dual) were calculated by subtracting the average number of 
SFCs in negative control wells from the number of SFCs in antigen-containing 
test wells for each donor. IFN-γ+IL-2- and IFN-γ-IL-2+ responses were 
calculated by subtracting the dual from the total total IFN-γ+ or total IL-2+ 
response respectively. The frequency of total cytokine-secreting cells to 
peptide pool antigens was calculated by summing the frequencies of the three 
functional subset IFN-γ+IL-2−, IFN-γ−IL-2+ and IFN-γ+IL-2+ T cells.  
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To assess reproducibility of the fluorescence-immunospot assay (results 
section 3.1), experiments were repeated on two to three separate occasions 
using cryopreserved PBMC with 5 – 6 replicates for 2 – 4 different antigen 
stimulations. Coefficient of variation (CV) was calculated using the following 
fomula: CV = Standard deviation (SD) / Mean 
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3 RESULTS 
3.1 Optimising IFN-γ/IL-2 fluorescence-immunospot assay 
In clinical studies with serial sampling conducted over a long duration with bio-
banked samples, assessing multiple-cytokine secreting T cell responses 
requires an assay suited to the inherent challenges of such settings. This 
includes quantifying functional antigen-specific T cells that are often rare 
populations in peripheral blood; where the quantity of biological samples may 
be limited; and samples from multiple longitudinal time-points may be 
cryopreserved and bio-banked to be processed in batch. Thus a 
comprehensive assessment of the basic parameters concerning the execution 
and performance of IFN-γ/IL-2 fluorescence-immunospot was performed.        
 
3.1.1 Lower background IFN-γ responses compared to IL-2 responses in 
fluorescence-immunospot 
Enumeration of antigen-specific responses requires the subtraction of non-
specific background responses. Background cytokine secretion in total IFN-γ+ 
and total IL-2+ responses were measured in 323 independent PBMC samples 
and individual well responses were normalised to spot forming cells (SFC) per 
million PBMC. Background IL-2 responses were higher and showed greater 
inter-individual variation than background IFN-γ responses (median =  12 and 
4, with range = 0 – 156 and 0 – 56 spot forming cells (SFC) per million PBMC 
respectively, p < 0.0001 Fig. 3.1.1). The greater variation in background IL-2 
responses was also evident when compared to other fluorescence-
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immunospot datasets using a similar assay protocol (two standard deviations 
(SD) above mean background IL-2 = 68 (n = 323) (present study), 48 (n = 90) 
(Casey et al., 2010), and 28 (n = 62) (Sridhar et al., 2012) SFC per million 
PBMC). Background IFN-γ responses were similar across different datasets 
(two SD above mean background IFN-γ  =  25 (present study), 32 (Casey et 
al., 2010) and 20 (Sridhar et al., 2012) SFC per million PBMC). 
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Figure 3.1.1 Background fluorescence-immunospot responses in negative control wells. 
Cryopreserved PBMC (2.5 x 105 per well) were unstimulated and background 
cytokine secretion in pre-coated fluorescence-immunospot assays was quantified (n 
= 323). Dot plot shows individual responses with lines at median for total IFN-γ+ and 
total IL-2+ responses normalised to spot forming cells (SFC) per million PBMC. 
Wilcoxon signed-rank test for difference between means, p < 0.0001. 
 
3.1.2 Effect of input PBMC quantity on fluorescence-immunospot responses  
Biological samples, especially in human studies are often limited and sample 
expenditure can determine the choice of assay used. Boulet et al. report 
200,000 input cells as optimal for detecting HIV-1 antigen-specific responses 
from HIV-1-infected patient samples using dual colour ELISpot and a range of 
input numbers from 150,000 to 300,000 cells per well (Boulet et al., 2007). To 
determine whether a similar optimal exists for fluorescence-immunospot using 
PBMC from healthy individuals, input cell numbers were used in the range 
100,000 – 400,000 per well. There were no significant changes in total IL-2+, 
total IFN-γ+ and IFN-γ+IL-2+ dual non-specific background responses over 
this input cell number range (Fig. 3.1.2). Linear regression shows lack of a 
significant non-zero slope in background responses (Fig. 3.1.2 A, B, C). 
Similarly, CMV lysate- specific total IFN-γ+ and IFN-γ+IL-2+ dual responses 
(Fig. 3.1.2 E and F) and EBV lysate-specific total IL-2+ and IFN-γ+IL-2+ dual 
responses (Fig. 3.1.2 G and I) enumerated did not vary significantly with 
increasing input cell number per well. However, due to well saturation with 
high frequency responses above 500 single-stained spots, increasing input 
cell number negatively affected quantification of EBV lysate-specific total IFN-
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γ+ responses (r2 = 0.17, p = 0.024, Fig. 3.1.2 H). Enumeration of CMV lysate- 
specific total IL-2+ response was also inversely affected by increased input 
cell number per well (r2 = 0.90, p = 0.004, Fig. 3.1.2 D). 
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Figure 3.1.2 Input T cell number per well in fluorescence-immunospot. 
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Cryopreserved PBMC were plated in fluorescence-immunospot plates at input T cell 
numbers ranging 1 – 4 x 105 PBMC (n = 4 - 6) per well unstimulated (background) or 
stimulated in duplicate for each donor with Cytomegalovirus (CMV) lysate (10 μg/mL) 
or Epstein Bar virus (EBV) (10 μg/mL). The mean and standard error of mean for 
total IL-2+ (A, D, G), total IFN-γ+ (B, E, H) and IFN-γ+IL-2+ dual (C, F, I) normalised 
spot forming cells (SFC) per million PBMC are shown for input PBMC range. One-
way ANOVA followed by Dunn’s Multiple comparison post-test comparing responses 
at each input PBMC number to each other, p > 0.05 in all comparisons. Equation of 
linear regression and p-values indicated on graph with linear regression and 95% 
confidence intervals shown by dotted lines. A representative image of well responses 
from total IFN-γ+, total IL-2+ and IFN-γ+IL-2+ dual responses from PBMC stimulated 
with EBV-lysate with increasing input T cells (J). 
    
 
3.1.3 Stronger correlation in IFN-γ responses than IL-2 responses between 
freshly isolated and frozen-thawed PBMC responses   
Clinical trials often involve high-throughput sample collection from multiple 
time-points necessitating cryopreservation of PBMC samples for later batch 
processing. To assess whether cryopreserved samples can be used in 
fluorescence-immunospot, freshly isolated and frozen-thawed PBMC 
responses were compared. Viability of cells used fresh or frozen aliquots of 
PBMC from the same donors after cryopreservation for at least 2 weeks was 
always >85% and average viability index (viability of frozen/viability of fresh x 
100) was 103%. Median frequencies of background or antigen-specific 
responses from frozen-thawed PBMC were not significantly different to 
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corresponding responses from freshly isolated PBMC in any of the three 
cytokine-secreting (IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+) populations 
(Fig. 3.1.3 A-C). Fresh and frozen-thawed total IFN-γ+ secreting cell 
responses were strongly correlated (r = 0.791, p < 0.0001, Fig. 3.1.3 E). 
Similarly, fresh and frozen-thawed IFN-γ+IL-2+ dual responses were strongly 
correlated (r = 0.741, p < 0.0001, Fig. 3.1.3 F). A moderate correlation was 
observed between fresh and frozen-thawed total IL-2+ responses (r = 0.598, p 
= 0.0013, Fig. 3.1.3 D). Importantly, the cytokine secretion profiles from 
frozen-thawed samples were similar to fresh PBMC responses in all antigens 
or individual antigens (Fig. 3.1.3 G). 
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Figure 3.1.3 Comparison of fluorescence-immunospot responses in fresh PBMC versus 
frozen-thawed PBMC from same donor samples. 
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PBMC (n = 3 – 6) freshly isolated or a frozen aliquot (cryopreserved for 2 weeks prior 
to thawing) were unstimulated (black circles) or stimulated with antigens 
phytohaemagglutinin (PHA, 0.2 μg/mL, red squares), Cytomegalovirus (CMV) lysate 
(10 μg/mL, blue triangles), Epstein Bar virus (EBV) lysate (10 μg/mL, green inverted 
triangles) or purified protein derivative (PPD, 16 μg/mL, purple diamonds) in 
fluorescence-immunospot. Dot plots show individual responses from fresh or frozen-
thawed PBMC with lines at median for IFN-γ-IL-2+ (A), IFN-γ+IL-2- (B) and IFN-γ+IL-
2+ (C) responses normalised to spot forming cells (SFC) per million PBMC. Wilcoxon 
signed-rank test between fresh and frozen cytokine-secreting responses to each 
antigen, not significant. Graphs show Spearman rank correlation between fresh 
PBMC and frozen-thawed PBMC responses for total IL-2+ (D), total IFN-γ+ (E) and 
IFN-γ+IL-2+ dual SFC (F) per million PBMC.  Pie charts show average proportion 
response from IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ dual subsets for all or each 
stimulation in fresh or frozen-thawed responses (G). 
 
3.1.4 Reproducibility of fluorescence-immunospot 
Reproducibility of measurements within and between assays is important to 
assess when an assay is used to process samples in batch and results are 
compared between different batches. Fluorescence-immunospot assays were 
performed on 2 to 3 separate occasions (with 5 – 6 replicates per antigen) to 
determine intra- and inter- assay coefficient of variation. A non-linear 
relationship is observed when intra-assay coefficient of variation (CV) is 
plotted against the mean SFC for 18 replicates (6 replicates per antigen and 3 
antigen stimulations per donor) in fluorescence-immunospot (Fig. 3.1.4). As 
the mean response approaches zero the intra-assay CV increases to 245% at 
2 SFC per million PBMC in total IL-2+ (Fig. 3.1.4 A), 78.4% at 20 SFC per 
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million PBMC in total IFN-γ+ (Fig. 3.1.4 B) and 245% at 1 SFC per million 
PBMC IFN-γ+IL-2+ dual responses (Fig. 3.1.4 C). Median intra-assay CV for 
6 replicates per antigen stimulation using three different antigens and 2 
independent donor samples were 12.20% (IQR = 3.71% - 20.70%), 12.10% 
(IQR = 6.18% - 18.03%) and 13.90% (IQR = 4.27% -  23.54%) for total IL-2+, 
total IFN-γ+ and IFN-γ+IL-2+ dual responses respectively (Fig. 3.1.4 A, B, C).  
 
To determine variability of fluorescence-immunospot responses from PBMC 
aliquots of the same sample in assays conducted on 2 to 3 separate 
occasions, inter-assay CV was determined. Median inter-assay CV was 
22.64% (IQR = 9.13% - 36.15%), 23.85% (IQR = 11.31% - 36.39%) and 
14.81% (IQR = 7.49% - 22.14%) for total IL-2+, total IFN-γ+ and IFN-γ+IL-2+ 
dual responses respectively (Fig. 1.4 D, E, F). 
 
PPD responses in fluorescence-immunospot were measured in 5 different 
donors during the above CV experiments, hence the means and standard 
deviations of SFC for total IL-2+, total IFN-γ+ and IFN-γ+IL-2+ dual responses 
were plotted to determine inter-individual variation (Fig. 3.1.4 G). PPD-specific 
responses measured by fluorescence-immunospot showed large inter-
individual differences as indicated by large standard deviations for total IL-2+, 
total IFN-γ+ and IFN-γ+IL-2+ dual responses (SD = 171.8, 218.6 and 105.3 
respectively, Fig. 3.1.4 G). The CV values are compared to those reported in 
other published studies in Table 3.1.1.  
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Figure 3.1.4 Intra-assay and inter-assay coefficient of variation and inter-individual variation in fluorescence-immunospot.  
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PBMC (2.5 x 105 per well) were stimulated with 5 μg/mL pH1N1 inactivated vaccine (A/California/07/09, NYMCX-179A), or sH1N1 inactivated 
vaccine (A/Brisbane/59/2007, IVR-148) (closed black symbols), 16 μg/mL purified protein derivative (PPD) (open symbols) and 10 μg/mL 
ESAT-6 (red symbols) in replicates of 5 – 6. Two – three independent experiments were conducted on separate occasions on the aliquots of 
cryopreserved PBMC samples from 5 different donors (different donors represented by different symbol shapes). Dot plot graphs show mean 
response in spot forming cells (SFC) per million PBMC against intra-assay coefficient of variation (CV) for total IL-2+ (A), total IFN-γ+ (B) and 
IFN-γ+IL-2+ dual (C) and inter-assay coefficient of variation across all experiments for total IL-2+ (D), total IFN-γ+ (E) and IFN-γ+IL-2+ dual (F) 
responses. All responses are shown after subtraction of background (unstimulated). Dotted horizontal lines show median intra-assay or inter-
assay CVs for each cytokine response. Inter-individual variation in fluorescence-immunospot responses to PPD shown by dot plot with 
individual responses represented by black circles and red lines at mean with standard deviation (G). 
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Assay 
 
Intra- 
or 
inter- 
assay 
CV 
 
IFN-γ+IL-2- 
response 
 
IFN-γ-IL-
2+ 
response 
 
 
IFN-γ+IL-
2+ dual 
response 
Reference 
 
Dual colour IFN-γ/IL-2 
ELISpot on human 
PBMC for HIV-1 
antigen-specific 
responses 
Intra-
assay 
 
10.8%  16.4%  17%  (Boulet et 
al., 2007) 
Inter-
assay 
11.1%  13.9%  12.8%  
IFN-γ single colour 
ELISpot on human 
PBMC for HIV-1 
antigen-specific 
responses 
Intra-
assay  
 
17% 
 
NA NA (Mwau et al., 
2002) 
Inter-
assay 
 
11% 
 
N/A N/A 
IFN-γ ICS on human 
PBMC for CMV pp65 
peptide pool-specific 
responses on same 
samples performed by 
different laboratories  
Intra-
assay  
 
Individual 
analysis: 28% 
-39% 
Central 
analysis: 18% 
– 23% 
 
N/A 
 
N/A 
 
(Maecker et 
al., 2005) 
Inter-
assay 
 
N/A N/A N/A 
Dual colour IFN-γ/IL-2 
fluorescence-
immunospot on 
human PBMC for 
pH1N1 or sH1N1 
vaccine, PPD, ESAT-6 
responses 
 
Intra-
assay 
 
12.1%  12.2%  13.9%  Present 
study  
Inter-
assay 
 
23.9%  22.6%  14.8%  
 
Table 3.1.1 Intra- and inter- assay CV values of fluorescence-immunospot compared to 
CVs reported in other studies.  
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3.1.5 Co-stimulatory anti-CD28 enhances the proportion of IFN-γ-IL-2+ 
response 
One of the technical challenges associated with the IFN- γ/IL-2 fluorescence-
immunospot is the dependence of IFN-γ secretion on IL-2 as the IL-2 is 
captured by the fluorescence-immunospot membrane. The addition of anti-
CD28 monoclonal antibody in the assay compensates for the effect of IL-2 
sequestration on IFN-γ responses (Quast et al., 2005). To determine the 
effect of anti-CD28 on the magnitude and phenotype of fluorescence-
immunospot responses, PBMC were unstimulated or stimulated with antigens 
without or with 0.5 g/mL anti-CD28 co-stimulation. A representative image of 
well responses from total IFN-γ+, total IL-2+ and IFN-γ+IL-2+ dual cytokine 
secreting responses is shown (Fig. 3.1.5 A). Anti-CD28 co-stimulation 
significantly increased IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ dual EBV 
lysate-specific responses (p = 0.001, 0.0024 and 0.0005 respectively, Fig. 
3.1.5 D) and CMV lysate-specific IFN-γ-IL-2+ and IFN-γ+IL-2+ dual responses 
(p = 0.0005 and 0.0098 respectively, Fig. 3.1.5 C). Anti-CD28 did not 
significantly alter CMV lysate-specific IFN-γ+IL-2- responses (p = 0.339, Fig. 
3.1.5 C). The frequency of non-specific background IFN-γ-IL-2+ and IFN-γ+IL-
2+ dual responses were significantly increased in the presence of anti-CD28 
(p = 0.002 and 0.008 respectively, Fig. 3.1.5 B). Low frequency M1 peptide 
pool-specific IFN-γ-IL-2+, IFN-γ+IL-2- or IFN-γ+IL-2+ dual responses were not 
significantly enhanced in the presence of anti-CD28 (Fig. 3.1.5 E), even when 
a higher anti-CD28 concentration was used (Fig. 3.1.5 F). Furthermore, anti-
CD28 co-stimulation increased the proportion IFN-γ-IL-2+ CMV lysate-specific 
and proportion IFN-γ-IL-2+ EBV-specific responses (p = 0.0117 and p = 0.117 
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respectively, Fig. 3.1.5 G), although increased background and M1- peptide 
pool-specific IFN-γ-IL-2+ proportion in the presence of anti-CD28 did not 
reach statistical significance. Importantly, this enhancement on proportion 
IFN-γ-IL-2+ responses with anti-CD28 was apparent whether the PBMC were 
fresh or frozen-thawed PBMC responses (Fig. 3.1.5 G). The relative 
contribution of CD4+ and CD8+ T cells to antigen-specific cytokine responses 
for the antigens used in fluorescence-immunospot was assessed by flow 
cytometry (Fig. 3.1.6). Negative control background IL-2 responses were 
mainly from CD4+ whereas IFN-γ responses were from CD8 (Fig. 3.1.6 B). 
EBV lysate-specific IL-2 and IFN-γ responses were mainly from CD4+ T cells 
(Fig. 3.1.6 B). M1 peptide pool-specific IL-2 and IFN-γ responses were from 
CD4+ and CD8+ T cell subsets Fig. 3.1.6 B). Similarly, CMV lysate-specific 
IL-2 responses were from both CD4+ and CD8+ T cells, whereas the majority 
of IFN-γ responses were from CD4+ T cells Fig. 3.1.6 C).     
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Figure 3.1.5 Anti-CD28 co-stimulation in fluorescence-immunospot preferentially 
enhances IL-2 responses.   
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A representative image of well responses from total IFN-γ+, total IL-2+ and IFN-γ+IL-
2+ dual responses from PBMC unstimulated or stimulated with Epstein Bar virus 
(EBV) lysate, or M1 peptide pool without or with addition of anti-CD28 monoclonal 
antibody (A).  Frequency of responses for unstimulated (Neg, B) or PBMC stimulated 
with CMV lysate (10 g/mL) (C) EBV lysate (10 μg/mL) (D) or influenza M1 antigen 
peptide pool (5 g/mL) (E) in duplicates for each donor without addition of anti-CD28 
monoclonal antibody prior to plating PBMCs (open symbols) or with anti-CD28 
(closed symbols). Dot plot graphs show individual donor responses with lines at 
median IFN-γ-IL-2+, IFN-γ+IL-2- and IFN-γ+IL-2+ responses in spot forming cells 
(SFC) per million PBMC. (F) Titration of anti-CD28 concentration in PBMC stimulated 
with influenza M1 antigen peptide pool (5 g/mL) in 2 donors (red and black lines 
represent different donors). (G) Pie charts show average proportion response from 
IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ dual subsets for all or each stimulation 
without or with anti-CD28 co-stimulation. P-values for Wilcoxon signed rank test 
between proportions of IFN-γ-IL-2+ in anti-CD28 co-stimulated or unstimulated 
conditions. 
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Figure 3.1.6 Relative contributions of CD4+ and CD8+ T cells to antigen-specific 
cytokine responses.  
PBMCs unstimulated or stimulated for 18 hours with CMV lysate (10 μg/mL), EBV 
lysate (10 g/mL) or influenza M1 antigen peptide pool (5 g/mL) were stained for 
surface and intracellular markers and analysed by flow cytometry. (A) Gating 
strategy. PBMCs were gated on live, single cells, low forward and side scatter and 
CD3+ for lymphocytes positive for IFN- + or IL-2+ followed by gating CD4+CD8- or 
CD4-CD8+ T cells within each cytokine positive population. Bar charts show mean 
and standard error of mean for the ratio of CD4+ to CD8+ cytokine positive T cell 
response to stimulation antigens, n = 4 (B), n = 54 or 60 (C).   
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3.2 pH1N1 cross-reactive cellular responses in pH1N1 naïve 
individuals 
Using the sensitive and optimized fluorescence-immunospot assay, PBMC 
responses to pH1N1 core antigen peptide pools, recombinant antigens, 
inactivated vaccine strain viruses and live virus was assessed. Influenza is 
considered an acute infection with rapid antigen clearance (Pantaleo & Harari, 
2006) and based on this model we hypothesized that pH1N1-naïve individuals 
unexposed to influenza for at least 6 months prior (last possible exposure in 
February 2009), would have memory T cells to core proteins (PB1, M1 and 
NP) of the pH1N1 virus with a cytokine signature predominantly IL-2 
secreting, representing Tcm (Sallusto et al., 1999).  
 
3.2.1 Cohort characteristics 
The 76 participants had a median age of 34 years with a range of 18 – 72 
years. 43% (33 individuals) were male and 57% (43 individuals) were female. 
All participants were seronegative (HAI  1:8) by HAI assay to detect pH1N1-
specific antibodies. None were vaccinated for pH1N1 at the time of 
recruitment and only 3 individuals gave a history of influenza-like illness in the 
3 months preceding recruitment.   
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3.2.2 High prevalence of pH1N1 core-antigen-specific cross-reactive cellular 
responses in pH1N1 naïve individuals 
PBMC responses to one or more of three core proteins of pH1N1 virus (PB1, 
M1, NP) were measured by fluorescence-immunospot and were found in 58% 
of individuals (44/76 individuals). All individuals with detectable responses had 
IFN-γ+IL-2- secreting pH1N1 cross-reactive cells to core proteins of pH1N1 
(Fig. 3.2.1A), while 34/76 (45%) and 38/76 (50%) had detectable IFN-γ-IL-2+ 
(Fig. 3.2.1B) and IFN-γ+IL-2+ dual (Fig. 3.2.1C) secreting cells respectively. 
 
The prevalence of cross-reactive cells was highest to PB1 (40/76 individuals, 
53%) followed by NP (31/76 individuals, 41%) and M1 (24/76 individuals, 
32%) proteins (Fig. 3.2.2A). However, 75% (57/76) of individuals had 
detectable cross-reactive cellular responses to live pH1N1 virus and a 
similarly high proportion of individuals had responses to pH1N1 inactivated 
vaccine (63%, 48/76 individuals), sH1N1 inactivated vaccine (76%, 58/76 
individuals) and the sH3N2 inactivated vaccine (72%) (Fig. 3.2.2B). 
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Figure 3.2.1 Pre-existing cross-reactive memory T cell responses to pH1N1 core proteins in pH1N1 sero-negative individuals.  
Total magnitude of ex vivo PBMC responses from the (A) IFN-γ+IL-2-, (B) IFN-γ-IL-2+, and (C) IFN-γ+IL-2+ dual cytokine-secreting subsets to 
overlapping peptide pools of PB1, M1 and NP of pH1N1 (A/California/04/09) virus in each individual was measured by fluorescence-
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immunospot. Individuals are shown in the same order in (A through C) (n = 76). PB1: polymerase basic protein 1, M1: matrix protein 1, NP: 
nucleoprotein, SFCs: spot forming cells, PBMCs: peripheral blood mononuclear cells. HAI assay was performed to confirm sero-negativity to 
H1 of A/England/195/09 and A/California/04/09. Magnitude of ex vivo PBMC responses from the IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ 
dual-secreting subsets to overlapping peptide pools of PB1 (D), M1 (E), NP (F), and the summed response to PB1, M1 and NP of pH1N1 
(A/California/04/09) virus (G). Each symbol represents a single individual and horizontal lines represent the mean response. Differences 
between subset responses were estimated by Friedman test. Pie charts represent mean proportions of cytokine-secreting responses. Non-
responders to antigens excluded, PB1: n = 70, M1: n = 70, NP: n = 69, Summed antigens: n = 63.
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Figure 3.2.2 Prevalence of pH1N1 cross-reactive memory T cell responses.  
The proportion of pH1N1 sero-negative individuals with ex vivo PBMC responses to 
overlapping peptide pools of (A) PB1, M1 and NP of pH1N1 (A/California/04/09) and 
(B) live pH1N1 virus, pH1N1 inactivated vaccine, sH1N1 inactivated vaccine and 
sH3N2 inactivated vaccine from IFN-γ+IL-2- (black bars), IFN-γ-IL-2+ (grey bars) and 
IFN-γ+IL-2+ dual (white bars) cytokine-secreting subsets (n = 76) was evaluated by 
fluorescence-immunospot. Each bar represents the average proportion. 
 
3.2.3 Predominance of IFN-γ+IL-2- secreting pH1N1 cross-reactive cellular 
responses in pH1N1 naïve individuals 
The frequency of the total cellular response summed to all three proteins PB1, 
M1 and NP was significantly higher (p < 0.001) in the IFN-γ+IL-2- secreting 
(mean 80 SFC/million PBMC, SEM 12) compared to the IFN-γ-IL-2+ (mean 
27 SFC/million PBMC, SEM 5) and IFN-γ+IL-2+ dual (mean 25 SFC/million 
PBMC, SEM 6) secreting cells (Fig. 3.2.1G). Similarly, the frequency of IFN-
γ+IL-2- secreting cells were significantly higher for the individual antigen 
responses PB1 (Fig. 3.2.1D) and NP (Fig. 3.2.1F) but not for M1 protein (Fig. 
3.2.1E). However, the relative proportion of IFN-γ+IL-2- secreting subset was 
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significantly higher compared to the IFN-γ-IL-2+ and IFN-γ+IL-2+ dual 
secreting subsets for each of the three core proteins and the summed total 
response (pie charts in Fig. 3.2.1D-G). 
 
We next assessed whether influenza-specific memory T cells that recognise 
synthetic peptides also recognise naturally processed peptides from APCs in 
PBMC infected with live virus and recombinant viral proteins. Despite absence 
of prior exposure to the pH1N1 virus or vaccine, 53/76 (70%) and 45/76 (59%) 
individuals had memory T cell responses recognising naturally processed 
peptides presented by APCs infected with live pH1N1 virus or the pH1N1 
inactivated vaccine respectively (Fig. 3.2.2B). Similar to responses to pH1N1 
core proteins, the frequency and proportion of antigen-specific T cells to 
pH1N1 virus was predominantly IFN-γ+IL-2- secreting cells (Fig. 3.2.3A). The 
frequency of IFN-γ+IL-2- secreting subset to live pH1N1 virus was 
significantly higher (mean 100 SFC/million PBMC, SEM 15) compared to the 
IFN-γ-IL-2+ (mean 31 SFC/million PBMC, SEM 5) and IFN-γ+IL-2+ dual 
(mean 28 SFC/million PBMC, SEM 5) secreting subsets. pH1N1 vaccine -
specific responses were not significantly different between the three cytokine 
secreting subsets (Fig. 3.2.3B).  
 
The predominance of IFN-γ+IL-2- secreting cells was not restricted to cross-
reactive responses only since PBMC stimulated with inactivated sH1N1 and 
sH3N2 viruses, the strains circulating prior to the emergence of pH1N1, were 
also prevalent (Fig. 3.2.2 B) and predominantly IFN-γ+IL-2- secreting subset 
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(Fig. 3.2.3C). However, the frequency of IFN-γ+IL-2- secreting T cell response 
to sH1N1 inactivated vaccine was significantly higher than IFN-γ+IL-2- 
secreting responses to live pH1N1 virus (p = 0.0421, Fig. 3.2.3 C compared to 
A) and pH1N1 inactivated vaccine (p < 0.0001, Fig. 3.2.3 C compared to B). 
The relative proportion IFN-γ+IL-2- secreting T cell response to homosubtypic 
sH1N1 inactivated vaccine was also significantly higher than cross-reactive 
pH1N1 inactivated vaccine (p < 0.0001, Fig. 3.2.3 C compared to B, pie 
charts), although there was no difference in the proportion IFN-γ+IL-2- 
secreting subset between homosubtypic responses to sH1N1 inactivated 
vaccine and cross-reactive responses to live pH1N1 virus (Fig. 3.2.3 A 
compared to C, pie charts). Interestingly, the IFN-γ+IL-2- secreting response 
to sH3N2 inactivated vaccine, was significantly higher than the sH3N2-
specific IFN-γ-IL-2+ response but not significantly different to the IFN- +IL-2+ 
dual response (Fig. 3.2.3 D). Furthermore, the frequency IFN-γ+IL-2- 
secreting T cell response to sH3N2 inactivated vaccine was significantly lower 
than IFN-γ+IL-2- secreting responses to live pH1N1 virus (p <0.0001, Fig. 
3.2.3 D compared to A) but not different to pH1N1 inactivated vaccine (p = 
0.762, Fig. 3.2.3 D compared to B).   
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Figure 3.2.3 Cross-reactive memory T cell responses to naturally processed pH1N1 epitopes.  
The magnitude of ex vivo PBMC responses from the IFN-γ+IL-2-, IFN-γ-IL-2+, and IFN-γ+IL-2+ dual cytokine-secreting subsets to (A) pH1N1 
live virus (A/England/195/2009), (B) pH1N1 inactivated vaccine (A/California/07/09, NYMCX-179A), (C) sH1N1 inactivated vaccine 
(A/Brisbane/10/2007, IVR-148) and (D) sH3N2 inactivated vaccine (A/Uruguay/716/2007, NYMC X-175C) in pH1N1 sero-negative individuals 
was determined by fluorescence-immunospot. Each symbol represents a single individual and horizontal lines represent means. Pie charts 
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represent mean proportions of cytokine-secreting responses. Differences between subset responses were estimated by Kruskall-Wallis test. 
Non-responders to stimulation excluded, pH1N1 live virus (n = 70), pH1N1 vaccine (n = 67), sH1N1 vaccine (n = 68), sH3N2 vaccine (n = 62).
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3.2.4 Effect of reported previous seasonal vaccination on pH1N1 cross-reactive 
responses 
To investigate the effect of seasonal influenza vaccination on maintaining 
cross-reactive T cell responses, the magnitude and cytokine-secreting profile 
of T cell responses were compared between previous vaccine recipients and 
unvaccinated individuals. Of the 76 individuals, 6 individuals reported 
vaccination with the 2008 seasonal influenza vaccine. While this is a small 
proportion of individuals to enable statistically meaningful comparisons, there 
was no difference in the magnitude or the functional profile of cytokine 
secreting T cells to pH1N1 core antigens PB1, M1 or NP (Fig. 3.2.4A-C) 
between previously vaccinated and unvaccinated individuals. Similarly, there 
was no difference in the magnitude or the functional profile of cytokine 
secreting T cells to naturally processed epitopes of live pH1N1 virus or pH1N1 
inactivated vaccine between previously vaccinated and unvaccinated 
individuals (Fig. 3.2.4D-E). 
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Figure 3.2.4 Previous influenza vaccination does not affect magnitude or cytokine-secreting profile of cross-reactive T cell memory responses to 
pH1N1.  
(A–C) Magnitude of ex vivo PBMC responses from the IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ dual-secreting subsets to overlapping peptide 
pools of (A) PB1, (B) M1, and (C) NP of pH1N1 (A/California/04/09) virus, (D) pH1N1 live virus or (E) pH1N1 inactivated vaccine in pH1N1 
sero-negative individuals among those who reported having the 2008 seasonal influenza vaccine (n = 6) and those who did not have the 
vaccine (n = 64) as determined by fluorescence-immunospot. Bars show mean responses with two standard error of the mean. Pie charts 
represent mean proportions of cytokine-secreting responses. 
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3.3 Cellular correlate of protection against symptomatic influenza 
The role of cross-reactive T cells in protection against influenza illness was 
addressed by correlating pre-existing cross-reactive cellular responses to 
pH1N1 virus and conserved CD8 T cell epitopes with favourable clinical 
outcomes of influenza infection in naturally infected individuals. The 
hypothesis was that pre-existing pH1N1 cross-reactive T cells would protect 
against symptomatic influenza disease following natural influenza infection. 
 
3.3.1 Study samples 
49 individuals were infected with pH1N1 influenza during the study period and 
had sufficient quantity stored PBMC for analysis. In 25 of these individuals, 
the date, symptoms and symptom score for the influenza infection episode 
could be reliably determined (analysis performed by Dr Saranya Sridhar). The 
median age of the 49 infected individuals was 33 years (IQR = 27 – 40 years) 
and 57% were female. 23 age- and gender- matched individuals that 
remained uninfected during the study were selected; they had a median age 
of 37 years (IQR = 18 – 53 years) and 65% were female. There were no 
significant differences in age or gender between infected and uninfected 
individuals.  
 
3.3.2 Pre-existing pH1N1 cross-reactive T cells and illness severity 
Firstly, the CD4 or CD8 dependency of cytokine secreting responses from 
PBMC in fluorescence-immunospot was checked by CD4+ or CD8+ T cell 
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depletion. Live pH1N1 virus-specific IFN-γ+IL-2- and IFN-γ+IL-2+ dual 
responses were from both CD4+ and CD8+ T cells since there was no 
abrogation of the responses on depletion on either T cell subset (Fig. 3.3.1 A). 
IFN-γ-IL-2+ responses were abrogated when CD4+ but not CD8+ T cells were 
depleted, confirming that the pH1N1 virus-specific IFN-γ-IL-2+ response is 
from the CD4+ T cells (Fig. 3.3.1 A). CD8+ depletion reduced IFN-γ+IL-2- 
response to CD8 conserved epitopes (but this did not reach statistical 
significance), suggesting that the response was mainly mediated by CD8+ T 
cells (Fig. 3.3.1 B).  
 
 
 
Figure 3.3.1 Contribution of CD4+ and CD8+ T cells to pH1N1 live virus and CD8 
conserved epitope pool responses. 
PBMCs undepleted or depleted of CD4+ or CD8+ T cells by labelling with CD4 or 
CD8 microbeads respectively and passing through LD columns, were stimulated 
overnight with pH1N1 live virus or CD8 conserved epitope pools. The purity of the 
depletion in each case was > 94% by flow cytometry staining (see Materials and 
methods section 2.9). Frequencies of cytokine secreting T cell subsets were 
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enumerated using fluorescence-immunospot (n = 9). Bars show mean and standard 
error of the mean. 
 
There were no significant differences in frequencies of pre-existing pH1N1 
cross-reactive total cytokine secreting or cytokine secreting subsets between 
individuals who subsequently became infected with pH1N1 and age- and 
gender- matched individuals who remained uninfected (Fig. 3.3.2). Higher 
frequencies of pre-existing cross-reactive total cytokine secreting T cell 
responses to live pH1N1 virus were detected in individuals who developed 
illness without fever and in individuals without fever and cough and sore 
throat, although this did not reach statistical significance (Fig. 3.3.3A). 
However, higher frequencies of total cytokine secreting T cells to conserved 
CD8 epitopes approached statistical significance (p = 0.0639) in individuals 
who developed illness without fever and cough and sore throat compared to 
individuals who developed illness with these ILI symptoms (Fig. 3.3.3D). 
Frequencies of total cytokine secreting T cells to control CMV lysate were not 
significantly different between the different symptomatic groups (Fig. 3.3.3G). 
Of the three functional subsets enumerated by fluorescence-immunospot, 
IFN-γ+IL-2- cytokine secreting cells were the predominant subset. Statistically 
non-significant higher frequencies of pre-existing cross-reactive total cytokine 
secreting T cell responses to live pH1N1 virus and conserved CD8 epitopes 
were detectable in individuals who developed illness without fever, and in 
individuals without fever and cough and sore throat compared to individuals 
who developed illness accompanied by fever or illness with fever and cough 
and sore throat (Fig. 3.3.3 B-C, E-F). 
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Figure 3.3.2 Pre-existing frequencies of influenza-specific cytokine-secreting T cells in 
individuals who develop infection versus uninfected individuals. 
Comparison of the magnitude of baseline ex vivo PBMC responses from the IFN-
γ+IL-2−, IFN-γ− IL-2+ and IFN-γ+IL-2+ dual subsets and the total cytokine secreting 
cells to pH1N1 live virus measured by fluorescence- immunospot between 
individuals who subsequently develop infection (n=49) and age and gender- matched 
individuals who remain uninfected (n=23). In the box plots, the box represents the 
third centile (75%) and first centile (25%), with the horizontal line representing the 
median (50%). The whiskers represent 1.5 times the IQR. SFC, spot-forming cells. 
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Figure 3.3.3 The frequencies of pre-existing cross-reactive T cells and illness severity in infected individuals.  
Responses to live pH1N1 virus stimulation (A, B, C), summed responses to conserved CD8 epitopes from PB1, M1 and NP proteins (D, E, F) 
and responses to CMV lysate (G, H, I) of total (clear), IFN-γ+IL-2− (blue), IFN-γ− IL-2+ (green) and IFN-γ+IL-2+ dual (yellow) cytokine-
secreting cells quantified by fluorescence-immunospot. The total frequency of cytokine-secreting T cells represents the summed frequencies of 
the three functional subsets: IFN-γ+IL-2−, IFN-γ−IL-2+ and IFN-γ+IL-2+. Cellular immune responses to live pH1N1 virus, CD8 conserved 
influenza epitopes and CMV lysates were determined in individuals (n = 25) developing an illness with fever (n = 13) compared to those with no 
fever (n = 12) and in individuals with fever and cough or sore throat (n = 15) compared to those without fever and cough or sore throat (n = 10). 
P values were estimated by Mann-Whitney nonparametric tests. In the box plots, the box represents the third centile (75%) and first centile 
(25%), with the horizontal line representing the median (50%). The whiskers represent 1.5 times the IQR. SFC, spot-forming cells. 
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Frequencies of pre-existing CD8 conserved epitope-specific total cytokine 
secreting and IFN-γ+IL-2- T cells most strongly inversely correlated with total 
symptom score during illness (r = -0.508, p = 0.0133 and r = -0.437, p = 
0.0371, Fig. 3.3.4B and E). The weaker inverse correlations were between 
total symptom score and frequencies of pH1N1 virus-specific total cytokine 
secreting (r = -0.387, p = 0.0678, Fig. 3.3.3A), IFN-γ+IL-2- (r = -0.367, p = 
0.0849, Fig. 3.3.4D) and IFN-γ+IL-2+ (r = -0.379, p = 0.0747, Fig. 3.3.4J) T 
cells. Conserved CD8 epitope-specific IFN-γ-IL-2+ T cells also weakly 
inversely correlated with total symptom score (r = -0.392, p = 0.0643, Fig. 
3.3.4H).  There was no correlation between the frequencies of CMV lysate-
specific total cytokine secreting or any of the cytokine secreting T cell subsets 
and total symptom score (Fig. 3.3.4 C, F, I, L).      
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Figure 3.3.4 Inverse correlation of cross-reactive T cells and symptom score.  
Correlation between symptom scores and the frequency of total (A, B, C), IFN-γ+IL-
2− (D, E, F), IFN-γ-IL-2+ (G, H, I), IFN-γ+IL-2+ (J, K, L), cellular responses to live 
pH1N1 virus (A, D, G, J), the summed responses to conserved CD8 epitopes from 
PB1, M1 and NP proteins (B, E, H, K) and the responses to CMV lysate (control 
antigen) (C, F, I, L) quantified by fluorescence-immunospot. Symptom score was 
defined by totaling the scores for each of the following symptoms: fever, sore throat, 
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cough, headache and myalgia. r values are the Spearman rank correlation 
coefficients. Each circle on the plot represents an individual (n = 25).  
 
3.3.3 Phenotype of pre-existing pH1N1 cross-reactive CD8+IFN-γ+IL-2- T 
cells and CD4+IFN-γ+IL-2- T cells and correlation with symptom scores 
The specific phenotype of the pre-existing pH1N1-specific protection-
associated T cells was determined by multiparameter flow cytometry on 
PBMC samples remaining from 22 of 25 infected donors. The gating strategy 
is shown in Fig. 3.3.5. The majority of the live pH1N1 virus-specific IFN-γ+IL-
2-CD3+ response on flow cytometry in these 22 donors was from CD3+CD8+ 
T cells (p = 0.007, Fig. 3.3.6). Importantly, CD45RA and CCR7 expression did 
not change during the 18 hour in vitro stimulation with live pH1N1 virus (Fig. 
3.3.7). Stratifying the IFN-γ+IL-2- T cell population into its constituent memory 
subsets using CD45RA and CCR7 showed a predominance of 
CD45RA+CCR7- late effector and CD45RA-CCR7- effector memory amongst 
both CD8+IFN-γ+IL-2- (Fig. 3.3.8A) and CD4+IFN-γ+IL-2- (Fig. 3.3.8 D) T 
cells in response to live pH1N1 virus. However, only the proportion of 
CD45RA+CCR7- late effectors of the CD8+IFN-γ+IL-2- T cells inversely 
correlated with total symptom score (r = -0.604, p = 0.0029, Fig. 3.3.8B). The 
proportion of CD45RA+CCR7- late effector subset of live pH1N1 virus-specific 
CD4+IFN-γ+IL-2- T cells was not associated with total symptom score (r = -
0.0384, p = 0.865, Fig. 3.3.8E). Furthermore, 70% and 33% of this pre-
existing protection-associated pH1N1 virus-specific CD8+IFN-γ+IL-2-
CD45RA+CCR7- T cell population expressed tissue-homing marker CCR5 
and degranulation marker CD107ab respectively (Fig. 3.3.8C). 
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Figure 3.3.5 Gating strategy for flow cytometric analysis of CD8+IFN-γ+IL-2- cells.  
Responses to live pH1N1 virus stimulation were measured by multi-parameter flow 
cytometry. PBMCs stimulated with live pH1N1 virus for 18 hours were stained for 
surface markers of memory, lung homing, degranulation and intracellular cytokines. 
PBMCs were gated on live, single cells, low forward and side scatter for 
lymphocytes, a negative dump gate for CD56, CD14 and CD19, CD3+, IFN-γ+IL-2- 
and CD8+CD4- gating. CD8+ cells of the CD45RA+CCR7- subset were analysed for 
expression of CCR5, CD107 (isotypes A and B) and TNF-α using Flowjo software. 
The Fluorescence Minus One (FMO) controls are shown for CCR7, CD45RA, CD107 
(isotypes A and B) and CCR5 which were used to set the gates to identify positive 
populations. 
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Figure 3.3.6 Percentages of pH1N1 stimulated IFN-γ+IL-2- cells that are CD3+CD4+ 
and CD3+CD8+.  
Responses to live pH1N1 virus stimulation were measured by multi-parameter flow 
cytometry. PBMCs stimulated with live pH1N1 virus for 18 hours were stained and 
analysed as per the gating strategy in Fig. 3.3.5. Dot plots show the percentage of 
the gated IFN-γ+IL-2- that is CD3+CD4+ or CD3+CD8+. P value was estimated by 
Wilcoxon signed-rank nonparametric test (n = 22). 
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Figure 3.3.7 CD45RA and CCR7 expression is not changed by in vitro stimulation.  
Phenotypic characterisation using multi-parameter flow cytometry of the different 
memory subsets of influenza virus-specific CD4+ and CD8+ T cells based on CCR7 
and CD45RA surface expression following overnight stimulation of PBMCs with live 
pH1N1 virus (open symbols) or unstimulated controls (closed symbols) in 46 
individuals (all baseline PBMC samples). Proportion of CD3+CD4+ (A) or 
CD3+CD8+ (B) T cells of effector memory (CD45RA-CCR7-), late effector 
(CD45RA+CCR7-), central memory (CD45RA-CCR7+) or naive (CD45RA+CCR7+) 
phenotype. Symbols represent responses for each individual with the horizontal line 
representing the median response. Statistical analysis by one-way ANOVA with 
Dunn’s post-test comparisons showed no statistically significant differences in 
proportions of the different memory subsets between unstimulated and live virus 
stimulated donor responses. 
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Figure 3.3.8 Inverse correlation of pre-existing pH1N1 cross-reactive late effector CD8+IFN-γ+IL-2− T cells and symptom scores.  
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Phenotypic characterisation was performed using multiparameter flow cytometry of the different memory subsets of influenza virus–specific 
CD8+IFN-γ+IL-2− cells on the basis of CCR7 and CD45RA surface expression after overnight stimulation of baseline (pre-infection) PBMCs 
with live pH1N1 virus in pH1N1-infected individuals (n = 22; in 3 of 25 infected individuals, samples were of insufficient quantity for flow 
cytometry analysis). (A) The proportions of CD8+IFN-γ+IL-2− or (D) CD4+IFN-γ+IL-2− secreting cells that were of the effector-memory 
(CD45RA−CCR7−), late-effector (CD45RA+CCR7−), central-memory (CD45RA−CCR7+) or naive (CD45RA+CCR7+) phenotype. (B) 
Correlation between the proportion of pre-existing CD3+CD8+IFN-γ+IL-2− cells of the late-effector CD45RA+CCR7− subset or (E) 
CD3+CD4+IFN-γ+IL-2− cells of the late-effector CD45RA+CCR7− subset and total symptom score. r values are the Spearman rank correlation 
coefficients. (C) In individuals with influenza-specific late-effector CD8+IFN-γ+IL-2−CD45RA+CCR7− cells (n = 17), further characterisation of 
these cells for expression of CD107AB, CCR5 and TNF-α was undertaken with multiparameter flow cytometry. Symbols represent the 
proportion of CD45RA+CCR7−CD8+IFN-γ+IL-2− cells expressing CD107AB, CCR5 and TNF-α for each individual, with the line showing the 
median response. Each symbol on the plot represents responses for an individual.
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3.4   Phenotype of pH1N1 cross-reactive CD4+ and CD8+ T cells 
In addition to the assessment of IFN-  and IL-2 cytokine secretion (Results 
section 3.2), the polyfunctional profile of influenza-specific memory T cells can 
be comprehensively characterised in terms of other cytokines and markers 
important in antiviral immunity. For example: the antiviral cytokine TNF- , the 
expression of CD57 as a surrogate of replicative senesence, (Akondy et al., 
2009). Furthermore, the expression of CCR5, a chemokine receptor 
responding to inflammatory signals (including the ligands CCL3, CCL4 and 
CCL5) resulting in cell migration and adhesion can be used to assess lung 
tissue homing potential (Rabin et al., 1999). A multiparameter flow cytometry 
panel was designed and optimised to comprehensively characterise the 
phenotype of T cells reacting to live pH1N1 virus.  
 
3.4.1 Study samples 
In 65 of the 76 pH1N1 seronegative individuals in whom cryopreserved PBMC 
remained after fluorescence-immunospot responses were measured (Results 
section 3.2), comprehensive characterisation of PBMC responses was 
undertaken by flow cytometry. 61/65 and 50/65 individuals had samples of 
sufficient quality and quantity of PBMC to enable assessment of responses to 
live pH1N1 virus and CMV respectively (unstimulated negative control and 
PMA/I positive control responses were also assessed for each individual). 
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3.4.2 Comparison of influenza and CMV –specific CD4+ T cell responses 
PBMC were stimulated for 18 hours with live pH1N1 virus, or CMV infected 
cell lysate (as a model of a latent infection). The gating strategy used to 
analyse the flow cytometry data is shown in Fig. 3.4.1. CD4+ T cell cytokine 
expression was compared between pH1N1 virus and CMV lysate -specific 
populations. The majority of individuals showed antigen-specific cytokine 
positive responses above background and the prevalence of responses were 
similar for pH1N1 virus-specific and CMV lysate –specific CD4+ T cells (90% 
and 84% of individuals respectively, Table 3.4.1). 70% (43/61), 59% (36/61) 
and 82% (50/61) of individuals responded to live pH1N1 virus stimulation by 
CD4+IFN-γ+, CD4+IL-2+ and CD4+TNF- + cytokine responses respectively 
(Table 3.4.1).  Similarly 70% (35/50), 54%(27/50) and 64% (32/50) of 
individuals responded to CMV-lysate stimulation by CD4+IFN-γ+, CD4+IL-2+ 
and CD4+TNF- + cytokine responses respectively (Table 3.4.1).  However, 
pH1N1-specific CD4+ cytokine responses showed a hierarchy with 
CD4+TNF-α+ (median = 0.05%, IQR = 0 – 0.30) response significantly higher 
than CD4+IFN-γ+ (median = 0.01%, IQR = 0 – 0.03) and CD4+IL-2+ (median 
= 0.01%, IQR = 0 - 0.02) whereas there was no hierarchy in CMV-lysate-
specific CD4+ cytokine responses (Fig. 3.4.2 A and B). Furthermore, the 
frequency of pH1N1-specific CD4+TNF- + T cells was significantly higher (p 
= 0.0082) than CMV-specific CD4+TNF- + (median = 0.02%, IQR = 0 - 0.08) 
T cells respectively (Fig. 3.4.2A-B). 
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Figure 3.4.1 Gating strategy for flow cytometric analysis of CD3+CD8+ and CD3+CD4+ T cells.  
Responses to live pH1N1 virus stimulation were measured by multi-parameter flow cytometry. PBMCs stimulated with live pH1N1 virus for 18 
hours were stained for surface or intracellular markers. PBMCs were gated on live, single cells, low forward and side scatter for lymphocytes, a 
negative dump gate for CD56, CD14 and CD19 and CD3+CD4+CD8- or CD3+CD4-CD8+ T cells. CD3+CD4+CD8- or CD3+CD4-CD8+ T cells 
were then gated on CD45RA and CCR7 for naïve, effector and memory subsets; CD107 (isotypes A and B) for degranulation; CD69 for early 
activation; CCR5 for lung homing; CD57 for replicative senescence markers and intracellular cytokines (IFN- , IL-2, TNF- ). The Fluorescence 
Minus One (FMO) or unstimulated controls are shown for respective markers that were used to set the gates to identify positive populations.
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Table 3.4.1 Prevalence of antigen-specific CD4+ T cell responses.  
The numbers and proportions of pH1N1 sero-negative individuals with ex vivo 
PBMC responses to live pH1N1 virus or CMV lysate from IFN-γ, IL-2, TNF-  
or any cytokine (IFN-γ+ or IL-2+ or TNF- +) secreting CD3+CD4+CD8- T 
cells evaluated by flow cytometry. 
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Figure 3.4.2 Comparison of pH1N1 live virus and CMV lysate -specific CD4+ T cells.  
Frequency of ex vivo PBMC responses from CD4+IFN-γ+, CD4+IL-2+ and 
CD4+TNF- + or CD4+CD69+ and CD4+CD107ab+ T cells evaluated by flow 
cytometry to live pH1N1 virus (A, C) or CMV lysate (B, D) and gated as shown in Fig. 
3.4.1. Each symbol represents a single individual and horizontal red lines represent 
the median response. Differences between subset responses were estimated by 
Friedman test within antigen-specific T cells or by Mann Whitney test between 
pH1N1 live virus and CMV lysate -specific T cells. Non-responders to antigens 
excluded, pH1N1 live virus: n = 55, CMV lysate: n = 42. 
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The seven possible cytokine expression combinations of IFN-γ, IL-2 and TNF-
α and the triple negative response were analysed using boolean gating in 
pH1N1- specific or CMV-specific CD4+ T cells (Fig. 3.4.3). CD4+TNF-α+ 
single cytokine positive T cells were the highest frequency of pH1N1-specific 
CD4+ T cells (mean = 0.716%, SEM = 0.423), which was significantly higher 
than all other boolean subsets (Fig. 3.4.3A). The other detectable boolean 
combinations of pH1N1-specific CD4+ T cells were IL-2+ single cytokine 
positive (mean = 0.0226%, SEM = 0.00921) that were significantly higher 
(p<0.001) than the dual IFN-γ-IL-2+TNF-α+ (mean = 0.0116%, SEM = 
0.0108) T cells, and IFN-γ+ single cytokine positive (mean = 0.0131%, SEM = 
0.00263) T cells.  
 
Although there was no hierarchy in CMV lysate-specific CD4+ cytokine 
responses at total cytokine level (Fig. 3.4.2B), frequencies of single IFN-γ+ 
(mean = 0.154%, SEM = 0.0532) CD4+ T cell subsets were significantly 
higher than all other boolean subsets except single TNF-α+ (mean = 
0.3058%, SEM = 0.277) which was also significantly higher than IFN-γ-IL-
2+TNF-α+ dual cytokine positive cells (mean = 0.00527%, SEM = 0.00448, p 
< 0.01) and triple negative (mean = 0.00714%, SEM = 0.0004, p < 0.001) T 
cells (Fig. 3.4.3B).  
 
Consistent with the difference between the antigen-specific CD4+TNF-α+ T 
cells at total cytokine level, only the pH1N1-specific IFN-γ-IL-2-TNF-α+CD4+ 
T cell boolean subset was significantly higher (p < 0.01) than the 
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corresponding CMV-specific boolean subset (Fig. 3.4.3). Notably, low 
frequencies of CMV lysate-specific triple IFN-γ+IL-2+TNF-α+CD4+ T cell 
responses (mean = 0.0132%, SEM = 0.00822) were detectable whereas very 
little pH1N1-specific IFN-γ+IL-2+TNF-α+CD4+ T cell response was detected 
(mean = 0.00195%, SEM = 0.000565).  
 
CD69 and CD107ab staining was used to identify antigen-specific cells 
expressing early activation and degranulation capacity respectively. 
Frequencies of pH1N1-specific CD4+CD69+ (median = 0.150%, IQR = 0 – 
0.42) and CD4+CD107ab+ (median = 0.20%, IQR = 0 - 0.45) were 
significantly higher than CMV-specific CD4+CD69+ (median = 0%, IQR = 0 - 
0.04) and CD4+CD107ab+ T cells (median = 0%, IQR = 0 - 0.13) (p < 0.001 
and p = 0.0004 respectively, Fig. 3.4.2C-D). 
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Figure 3.4.3 Cytokine profiles of pH1N1 live virus and CMV lysate -specific CD4+ T cells.  
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Boolean analysis using SPICE software was performed to analyse CD3+CD4+CD8- T cells for each cytokine profile of ex vivo PBMC 
responses to live pH1N1 virus (A) or CMV lysate (B) following flow cytometry staining and gating as in Fig. 3.4.1. Bars represent mean and 
standard error of the mean percentage positive of CD3+CD4+CD8- T cells. Differences between subset responses were estimated by 
Friedman test within antigen-specific T cells or by Kruskal Wallis test between pH1N1 live virus and CMV lysate -specific T cells. Pie charts 
represent mean proportions for each cytokine profile. Non-responders to antigens excluded, pH1N1 live virus: n = 55, CMV lysate: n = 42. * p 
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. IFN_ = IFN-γ, IL2 = IL-2, TNF_ = TNF- .
 130 
Together these results indicate pH1N1-specific CD4+ T cells are mainly 
single-TNF-α+ and a lower frequency of single IFN-γ+, single IL-2+ and dual 
IFN-γ-IL-2+TNF-α+ cytokine positive cells. CMV-lysate specific CD4+ T cells 
are also mainly single-TNF-α+ and single IFN-γ+ cytokine positive cells but 
there was no significant difference in the frequency of these two cytokine 
positive subsets. The frequency of pH1N1-specific CD4+TNF-α+ T cells was 
significantly higher compared to CMV lysate-specific CD4+TNF-α+ T cells. 
Furthermore, pH1N1-specific CD4+ T cells show more degranulating 
(CD107ab+) and recently activated  (CD69+) phenotype compared to CMV 
lysate-specific CD4+ T cells.  
 
3.4.3 Memory phenotype of cytokine-expressing CD4+ T cells in influenza or 
CMV stimulation 
To characterise the memory phenotype for each cytokine secreting CD4+ T 
cell population in live pH1N1 virus stimulated or CMV lysate stimulated 
PBMC, the expression of CD45RA and CCR7 was assessed. CD4+IFN- + 
cells were predominantly CCR7- effector memory (CCR7-CD45RA-) or late 
effector (CCR7-CD45RA+) cells in both live pH1N1 virus (Fig. 3.4.4A) and 
CMV lysate (Fig. 3.4.4B) stimulation.  Non-specific IFN-γ+ cells also showed a 
similar predominance of effector memory and late effector phenotype (Fig. 
3.4.4C), however, all subsets were significantly different to corresponding 
subsets in live pH1N1 virus stimulation, hence non-specific and antigen-
specific IFN-γ+ cells showed distinct memory/differentiation phenotypes.  
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CMV-lysate stimulated CD4+IL-2+ and CD4+TNF-α+ T cells were also 
predominantly CCR7- effector memory or late effector memory cells (Fig. 
3.4.4E and H), however, pH1N1 stimulated CD4+IL-2+ cells had similar 
frequencies of naïve, Temra and Tem (Fig. 3.4.4D) and CD4+TNF- + T cells 
had similar frequencies of naïve and Temra (Fig. 3.4.4G). The most striking 
differences were apparent when the mean proportion of each phenotypic T 
cell subset was expressed in pie charts for each cytokine positive CD4+ T cell 
population. 45.68% of CD4+IFN-γ+ pH1N1 stimulated cells were Temra, 
whereas only 28.45% and 36.01% of CD4+IL-2+ and CD4+TNF-α+ pH1N1 
stimulated T cells respectively were Temra. Tem predominated the CMV 
stimulated CD4+IFN-γ+ (55.32%), CD4+IL-2+ (46.45%) and CD4+TNF-α+ 
(44.25%) T cells.  
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Figure 3.4.4 Effector and memory phenotype of pH1N1 live virus and CMV lysate -
specific CD4+ T cells.  
 133 
Phenotypic characterisation was performed using multiparameter flow cytometry of 
the different memory subsets of CD3+CD4+CD8-IFN-γ+ (A, B, C), CD3+CD4+CD8-
IL-2+ (D, E, F) and CD3+CD4+CD8-TNF- + (G, H, I) T cells on the basis of CCR7 
and CD45RA surface expression after 18 hour stimulation of PBMCs with live pH1N1 
virus (A, D, G), CMV lysate (B, E, H) or medium only (C, F, I) stimulation. The 
proportion of CD3+CD4+CD8- cytokine positive T cells that were of the effector-
memory (CD45RA−CCR7−), late-effector (CD45RA+CCR7−), central-memory 
(CD45RA−CCR7+) or naive (CD45RA+CCR7+) phenotype are shown; each symbol 
represents a single individual with horizontal lines at the median response. 
Differences between subset responses were estimated by Friedman tests within 
antigen-specific T cells or by Kruskal Wallis tests between live pH1N1 virus 
stimulation, CMV lysate stimulation and unstimulated conditions. Pie charts represent 
mean proportions for each cytokine profile. Non-responders to antigens excluded, n 
= 43, 35, 43, IFN-γ+ responses to live pH1N1 virus, CMV, or unstimulated; n = 36, 
27, 33, IL-2+ responses to live pH1N1 virus, CMV, or unstimulated; n = 50, 32, 53, 
TNF- + responses to live pH1N1 virus, CMV lysate, or unstimulated.  
 
In summary, live pH1N1 virus and CMV lysate stimulated CD4+IFN-γ+, 
CD4+IL-2+ and CD4+TNF-α+ T cells were heterogeneous with respect to the 
mean proportion of cytokine positive cells that expressed Tem and Temra 
phenotypes.     
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3.4.4 Other marker expression of cytokine-expressing CD4+ T cells in influenza 
or CMV stimulation 
To further characterise the phenotype of antigen-specific cells, the expression 
of degranulation (CD107ab), activation (CD69) and tissue-homing (CCR5) 
markers as well as cellular senescence-associated marker (CD57) was 
assessed on each cytokine secreting cell population. Cytokine positive CD4+ 
T cells stimulated by live pH1N1 virus or CMV lysate showed a high level of 
inter-individual heterogeneity in expression of CD107ab, CD69, CCR5 and 
CD57 and the only significant difference between the two stimulations was in 
the proportion of CD4+IFN-γ+CD69+ T cells (median = 42.90%, IQR = 7.20% 
- 78.60% in pH1N1 stimulated and median = 14.30% and IQR = 0 – 29.40% in 
CMV lysate stimulated, p = 0.0085) (Fig. 3.4.5A-F). However, live pH1N1 
virus stimulated CD4+IFN- + T cells had significantly higher proportions of 
CD107ab+ cells (median = 20.0%, IQR = 0 - 41.37%) than CD4+TNF-
+CD107ab+ (median = 0.590%, IQR = 0 – 10.65%, p < 0.01) T cells. Live 
pH1N1 virus stimulated CD4+IFN- + T cells also had significantly higher 
proportions of CD69+ (median = 42.9%, IQR = 7.2% - 78.6%) than CD4+IL-
2+CD69+ (median = 11.4%, IQR = 0 – 40.70%, p < 0.05) although the 
proportion of CD4+IL-2+CD69+ was significantly higher than CD4+TNF-
+CD69+ (median = 5.83%, IQR = 0 – 16.27%, p < 0.01) T cells.  
 
In CMV lysate stimulation, the proportion of CD4+IFN-γ+CD107ab+ T cells 
(median = 25.0%, IQR = 0 - 53.70%) was significantly higher (p < 0.05) than 
CD4+IL-2+CD107ab+ (median = 5.56%, IQR = 0 - 23.1%) T cells, and the 
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proportion of CD4+IFN-γ+CD69+ (median = 14.3%, IQR = 2.75% -  29.0%) T 
cells was also significantly higher than CD4+TNF-α+CD69+ (median = 3.70%, 
IQR = 0 – 11.0%) T cells (p <0.05). 
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Figure 3.4.5 Phenotype of cytokine positive pH1N1 live virus and CMV lysate -specific CD4+ T cells.  
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Phenotypic characterisation was performed using multiparameter flow cytometry and gating as shown in Fig. 3.4.1 of CD3+CD4+CD8-IFN-γ+ 
(A, D), CD3+CD4+CD8-IL-2+ (B, E) and CD3+CD4+CD8-TNF- + (C, F) T cells after 18 hour stimulation of PBMCs with live pH1N1 virus (A, B, 
C) or CMV lysate (D, E, F). The proportion of CD3+CD4+CD8- cytokine positive T cells that expressed CD107 (isotypes A and B), CCR5, 
CD57 and CD69 are shown; each symbol represents a single individual with horizontal lines at the median response. Differences between 
subset responses were estimated by Kruskal Wallis test within antigen-specific T cells or by Mann Whitney test between live pH1N1 virus 
stimulation and CMV lysate stimulation for each phenotypic marker. Non-responders to antigens excluded, n = 43, 35, IFN-γ+ responses to live 
pH1N1 virus or CMV lysate; n = 36, 27, IL-2+ responses to live pH1N1 virus or CMV lysate; n = 50, 37, TNF- + responses to live pH1N1 virus 
or CMV lysate. 
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To summarise, the proportion of degranulation (CD107ab) and early activation 
(CD69) marker positive cells differ between the different cytokine positive 
populations in both pH1N1 stimulated and CMV-lysate stimulated CD4+ T 
cells. The proportion of tissue homing marker positive (CCR5) and replicative 
senescence marker positive (CD57) cells did not differ between different 
cytokine positive populations for pH1N1 stimulated or CMV-lysate stimulated 
CD4+ T cells.  
 
3.4.5 Phenotype of pH1N1 cross-reactive CD8+ T cell responses 
Cytokine expression, activation, degranulation, cellular senescence markers 
and memory phenotype of antigen-specific CD8+ T cells were also assessed. 
92% (56/61) of individuals had pH1N1 virus-specific cytokine positive 
responses above background (Table 3.4.2). 69% (42/61), 62% (38/61) and 
74% (45/61) of individuals responded to live pH1N1 virus stimulation by 
CD8+IFN-γ+, CD8+IL-2+ and CD8+TNF- + cytokine responses respectively 
(Table 3.4.2).  Unlike pH1N1-specific CD4+ T cell responses, there was no 
hierarchy in pH1N1-specific responses between CD8+IFN-γ+ (median = 
0.025%, IQR = 0 - 0.07%), CD8+IL-2+ (median = 0.005%, IQR = 0 – 0.02%) 
and CD8+TNF- + (median = 0.025%, IQR = 0 – 0.11%) responses (Fig. 
3.4.6).  
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Table 3.4.2 Prevalence of antigen-specific CD8+ T cell responses.  
The numbers and proportions of pH1N1 sero-negative individuals with ex vivo 
PBMC responses to live pH1N1 virus or CMV lysate from IFN-γ, IL-2, TNF-  
or any cytokine (IFN-γ+ or IL-2+ or TNF- +) secreting CD3+CD4-CD8+ T 
cells evaluated by flow cytometry. 
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Figure 3.4.6 pH1N1 live virus and CMV lysate -specific CD8+ T cells.  
Frequency of ex vivo PBMC responses from CD8+IFN-γ+, CD8+IL-2+ and 
CD8+TNF- + or CD8+CD69+ and CD8+CD107ab+ T cells evaluated by flow 
cytometry to live pH1N1 virus (A, C) or CMV lysate (B, D) and gated as shown in Fig. 
3.4.1. Each symbol represents a single individual and horizontal red lines represent 
the median response. Differences between subset responses were estimated by 
Friedman test within antigen-specific T cells or by Mann Whitney test between 
pH1N1 live virus and CMV lysate -specific T cells. Non-responders to antigens 
excluded, pH1N1 live virus: n = 56, CMV lysate: n = 39. 
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Boolean analysis showed a predominance of TNF-α-single cytokine positive 
(mean = 0.326%, SEM = 0.263) and single IFN-γ+IL-2- (mean = 0.0998%, 
SEM = 0.035) pH1N1-specific CD8+ T cells (Fig. 3.4.7). Both these 
populations were significantly higher than the other triple CD8+IFN-γ+IL-
2+TNF-α+ (mean = 0.001%, SEM = 0.000413), dual CD8+IFN-γ+IL-2+TNF-α- 
(mean = 0.00355%, SEM = 0.001), dual CD8+IFN-γ+IL-2-TNF-α+ (mean = 
0.00712%, SEM = 0.00210), dual CD8+IFN-γ-IL-2+TNF-α+ (mean = 
0.0769%, SEM = 0.0751), single CD8+IFN-γ-IL-2+TNF-α- (mean = 0.0897%, 
SEM = 0.001) cytokine positive, and triple negative CD8+IFN-γ-IL-2-TNF-α- 
(mean = 0.0429%, SEM = 0.0290) pH1N1-specific T cells (Fig. 3.4.7).  
 
pH1N1-specific CD8+ T cells also expressed the early activation and 
degranulation markers CD8+CD69+ (median = 0.20%, IQR = 0 - 2.82%) and 
CD8+CD107ab+ (median = 0.31%, IQR = 0 – 3.48%) respectively (Fig. 
3.4.6C). Although CMV lysate is not expected to optimally stimulate CD8+ T 
cells, 78% (39/50) of individuals had responses above background, with 52%, 
52% and 52% of individuals responding with CD8+IFN-γ+, CD8+IL-2+ and 
CD8+TNF- + cytokine responses respectively (Table 3.4.2). The median 
frequency of antigen-specific cytokine positive responses were: CD8+IFN-γ+ 
(median = 0.01%, IQR = 0 - 0.03), CD8+IL-2+ (median = 0%, IQR = 0 - 
0.02%) and CD8+TNF- + (median = 0.01%, IQR = 0 – 0.03%) (Fig. 3.4.6B). 
These were mainly single CD8+IFN-γ-IL-2-TNF-α+ (mean = 0.487%, SEM = 
0.471), single CD8+IFN-γ+IL-2-TNF-α- (mean = 0.1146%, SEM = 0.0568), 
and an intriguing population of single CD8+IFN-γ-IL-2+TNF-α- T cells (mean = 
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0.0937%, SEM = 0.0858) (Fig. 3.4.7). Dual cytokine positive CD8+IFN-γ-IL-
2+TNF-α+ (mean = 0.0843%, SEM = 0.0823) and CD8+IFN-γ+IL-2-TNF-α+ 
(mean = 0.0135%, SEM = 0.00767) were also detectable (Fig. 3.4.7B).     
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Figure 3.4.7 Cytokine profiles of pH1N1 live virus and CMV lysate -specific CD8+ T cells.  
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Boolean analysis using SPICE software was performed to analyse CD3+CD4-CD8+ T cells for each cytokine profile of ex vivo PBMC 
responses to live pH1N1 virus (A) or CMV lysate (B) following flow cytometry staining and gating as in Fig. 3.4.1. Bars represent mean and 
standard error of the mean percentage positive of CD3+CD4-CD8+ T cells. Differences between subset responses were estimated by 
Friedman test within antigen-specific T cells or by Kruskal Wallis test between pH1N1 live virus and CMV lysate -specific T cells. Pie charts 
represent mean proportions for each cytokine profile. Non-responders to antigens excluded, pH1N1 live virus: n = 56, CMV lysate: n = 39. * p 
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. IFN_ = IFN-γ, IL2 = IL-2, TNF_ = TNF- . 
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Together these results indicate pH1N1-specific CD8+ T cells are mainly 
single-TNF-α+, single IFN-γ+ and single IL-2+ and a lower frequency of dual 
IFN-γ-IL-2+TNF-α+ cytokine positive cells. CMV-lysate specific CD8+ T cells 
are also single-TNF-α+, single IFN-γ+ and single IL-2+ cytokine positive cells.  
 
3.4.6 Memory phenotype of cytokine secreting CD8+ T cells in influenza or 
CMV stimulation 
Similar to the memory phenotype of CD4+IFN- + cells (Fig. 3.4.4), CD8+IFN-
+ cells were predominantly CCR7- effector memory (CCR7-CD45RA-) or late 
effector (CCR7-CD45RA+) T cells in both live pH1N1 virus (Fig. 3.4.8A) and 
CMV lysate (Fig. 3.4.8B) stimulation and this was not different from the 
phenotype of non-specific CD8+IFN-γ+ T cells (Fig. 3.4.8C).  pH1N1 
stimulated CD8+IL-2+ T cells were predominantly effector memory (Fig. 
3.4.8D), however 24.7% of CD8+IL-2+ had a naïve phenotype 
(CCR7+CD45RA+) (Fig. 3.4.8D, pie chart). Similarly, 30.2% of CMV lysate 
stimulated CD8+IL-2+ T cells were of a naïve phenotype (Fig. 3.4.8E pie 
chart), and a similar proportion of naïve CD8+IL-2+ T cells is also represented 
in the non-specific CD8+IL-2+ T cell response (Fig. 3.4.8F pie chart).  
 
In live pH1N1 virus stimulated CD8+TNF- + T cells, the proportion of late 
effector T cells was significantly higher than CD8+TNF- + with central 
memory and naïve phenotype, but not significantly different to the proportion 
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of CD8+TNF- + with an effector memory phenotype (Fig. 3.4.8G). 
Furthermore, the frequency of pH1N1 stimulated CD8+TNF- + T cells with 
late effector phenotype was significantly higher than non-specific CD8+TNF-
+ T cells with late effector phenotype (Fig. 3.4.8I).  In CMV lysate 
stimulation, CD8+TNF- + had similar proportions of cells with naïve, late 
effector and effector memory phenotypes, and the only significant difference 
was between the proportions of CD8+TNF- + with central memory compared 
to late effector phenotype (Fig. 3.4.8H).  
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Figure 3.4.8 Effector and memory phenotype of pH1N1 live virus and CMV lysate -
specific CD8+ T cells.  
Phenotypic characterisation was performed using multiparameter flow cytometry of 
the different memory subsets of CD3+CD4-CD8+IFN-γ+ (A, B, C), CD3+CD4-
CD8+IL-2+ (D, E, F) and CD3+CD4-CD8+TNF- + (G, H, I) T cells on the basis of 
 148 
CCR7 and CD45RA surface expression after 18 hour stimulation of PBMCs with live 
pH1N1 virus (A, D, G), CMV lysate (B, E, H) or medium only (C, F, I) stimulation. The 
proportion of CD3+CD4-CD8+ cytokine positive T cells that were of the effector-
memory (CD45RA−CCR7−), late-effector (CD45RA+CCR7−), central-memory 
(CD45RA−CCR7+) or naive (CD45RA+CCR7+) phenotype are shown; each symbol 
represents a single individual with horizontal lines at the median response. 
Differences between subset responses were estimated by Friedman test within 
antigen-specific T cells or by Kruskal Wallis test between live pH1N1 virus 
stimulation, CMV lysate stimulation and unstimulated conditions. Pie charts represent 
mean proportions for each cytokine profile. Non-responders to antigens excluded, n 
= 42, 26, 59 IFN-γ+ responses to live pH1N1, CMV, or unstimulated; n = 38, 26, 39 
IL-2+ responses to live pH1N1, CMV, or unstimulated; n = 45, 26, 57 TNF- + 
responses to live pH1N1, CMV, or unstimulated. 
 
To summarise, live pH1N1 virus stimulated CD8+IFN-γ+, CD4+IL-2+ and 
CD4+TNF-α+ T cells were predominantly of late effector phenotype, however, 
the mean proportion of CD8+ cytokine positive T cells with a naïve phenotype 
was lower in CD8+IFN-γ+ compared to CD8+IL-2+ and CD8+TNF-α+ positive 
T cells. CMV lysate stimulated CD8+IFN-γ+ T cells were also predominantly 
of late effector phenotype, however, CMV lysate stimulated CD8+IL-2+ and 
CD8+TNF-α+ T cells were more heterogeneous with respect to mean 
proportions of cytokine positive T cells with naïve and central memory 
phenotypes.  
 
 149 
3.4.7 Other marker expression of cytokine secreting CD8+ T cells in influenza 
or CMV stimulation 
Similar to the individual-level heterogeneity of CD4+ cytokine positive T cells 
(Fig. 3.4.5), CD8+ cytokine positive T cells stimulated by live pH1N1 virus or 
CMV lysate also showed a high level of inter-individual heterogeneity in 
expression of CD107ab, CD69, CCR5 and CD57 (Fig. 3.4.9). Additionally, live 
pH1N1 virus stimulated CD8+IFN- + T cells and CD8+IL-2+ T cells differed in 
expression of all four of these markers. CD8+IFN- + T cells contained 
significantly higher frequencies of CD107ab+ T cells (median 47.4%, IQR = 
27.8% - 67.0%) than CD8+IL-2+ (median = 5.56%, IQR = 0 – 21.0%) or 
CD8+TNF- + (median = 8.59%, IQR = 0 – 32.40%) T cells (p < 0.001 and p < 
0.001 respectively). CD8+IFN-γ+CCR5+ T cells (median = 53.7%, IQR = 
33.27% – 74.14%) were also significantly higher (p < 0.05) than CD8+IL-
2+CCR5+ T cells (median = 27.3%, IQR = 0 – 57.10%), whereas CD8+IFN-
γ+CD57+ T cells were significantly lower (p < 0.05) than CD8+IL-2+CD57+ T 
cells. The proportion of CD69 expressing cells in live pH1N1 virus stimulated 
CD8+IFN- + (median = 19.35%, IQR = 0 – 50.52%) and CD8+TNF- + 
(median = 11.8%, IQR = 0 – 49.19%) T cells was significantly higher than 
CD8+IL-2+ T cells expressing CD69 (median = 0.512%, IQR = 0 - 7.14%) (p < 
0.01 and p < 0.01 respectively).  
Proportions of CD107ab+ degraulating and early activation marker CD69+ T 
cells were significantly higher (p < 0.05 and p< 0.05 respectively) in CMV 
lysate stimulated CD8+IFN-γ+ (median = 26.4%, IQR = 6.75% - 46.05% and 
median = 15.6%, IQR = 1.45% - 29.75% respectively) compared to CD8+IL-
2+ T cells (median = 1.15%, IQR = 0 – 24.3% and median = 0%, IQR = 0 – 
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10.5% respectively). CMV lysate stimulated CD8+IFN-γ+ also contained a 
higher proportion of CD107ab+ but a lower proportion of CCR5+ T cells 
(median = 5.84%, IQR = 0 - 16.55%) compared to CD8+TNF-α+ T cells 
(median = 1.15%, IQR = 0 - 24.3% and median = 55.15%, IQR = 32.80% - 
77.50% respectively). 
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Figure 3.4.9 Phenotype of cytokine positive pH1N1 live virus and CMV lysate -specific CD8+ T cells.  
Phenotypic characterisation was performed using multiparameter flow cytometry and gating as shown in Fig. 3.4.1 of CD3+CD4-
CD8+IFN-γ+ (A, D), CD3+CD4-CD8+IL-2+ (B, E) and CD3+CD4-CD8+TNF- + (C, F) T cells after 18 hour stimulation of PBMCs 
with live pH1N1 virus (A, B, C) or CMV lysate (D, E, F). The proportion of CD3+CD4-CD8+ cytokine positive T cells that expressed 
CD107 (isotypes A and B), CCR5, CD57 and CD69 are shown; each symbol represents a single individual with horizontal lines at 
the median response. Differences between subset responses were estimated by Kruskal Wallis test within antigen-specific T cells 
or by Mann Whitney test between live pH1N1 virus stimulation and CMV lysate stimulation for each phenotypic marker. Non-
responders to antigens excluded, n = 42, 26, IFN-γ+ responses to live pH1N1 virus or CMV lysate; n = 38, 26, IL-2+ responses to 
live pH1N1 virus or CMV lysate; n = 45, 26, TNF- + responses to live pH1N1 virus or CMV lysate.
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In summary, there was heterogeneity between CD8+IFN-γ+, CD8+IL-2+ and 
CD8+TNF-α+ T cells with respect to the proportions of cells positive for 
CD107ab, CD69, CCR5 and CD57 markers in both pH1N1 virus and CMV 
lysate stimulation.  
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3.5 The longitudinal development of influenza-specific memory T 
cells  
Antigen-specific T cell responses were assessed in longitudinal PBMC 
samples from individuals who were naturally infected with pH1N1 or 
individuals who received the pH1N1 vaccine over the study period. The 
hypothesis was that natural influenza infection would alter the frequency of 
pH1N1 virus-specific T cells and would differentially induce and maintain T 
cell responses compared to vaccination. 
 
3.5.1 Study samples 
All available stored PBMC samples from 82 individuals with various outcomes 
during the study seasons 1 and 2 (Table 3.5.1) were comprehensively 
characterised by flow cytometry. This included 51 naturally infected 
individuals (26 and 25 in season 1 and season 2 respectively); 29 individuals 
vaccinated and seroconverted to pH1N1 vaccine (19 and 10 in season 1 and 
season 2 respectively); 16 individuals vaccinated but did not seroconvert to 
pH1N1 vaccine (8 and 8 in season 1 and season 2 respectively) and 43 
individuals that were uninfected (28 and 15 in season 1 and season 2 
respectively). Not all of these 82 individuals had stored PBMC from all four 
study time-points, but all available samples were used where possible and 
sample numbers are indicated in relevant figures.  
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 Table 3.5.1 Number of individuals with infection or vaccination status and longitudinal 
time-points analysed by flow cytometry.  
Number of individuals with analysis on CD4+/CD8+. 
 
3.5.2 Kinetics of pH1N1-specific fluorescence-immunospot responses following 
natural infection 
PBMC from pre- and post- infection were stimulated with live pH1N1 virus or 
control antigens and responses were enumerated by fluorescence-
immunospot. No significant changes were detectable in frequencies of 
pH1N1-specific T cells from any of the three cytokine secreting subsets in 
either season alone (Fig. 3.5.1). However, frequencies of live pH1N1 virus-
specific IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ T cells were increased 
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following infection when data from individuals infected in either season was 
combined (p = 0.0673, p = 0.0019 and p = 0.0395 respectively, Fig. 3.5.1 E, K 
and Q). No differences were observed in the frequencies of CMV lysate-
specific IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-2+ T cells between pre- and 
post-infection in either season or in the combined seasons analysis (Fig. 3.5.1 
B, D, F, H, J, L, N, P, R).  
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Figure 3.5.1 Kinetics of pH1N1-specific T cell responses by fluorescence-immunospot.  
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The magnitude of ex vivo PBMC responses from the IFN-γ+IL-2- (A, B, C, D, E, F), IFN-γ-IL-2+ (G, H, I, J, K, L), and IFN-γ+IL-2+ dual (M, N, 
O, P, Q, R) cytokine secreting subsets to live pH1N1 virus (A, C, E, G, I, K, M, O, Q) and CMV lysate (B, D, F, H, J, L, N, P, R) in individuals 
with incident pH1N1 infection during season 1 (A, B, G, H, M, N), season 2 (C, D, I, J, O, P) or the combined seasons data (E, F, K, L, Q, R) 
was determined by fluorescence-immunospot. Each symbol represents a single individual and horizontal lines represent medians. Differences 
between study time-points in subset responses were estimated by Kruskall-Wallis test. Non-responders to stimulation excluded, season 1: n = 
28, 28, 17 to live pH1N1 virus; n = 26, 26, 16 to CMV lysate; season 2: n = 17, 26 to live pH1N1 virus; n = 14, 25 to CMV lysate; combined 
seasons: n = 45, 54 to live pH1N1 virus; n = 40,51 to CMV lysate. SFC, spot-forming cells; Season 1, T0: baseline (pre-infection), T1: up to 6 
months post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-infection), T3: up to 6 months post-infection. Combined 
seasons, Pre-inf: baseline (pre-infection), Post-inf: up to 6 months post-infection. 
 159 
 
3.5.3 Kinetics of pH1N1 virus-specific CD4+ and CD8+ T cell responses 
following natural infection 
To characterise the phenotype of pH1N1 infection induced T cell responses, 
PBMC samples remaining from infected individuals were used in multi-
paratemter flow cytometry.  pH1N1-specific CD4+IFN-γ+ responses were 
significantly increased (p = 0.0035) in naturally infected individuals during 
season 2, whilst CMV-specific CD4+IFN-γ+ responses remained unaltered (p 
= 0.698, Fig. 3.5.2B). This finding was consistent when CD4+IFN-γ+ data 
from individuals infected in either season were combined (p = 0.0348 for 
pH1N1 virus-specific and p = 0.502 for CMV lysate-specific, Fig. 3.5.2C).  
 
Boolean analysis revealed that the pH1N1-specific CD4+IFN-γ+ response 
was mainly single IFN-γ+IL-2-TNF-α- (Fig. 3.4.3). The significant increase in 
response post-infection was also evident within this pH1N1-specific single- 
IFN-γ+IL-2-TNF-α- CD4+ T cell (p = 0.0147, Fig. 3.5.2D) but not CMV lysate-
specific single- IFN-γ+IL-2-TNF-α- CD4+ T cell (p = 0.324, Fig. 3.5.2D) 
population.  Interestingly, the frequencies of CD4+IL-2+ and CD4+ IFN-γ-IL-
2+TNF-α- T cells were significantly lower post-infection for pH1N1-specific 
CD4+ T cells in season 1 (p < 0.001, Fig. 3.5.2E and Table 3.5.2) and in the 
combined seasons analysis (p = 0.0041 and p = 0.0015 Fig. 3.5.2G and H), 
whereas CMV-specific CD4+IL-2+ and CD4+ IFN-γ-IL-2+TNF-α- T cells in the 
corresponding analyses were not significantly altered (p = 0.127, p = 0.109 
and p = 0.104, Fig. 3.5.2E, G and H). Frequencies of pH1N1-specific 
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CD4+TNF-α+ and CD4+ IFN-γ-IL-2-TNF-α+ T cells were not significantly 
altered post-infection, and this was also consistent for CMV-specific 
CD4+TNF-α+ and CD4+ IFN-γ-IL-2-TNF-α+ T cells (Fig. 3.5.2 I-L, Table 
3.5.2).          
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Figure 3.5.2 Kinetics of pH1N1-specific CD4+ T cell responses.  
The magnitude of ex vivo PBMC responses from the IFN-γ+ (A, B, C) and single IFN-γ+ (D), IL-2+ (E, F, G) and single IL-2+ (H), TNF- + (I, J, 
K) and single TNF- + (L) CD3+CD4+CD8- subsets to live pH1N1 virus and CMV lysate in individuals with incident pH1N1 infection during 
season 1 (A, E, I), season 2 (B, F, J) or the combined seasons data (C, D, G, H, K, L) was determined by flow cytometry and gating as shown 
in Fig. 3.4.1.  In the box plots, the box represents the third centile (75%) and first centile (25%), with the horizontal line representing the median 
(50%). The whiskers represent 1.5 times the IQR. Differences between study time-points in subset responses were estimated by Kruskall-
Wallis test. Non-significant p-values shown in Table 3.5.2. Non-responders to stimulation excluded, season 1: n = 23, 19, 14 to live pH1N1 
virus; n = 18, 13, 9 to CMV lysate; season 2: n = 11, 16 to live pH1N1 virus; n = 13, 14 to CMV lysate; combined seasons: n = 34, 35 to live 
pH1N1 virus; n = 31, 27 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months post-infection, T2: up to 1.5 years post-infection. 
Season 2, T2: baseline (pre-infection), T3: up to 6 months post-infection. Combined seasons, Pre-inf: baseline (pre-infection), Post-inf: up to 6 
months post-infection. 
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Table 3.5.2 Significance tests between pre-infection and post-infection antigen-specific CD4+ cytokine positive T cell responses.
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Similar to the changes in pH1N1-specific CD4+IFN-γ+ responses (Fig. 3.5.2), 
the frequencies of pH1N1-specific CD8+IFN-γ+ and CD8+IFN-γ+IL-2-TNF-α- 
T cells were significantly increased (p = 0.0072 in season 2, Fig. 3.5.3B; p = 
0.0018 and p = 0.0006 in combined seasons, Fig. 3.5.3 C and D) post-
infection without significant alterations in the frequencies of corresponding 
cytokine positive CMV-specific CD8+ T cells (Fig. 3.5.3B, C, D and Table 
3.5.3). pH1N1-specific CD8+IL-2+ and a population of CD8+IFN-γ-IL-2+TNF-
α- T cells were significantly lower in post-infection samples,  but this was also 
the case for CMV-lysate specific CD8+IL-2+ and CD8+IFN-γ-IL-2+TNF-α- T 
cells (Fig. 3.5.3E-H, Table 3.5.3). Frequencies of pH1N1-specific or CMV-
lysate-specific CD8+TNF-α+ and CD8+ IFN-γ-IL-2-TNF-α+ T cells were not 
significantly altered post-infection (Fig. 3.5.3 I-L, Table 3.5.3).  
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Figure 3.5.3 Kinetics of pH1N1-specific CD8+ T cell responses.  
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The magnitude of ex vivo PBMC responses from the IFN-γ+ (A, B, C) and single IFN-γ+ (D), IL-2+ (E, F, G) and single IL-2+ (H), TNF- + (I, J, 
K) and single TNF- + (L) CD3+CD4-CD8+ subsets to live pH1N1 virus and CMV lysate in individuals with incident pH1N1 infection during 
season 1 (A, E, I), season 2 (B, F, J) or the combined seasons data (C, D, G, H, K, L) was determined by flow cytometry and gating as shown 
in Fig. 3.4.1.  In the box plots, the box represents the third centile (75%) and first centile (25%), with the horizontal line representing the median 
(50%). The whiskers represent 1.5 times the IQR. Differences between study time-points in subset responses were estimated by Kruskall-
Wallis test. Non-significant p-values shown in Table 3.5.3. Non-responders to stimulation excluded, season 1: n = 24, 19, 15 to live pH1N1 
virus; n = 18, 12, 11 to CMV lysate; season 2: n = 13, 16 to live pH1N1 virus; n = 11, 15 to CMV lysate; combined seasons: n = 37, 35 to live 
pH1N1 virus; n = 29, 27 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months post-infection, T2: up to 1.5 years post-infection. 
Season 2, T2: baseline (pre-infection), T3: up to 6 months post-infection. Combined seasons, Pre-inf: baseline (pre-infection), Post-inf: up to 6 
months post-infection.
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Table 3.5.3 Significance tests between pre-infection and post-infection antigen-specific CD8+ cytokine positive T cell responses. 
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In summary, natural pH1N1 infection appears to increase the frequency of 
CD4+ and CD8+ IFN-γ+ and IFN-γ+IL-2-TNF-α- T cells. Only pH1N1-specific 
CD4+IL-2+ and CD4+IFN-γ-IL-2+TNF-α- T cells were significantly lower post-
infection, whereas both live pH1N1 virus and CMV lysate -specific CD8+IL-2+ 
and CD8+IFN-γ-IL-2+TNF-α- T cells were significantly lower post-infection.  
       
3.5.4 Differences in pH1N1-specific CD4+ and CD8+ T cell responses between 
naturally infected and vaccinated individuals 
Next, we hypothesised that influenza vaccination and natural infection would 
differentially induce and maintain T cell responses. A small number of 
individuals were vaccinated with pH1N1 vaccine and either seroconverted (4-
fold rise in HAI titre) or did not seroconvert following vaccination. CD4+IFN-γ+ 
and CD4+IFN-γ+IL-2-TNF-α- T cell responses (Fig. 3.5.4) and CD8+IFN-γ+ 
and CD8+IFN-γ+IL-2-TNF-α- T cell responses (Fig. 3.5.5) pre- and post-
vaccination were compared alongside the corresponding cytokine positive 
responses in naturally infected individuals.  
 
Unlike infection, vaccination either with or without seroconversion did not alter 
frequencies of IFN-γ+ or single-IFN-γ+IL-2-TNF-α- CD4+ (Fig. 3.5.4) or CD8+ 
(Fig. 3.5.5) T cells. Furthermore, frequencies of CD4+IL-2+, CD4+IFN-γ-IL-
2+TNF-α-, CD4+TNF-α+ or CD4+IFN-γ-IL-2-TNF-α+ (or CD8+IL-2+, 
CD8+IFN-γ-IL-2+TNF-α-, CD8+TNF-α+ or CD8+IFN-γ-IL-2-TNF-α+) T cells 
were also not significantly altered in vaccinated individuals between pre- and 
post- vaccination. 
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Figure 3.5.4 pH1N1-specific CD4+ T cell responses in naturally infected individuals compared to vaccinated individuals.  
The magnitude of ex vivo PBMC responses from the IFN-γ+ (A, B, C) and single IFN-γ+ (D, E, F), CD3+CD4+CD8- subsets to live 
pH1N1 virus individuals with incident pH1N1 infection or were vaccinated during season 1 (A, D), season 2 (B, E) or the combined 
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seasons data (C, F) was determined by flow cytometry and gating as shown in Fig. 3.4.1. In the box plots, the box represents the 
third centile (75%) and first centile (25%), with the horizontal line representing the median (50%). The whiskers represent 1.5 times 
the IQR. Differences between study time-points in subset responses in season 1 were estimated by Kruskall-Wallis test and by 
Mann Whitney test in season 2 and combined season data. Non-responders to stimulation excluded, Season 1: n = 23, 19, 14, 
Natural infection; n = 15, 13, 7 Vaccinated and seroconversion; n = 3, 4, 2 Vaccinated but no seroconversion. Season 2: n = 11, 16, 
Natural infection; n = 6, 8 (CD4+IFN- +) and n = 4, 6 (CD4+IFN- +IL-2-TNF- ) Vaccinated and seroconversion; n = 4, 2, 
Vaccinated but no seroconversion; Combined seasons: n = 34, 35, Natural infection; n = 21, 21 (CD4+IFN- +) and n = 19, 19 
(CD4+IFN- +IL-2-TNF- ) Vaccinated and seroconversion; n = 7, 7, Vaccinated but no seroconversion. T0: baseline (pre-infection), 
T1: up to 6 months post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-infection), T3: up to 6 months 
post-infection. Combined seasons, Pre-inf: baseline (pre-infection), Post-inf: up to 6 months post-infection. 
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Figure 3.5.5 pH1N1-specific CD8+ T cell responses in naturally infected individuals compared to vaccinated individuals.   
The magnitude of ex vivo PBMC responses from the IFN-γ+ (A, B, C) and single IFN-γ+ (D, E, F), CD3+CD4-CD8+ subsets to live pH1N1 virus 
individuals with incident pH1N1 infection or were vaccinated during season 1 (A, D), season 2 (B, E) or the combined seasons data (C, F) was 
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determined by flow cytometry and gating as shown in Fig. 3.4.1. In the box plots, the box represents the third centile (75%) and first centile 
(25%), with the horizontal line representing the median (50%). The whiskers represent 1.5 times the IQR. Differences between study time-
points in subset responses in season 1 were estimated by Kruskall-Wallis test and by Mann Whitney test in season 2 and combined season 
data. Non-responders to stimulation excluded, Season 1: n = 24, 19, 15, Natural infection; n = 14, 13, 7 Vaccinated and seroconversion; n = 3, 
4, 2 Vaccinated but no seroconversion. Season 2: n = 13, 16, Natural infection; n = 5, 6, Vaccinated and seroconversion; n = 4, 3, Vaccinated 
but no seroconversion; Combined seasons: n = 37, 35, Natural infection; n = 19, 19, Vaccinated and seroconversion; n = 7, 7, Vaccinated but 
no seroconversion. T0: baseline (pre-infection), T1: up to 6 months post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline 
(pre-infection), T3: up to 6 months post-infection. Combined seasons, Pre-inf: baseline (pre-infection), Post-inf: up to 6 months post-infection.
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3.5.5 Changes in CD4+ and CD8+ memory subsets in naturally infected 
individuals 
Pre-existing pH1N1-specific CD8+IFN-γ+IL-2- T cells with a late effector 
phenotype (CD45RA+CCR7-) were associated with protection against 
symptomatic influenza infection (Fig. 3.3.7). However, the evolution of long-
lasting virus-specific effector T cells following acute natural infection in 
humans is unknown. The proportions of naïve, central memory, late effector 
and effector memory T cells stratified by the expression of CD45RA and 
CCR7 within CD4+ cytokine positive and CD8+ cytokine positive T cells were 
followed in infected individuals pre- and post-infection (Fig. 3.5.6).  
 
There was a delayed increase (p < 0.05, Fig. 3.5.6A) in the proportion of late 
effector T cells within pH1N1 stimulated CD4+IFN-γ+ at time-point 2 (up to 1.5 
years following infection) in season 1. The proportion of late effector T cells 
within pH1N1 stimulated CD4+TNF-α+ T cells increased (p < 0.05, Fig. 3.5.6I) 
at time-point 1 (up to 6 months post-infection) and were maintained to time-
point 2 in season 1. No significant changes were seen in pH1N1 stimulated 
CD4+ cytokine positive phenotypic subsets in season 2 (Fig. 3.5.6 B, F, J), or 
in CMV lysate stimulated CD4+IFN-γ+ and CD4+TNF-α+ T cells in either 
season (Fig. 3.5.6 C -D and Fig. 3.5.6 K -L). The proportion of effector 
memory cells within pH1N1 virus stimulated CD4+IL-2+ T cells was 
significantly reduced post-infection at time-point 1 (p <0.05, Fig. 3.5.6E) but 
returned back up to baseline levels by time-point 2 in season 1. Interestingly, 
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the proportion of late effector CD4+IL-2+ T cells in CMV lysate stimulation 
was increased at time-point 1 post-infection in season 1 (p < 0.05, Fig. 
3.5.6G). Hence the increase in proportions of late effector T CD4+IFN-γ+ and 
CD4+TNF-α+ T cells were specific to pH1N1 stimulation whereas the 
increase in proportion of CD4+IL-2+ late effector T cells was specific to CMV-
lysate stimulation. The decrease in proportion of CD4+IL-2+ effector memory 
T cells was specific to pH1N1 stimulation only.  
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Figure 3.5.6 Longitudinal development in effector and memory subsets of pH1N1 live virus and CMV lysate -specific CD4+ T cells.  
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Phenotypic characterisation was performed using multiparameter flow cytometry of the different memory subsets of CD3+CD4+CD8-IFN-γ+ (A, 
B, C, D), CD3+CD4+CD8-IL-2+ (E, F, G, H) and CD3+CD4+CD8-TNF- + (I, J, K, L) T cells on the basis of CCR7 and CD45RA surface 
expression after 18 hour stimulation of PBMCs with live pH1N1 virus (A, B, E, F, I, J) or CMV lysate (C, D, G, H, K, L) from individuals with 
incident pH1N1 infection during season 1 (A, C, E, G, I, K) or season 2 (B, D, F, H, J, L). The proportion of CD3+CD4+CD8- cytokine positive T 
cells that were of the effector-memory (CD45RA−CCR7−), late-effector (CD45RA+CCR7−), central-memory (CD45RA−CCR7+) or naive 
(CD45RA+CCR7+) phenotype are shown; in the box plots, the box represents the third centile (75%) and first centile (25%), with the horizontal 
line representing the median (50%). The whiskers represent 1.5 times the IQR. Differences between study time-points in subset responses 
were estimated by Kruskal Wallis test (season 1) or by Mann Whitney test (season 2). Non-responders to stimulation excluded for each 
cytokine, Season 1 CD4+IFN- +: n = 20, 15, 12 to live pH1N1 virus and n = 15, 11, 8 to CMV lysate; Season 1 CD4+IL-2+: n = 20, 9, 5 to live 
pH1N1 virus and n = 11, 6, 4 to CMV lysate; Season 1 CD4+TNF- +: n = 19, 15, 9 to live pH1N1 virus and n = 12, 9, 3 to CMV lysate; Season 
2 CD4+IFN- +: n = 8, 15 to live pH1N1 virus and n = 12, 13 to CMV lysate; Season 2 CD4+IL-2+: n = 4, 6 to live pH1N1 virus and n = 6, 7 to 
CMV lysate; Season 2 CD4+TNF- +: n = 5, 10 to live pH1N1 virus and n = 9, 11 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months 
post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-infection), T3: up to 6 months post-infection.
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Similar analysis based on the expression of CD45RA and CCR7 was 
undertaken on CD8+IFN-γ+, CD8+IL-2+ and CD8+TNF-α+ T cells in pH1N1 
or CMV lysate stimulation (Fig. 3.5.7). Only pH1N1-stimulated CD8+IFN-γ+ 
showed a significant increase (p < 0.05, Fig. 3.5.7A) in the proportion of late 
effector T cells at time-point 2 (up to 1.5 years following infection) in season 1. 
CMV lysate stimulated CD8+IFN-γ+ showed a significant increase (p < 0.05, 
Fig. 3.5.7C) in the proportion of naïve T cells at time-point 2 in season 1.   
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Figure 3.5.7 Longitudinal development in effector and memory subsets of pH1N1 live virus and CMV lysate -specific CD8+ T cells.  
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Phenotypic characterisation was performed using multiparameter flow cytometry of the different memory subsets of CD3+CD4-CD8+IFN-γ+ (A, 
B, C, D), CD3+CD4-CD8+IL-2+ (E, F, G, H) and CD3+CD4-CD8+TNF- + (I, J, K, L) T cells on the basis of CCR7 and CD45RA surface 
expression after 18 hour stimulation of PBMCs with live pH1N1 virus (A, B, E, F, I, J) or CMV lysate (C, D, G, H, K, L) from individuals with 
incident pH1N1 infection during season 1 (A, C, E, G, I, K), season 2 (B, D, F, H, J, L). The proportion of CD3+CD4-CD8+ cytokine positive T 
cells that were of the effector-memory (CD45RA−CCR7−), late-effector (CD45RA+CCR7−), central-memory (CD45RA−CCR7+) or naive 
(CD45RA+CCR7+) phenotype are shown; in the box plots, the box represents the third centile (75%) and first centile (25%), with the horizontal 
line representing the median (50%). The whiskers represent 1.5 times the IQR. Differences between study time-points in subset responses 
were estimated by Kruskal Wallis test (season 1) or by Mann Whitney test (season 2). Non-responders to stimulation excluded for each 
cytokine, Season 1 CD8+IFN- +: n = 20, 19, 12 to live pH1N1 virus and n = 12, 12, 8 to CMV lysate; Season 1 CD8+IL-2+: n = 21, 8, 10 to live 
pH1N1 virus and n = 13, 3, 8 to CMV lysate; Season 1 CD8+TNF- +: n = 18, 11, 7 to live pH1N1 virus and n = 10, 8, 7 to CMV lysate; Season 
2 CD8+IFN- +: n = 8, 15 to live pH1N1 virus and n = 10, 14 to CMV lysate; Season 2 CD8+IL-2+: n = 11, 4 to live pH1N1 virus and n = 9, 5 to 
CMV lysate; Season 2 CD8+TNF- +: n = 6, 11 to live pH1N1 virus and n = 6, 11 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months 
post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-infection), T3: up to 6 months post-infection.
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3.5.6 Phenotype of pH1N1 virus-specific CD4+IFN-γ+ and CD8+IFN-γ+ T 
cells following natural infection 
Since frequencies of pH1N1-specific CD4+IFN-γ+ and CD8+IFN-γ+ 
responses were increased following infection (Fig. 3.5.2 and Fig. 3.5.3), the 
expression of degranulation (CD107ab), early activation (CD69), tissue-
homing (CCR5) and cellular senescence-associated (CD57) markers by these 
CD4+IFN-γ+ and CD8+IFN-γ+ T cells was assessed in infected individuals. 
Infection did not alter the proportion of pH1N1-specific CD4+IFN-γ+ (Fig. 
3.5.8A-F) or CD8+IFN-γ+ (Fig. 3.5.9A-F) T cells expressing CCR5, CD57 or 
CD107ab compared to pre-infection. However, the proportion of pH1N1-
specific and CMV lysate-specific CD4+IFN-γ+ and CD8+IFN-γ+ T cells 
expressing CD69 was significantly increased post-infection compared to pre-
infection (Fig. 3.5.8G-H and Fig. 3.5.9G). Of note, non-specific CD8+IFN-
γ+CD69+ T cells in unstimulated condition were also significantly increased in 
season 1.   
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Figure 3.5.8 Longitudinal changes in pH1N1 live virus and CMV lysate -specific 
CD4+IFN- + T cells.  
Phenotypic characterisation was performed using multiparameter flow cytometry and 
gating as shown in Fig. 3.4.1 of CD3+CD4+CD8-IFN-γ+ T cells after 18 hour 
stimulation of PBMCs with live pH1N1 virus or CMV lysate in individuals with incident 
pH1N1 infection during season 1 (A, C, E, G) or season 2 (B, D, F, H). The 
proportion of CD3+CD4+CD8- cytokine positive T cells that expressed CCR5 (A, B), 
CD57 (C, D), CD107 (isotypes A and B) (E, F), and CD69 (G, H) are shown. In the 
box plots, the box represents the third centile (75%) and first centile (25%), with the 
horizontal line representing the median (50%). The whiskers represent 1.5 times the 
IQR. Differences between study time-points in each phenotypic marker were 
estimated by Kruskal Wallis test (season 1) or by Mann Whitney test between 
(season 2). Non-responders to stimulation excluded, Season 1: n = 20, 15, 12 to live 
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pH1N1 virus and n = 15, 11, 8 to CMV lysate; Season 2: n = 8, 15 to live pH1N1 
virus and n = 12, 13 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months 
post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-
infection), T3: up to 6 months post-infection.  
 
 
 
Figure 3.5.9 Longitudinal changes in pH1N1 live virus and CMV lysate -specific 
CD8+IFN- + T cells.  
Phenotypic characterisation was performed using multiparameter flow cytometry and 
gating as shown in Fig. 3.4.1 of CD3+CD4-CD8+IFN-γ+ T cells after 18 hour 
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stimulation of PBMCs with live pH1N1 virus or CMV lysate in individuals with incident 
pH1N1 infection during season 1 (A, C, E, G) or season 2 (B, D, F, H). The 
proportion of CD3+CD4-CD8+ cytokine positive T cells that expressed CCR5 (A, B), 
CD57 (C, D), CD107 (isotypes A and B) (E, F), and CD69 (G, H) are shown. In the 
box plots, the box represents the third centile (75%) and first centile (25%), with the 
horizontal line representing the median (50%). The whiskers represent 1.5 times the 
IQR. Differences between study time-points in each phenotypic marker were 
estimated by Kruskal Wallis test (season 1) or by Mann Whitney test between 
(season 2). Non-responders to stimulation excluded, Season 1: n = 20, 19, 12 to live 
pH1N1 virus and n = 12, 12, 8 to CMV lysate; Season 2: n = 8, 15 to live pH1N1 
virus and n = 10, 14 to CMV lysate. T0: baseline (pre-infection), T1: up to 6 months 
post-infection, T2: up to 1.5 years post-infection. Season 2, T2: baseline (pre-
infection), T3: up to 6 months post-infection. 
    
3.5.7 Baseline predictors of post-infection pH1N1 virus-specific T cell responses 
Frequencies of pH1N1 virus-specific IFN-γ+IL-2-, IFN-γ-IL-2+ and IFN-γ+IL-
2+ T cell responses in fluorescence-immunospot (Fig. 3.5.1D, I and N) and 
pH1N1-specific CD4+ and CD8+ IFN-γ+ and IFN-γ+IL-2-TNF-α- T cells (Fig. 
3.5.2 and Fig. 3.5.3) were increased post-infection compared to pre-infection. 
Next, correlations between pre-infection and post-infection responses were 
determined. The hypothesis was that pre-existing pH1N1 cross-reactive T cell 
responses would predict the increase in frequency of pH1N1-specific T cells 
post-infection.  
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The increase in frequencies of pH1N1 virus-specific IFN-γ+IL-2- and IFN-γ-IL-
2+ responses post-infection compared to pre-infection was not significantly 
correlated with pre-infection frequencies of any of the three functional subsets 
enumerated by fluorescence-immunospot (Fig. 3.5.10). However, the increase 
in frequency of pH1N1 virus-specific dual IFN-γ+IL-2+ response post-infection 
was positively correlated (r = 0.438, p = 0.0175) with pre-existing pH1N1-
specific IFN-γ+IL-2- responses (Fig. 3.5.10G).         
 
 
Figure 3.5.10 Correlation between baseline and post-infection pH1N1 virus-specific 
responses by fluorescence-immunospot.  
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Correlation between the increase in frequency between pre-infection and post-
infection time-points in the IFN-γ+IL-2− (A, B, C), IFN-γ-IL-2+ (D, E, F), IFN-γ+IL-2+ 
(G, H, I) cellular responses to live pH1N1 virus quantified by fluorescence-
immunospot and the pre-infection IFN-γ+IL-2− (A, D, G), IFN-γ-IL-2+ (B, E, H), IFN-
γ+IL-2+ (C, F, I) cellular responses to live pH1N1 virus in individuals with incident 
pH1N1 infection during the study (seasons 1 and 2 combined). r values are the 
Spearman rank correlation coefficients. Each symbol on the plot represents an 
individual (n = 29 pairs). SFC, spot-forming cells.
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Conversely, frequencies of pH1N1-specific pre-infection CD4+IFN-γ+ and 
CD4+TNF-α+ T cells were inversely associated (r = -0.693, p = 0.0001 and r = 
-0.506, p = 0.0099) with the increase in post-infection pH1N1-specific 
CD4+IFN-γ+ response (Fig. 3.5.11 B and C). Furthermore, the increase in 
post-infection pH1N1-specific CD4+IFN-γ+IL-2-TNF-α- T cells was also 
inversely correlated with pre-infection pH1N1-specific CD4+IFN-γ+IL-2-TNF-
α- T cells (r = -0.479, p = 0.0134, Fig. 3.5.9E). Pre-infection pH1N1-specific 
CD4+IL-2+ or CD4+IFN-γ-IL-2+TNF-α- T cell responses were not significantly 
correlated with the increase in post-infection pH1N1-specific CD4+IFN-γ+ or 
CD4+IFN-γ+IL-2-TNF-α- T cell response respectively (r = -0.326, p = 0.111 
and r = -0.118, p = 0.565, Fig. 3.5.11 A and D). In pH1N1-specific CD8+IFN-
γ+ and CD8+IFN-γ+IL-2-TNF-α- T cells, only the frequencies of pre-infection 
pH1N1-specific CD8+IFN-γ+ and CD8+IFN-γ+IL-2-TNF-α- T cells respectively 
were inversely correlated with post-infection responses (r = -0.541, p = 0.0025 
and r = -0.569, p = 0.0013, Fig. 3.5.12 B and E).
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Figure 3.5.11 Correlation between baseline and post-infection pH1N1 virus-specific CD4+ T cell responses.  
Correlation between the increase in frequency between pre-infection and post-infection time-points in the CD3+CD4+CD8-IFN- + (A, B, C) and 
CD3+CD4+CD8-IFN-γ+ IL-2-TNF- - (D, E, F) T cells to live pH1N1 virus and the pre-infection CD3+CD4+CD8-IL-2+ (A), CD3+CD4+CD8-IFN-
γ+ (B), CD3+CD4+CD8-TNF- +(C), CD3+CD4+CD8-IFN-γ-IL-2+TNF- - (D), CD3+CD4+CD8-IFN-γ+IL-2-TNF- - (E), CD3+CD4+CD8-IFN-γ-
IL-2-TNF- + (F) T cell responses to live pH1N1 virus in individuals with incident pH1N1 infection during the study (seasons 1 and 2 combined). 
r values are the Spearman rank correlation coefficients. Each symbol on the plot represents an individual, non-responders to stimulation 
excluded (n = 25 pairs).
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Figure 3.5.12 Correlation between baseline and post-infection pH1N1 virus-specific CD8+ T cell responses.  
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Correlation between the increase in frequency between pre-infection and post-infection time-points in the CD3+CD4-CD8+IFN- + (A, B, C) and 
CD3+CD4-CD8+IFN-γ+ IL-2-TNF- - (D, E, F) T cells to live pH1N1 virus and the pre-infection CD3+CD4-CD8+IL-2+ (A), CD3+CD4-CD8+IFN-
γ+ (B), CD3+CD4-CD8+TNF- +(C), CD3+CD4-CD8+IFN-γ-IL-2+TNF- - (D), CD3+CD4-CD8+IFN-γ+IL-2-TNF- - (E), CD3+CD4-CD8+IFN-γ-
IL-2-TNF- + (F) T cell responses to live pH1N1 virus in individuals with incident pH1N1 infection during the study (seasons 1 and 2 combined). 
r values are the Spearman rank correlation coefficients. Each circle on the plot represents an individual, non-responders to stimulation 
excluded (n = 29 pairs). 
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4 DISCUSSION 
 
The role of T cell-mediated HSI against natural influenza infection in humans has not 
been demonstrated prior to our study. This is partly due to requirement for a setting 
where a novel influenza virus enters a population naïve to this novel strain, a 
scenario that only occurs during influenza pandemics. Such a setting allows testing 
of the role of T cells in protecting against symptomatic influenza illness in the 
absence of strain-specific antibodies. We therefore exploited the 2009 H1N1 
pandemic to test the association of pH1N1 cross-reactive T cells with natural 
influenza infection outcomes, and to characterise the longitudinal development of 
pH1N1-specific responses in infected individuals. 
 
4.1 A sensitive and reproducible fluorescence-immunospot assay 
Functional T-cell subsets are critical determinants of protection and pathogenesis in 
infectious diseases. Multiple-cytokine-secreting T cells have been associated with 
protective immunity to viral (Betts et al., 2006), bacterial (Wilkinson & Wilkinson, 
2010) and parasitic infections (Darrah et al., 2007); hence measurement of a single 
cytokine may not be sufficient for detection of a clinically effective pathogen-specific 
immune response (Slota et al., 2011). Therefore, the accurate quantitative 
enumeration of functional T cell subsets is central to immunology. The findings 
presented in Results section 3.1 demonstrate fluorescence-immunospot as a 
sensitive and reproducible assay for multiple-cytokine profiling of ex vivo T cell 
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responses in the context of human clinical studies. The assay has low background 
facilitating high signal-to-noise output to detect low frequency antigen-specific 
responses; intra-assay and inter-assay CVs of less than 14% and 24% respectively, 
and stability of response across a range of input T cell number. Notably, IL-2 
responses in fluorescence-immunospot were more sensitive to the effects of 
cryopreservation and anti-CD28 co-stimulation compared to IFN-γ responses.  
 
In longitudinal studies conducted over long periods of time using human samples, 
reproducibility and sample expenditure of an immunological assay are important 
considerations. We have demonstrated intra- and inter- assay CV values of 
fluorescence-immunospot that are low and similar to dual-colour IFN-γ/IL-2 ELISpot 
(Boulet et al., 2007) and IFN-γ single-colour ELISpot (Mwau et al., 2002) reported in 
other studies. The inclusion of a number of different antigens to stimulate both CD4 
T cell (PPD, CMV- lysate and EBV- lysate) and CD8 T cell (influenza M1 peptide 
pool) subsets demonstrates that fluorescence-immunospot can measure responses 
from both CD4 and CD8 T cells. Reproducibility is essential for clinical trials 
measuring responses to infection and vaccination. Hence low CVs will enable the 
confident use of fluorescence-immunospot for monitoring multiple-cytokine-secreting 
functional T cell responses in human cohort studies.  
 
In comparison to the optimal input T cell number reported for dual colour ELISpot in 
a 96-well plate format (Boulet et al., 2007), our results suggest that using 200, 000 
cells per well is sufficient to detect antigen-specific responses ex vivo in 
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fluorescence-immunospot (Results section 3.1). Unlike in the dual colour ELISpot 
(Boulet et al., 2007), we did not detect a linear increase in any cytokine responses 
with increasing cell input, or an upper limit of detection using a range of 1 – 4 x 105 
cells per well in fluorescence-immunospot (Results section 3.1). This may be due to 
the lower ambiguity of detection in fluorescence-immunospot compared to dual 
colour ELISpot. Hence in cases where sample availability is extremely limited, 
fluorescence-immunospot could still be employed to reliably quantify antigen-specific 
responses using inputs of 1 – 2 x 105 cells per well. Importantly, fluorescence-
immunospot enables measurement of two cytokine-secreting populations 
simultaneously, but uses only half the number of cells than would be required if 
measuring each cytokine alone in single colour ELISpot. Low sample expenditure is 
a significant factor in human studies with limited cell availability and fluorescence-
immunospot demonstrates this advantage.    
 
There are some aspects of IFN-γ/IL-2 fluorescence-immunospot assay that have 
been highlighted during this comprehensive assessment of the basic parameters 
concerning the execution and performance of this assay. Casey et al. demonstrated 
that negative control well responses are significantly higher in fluorescence-
immunospot compared to single-colour ELISpot (attributed to co-stimulatory anti-
CD28 in fluorescence-immunospot) (Casey et al., 2010). We incorporate the largest 
data set to date reporting low background responses in fluorescence-immunospot 
from PBMC of healthy individuals (Results section 3.1). We also demonstrate 
higher background IL-2 responses than IFN-γ responses. Hence the signal-to-noise 
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ratio in fluorescence-immunospot may be lower than in single-colour ELISpot, 
especially for IL-2 responses (Results section 3.1). However, this factor may be 
outweighed by the significant advantage of fluorescence-immunospot in lower 
sample expenditure to gain information on three cytokine-secreting profiles 
simultaneously.         
 
The use of cryopreserved samples in clinical trials and longitudinal studies greatly 
enhances immune monitoring capabilities of an assay. We found significant strong 
correlations between fresh and frozen-thawed PBMC for total IFN-γ+ and IFN-γ+IL-
2+ dual responses in fluorescence-immunospot using PBMC cryopreserved for 2 
weeks (Results section 3.1). This is consistent with previously published literature 
on the effects of cryopreservation on single-colour IFN-γ and IL-2 antigen-specific 
ELISpot responses (Kreher et al., 2003). However, total IL-2+ responses from fresh 
and frozen-thawed PBMC were only moderately correlated (Results section 3.1). 
Increased apoptosis of antigen-specific CD4+ T cells compared to CD8+ T cells 
following long-term cryopreservation (> 300 days) has been reported (Owen et al., 
2007), hence the same mechanism could have accounted for lower antigen-specific 
CD4+ T cell-derived IL-2 in frozen-thawed PBMC responses in our observations. 
This implies that consistent use of either fresh or frozen-thawed samples in 
fluorescence-immunospot is required to ensure comparability of responses 
throughout a study.    
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One other caveat is the effect of anti-CD28 to compensate for antibody sequestration 
in IFN-γ/IL-2 fluorescence-immunospot. Interestingly, the anti-CD28 compensation 
for antibody capture does not enhance cytokine responses for all antigens equally. 
The frequencies of CMV-lysate or M1 peptide pool-specific responses were not 
significantly enhanced with anti-CD28, and this was independent of the 
concentration of anti-CD28 used (Results section 3.1). In cases such as EBV-
lysate-specific responses, antibody capture effect is significant and using anti-CD28 
enables detection of a higher frequency of responses overall and especially for IL-2 
responses (Results section 3.1). A previous study using anti-CD28 in IFN-γ 
ELISpot proposed that the T cell activation threshold may be reduced by the 
costimulatory signal, thus a higher frequency of cytokine-secreting memory T cells 
can be detected even at saturating antigen concentrations (Ott et al., 2004). We 
demonstrate that IL-2 in EBV lysate stimulation is mainly secreted by CD4+ T cells, 
whereas IL-2 in M1 peptide pool or CMV lysate stimulated PBMC is from both CD4+ 
and CD8+ T cells (Results section 3.1). Hence the difference in responses to anti-
CD28 between EBV-lysate compared to M1 peptide pool may be due to the 
enhanced effect of co-stimulation on CD4 T cell derived IL-2 secretion. This 
suggests that the use of anti-CD28 (and the concentration used) in IFN-γ/IL-2 
fluorescence-immunospot could be considered on an individual antigen basis. 
However, for consistency and comparability between stimulation conditions, we used 
the manufacturer’s recommended concentration of 0.5 µg/mL anti-CD28 co-
stimulation in all subsequent experimental results presented (Results sections 3.2 – 
3.3).        
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IFN-γ and IL-2 fluorescence-immunospot has been exemplified (Results section 
3.1), but other commercially available kits (© Mabtech AB) include detection of IL-5, 
IL-13 and IL-17A in addition to IFN-γ. Future studies could assess similar basic 
parameters in fluorescence-immunospot available with other cytokine combinations.  
Our data in conjunction with previous work conducted in our laboratory (Casey et al., 
2010) demonstrate fluorescence-immunospot as an assay with sensitivity and 
reproducibility similar to single-colour ELISpot. Hence IFN-γ and IL-2 fluorescence-
immunospot has been used to characterise low frequency pH1N1-specific T cells in 
PBMC stored cryopreserved from individuals at pre- and post- influenza infection 
time-points. Pre-stimulation of cryopreserved-thawed PBMC with 0.5 µg/mL anti-
CD28 prior to plating (2 – 2.5 x 105 PBMC per well) in fluorescence-immunospot was 
kept consistent throughout experiments. This was to minimise the variability in 
effects of cryopreservation and anti-CD28 co-stimulation on IL-2 fluorescence-
immunospot responses. 
 
4.2 Phenotype of pH1N1 cross-reactive cellular responses in pH1N1 naïve 
individuals   
In a cohort of 76 pH1N1-naive healthy young adults, there were a high proportion of 
individuals with circulating cross-reactive T cells to at least one of the three 
immunodominant pH1N1 core proteins (PB1, M1 and NP) (58% of individuals); to 
live pH1N1 virus (75% of individuals) and to pH1N1 inactivated vaccine (63% of 
individuals)   (Results section 3.2). This is consistent with other studies (Tu et al., 
2010, Ge et al., 2010, Richards et al., 2010, Gras et al., 2010, Scheible et al., 2011) 
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identifying cross-reactive CD4+ and CD8+ T cells pre-existing in naïve individuals 
that recognise and respond to novel pH1N1 virus ex vivo.   
 
The difference in prevalence response to the peptide pools and live virus or 
inactivated vaccines in our results may be due to differences in antigen processing 
and presentation (Germain, 1986). The 15-mer synthetic peptides used (Results 
section 3.2) would be expected to predominantly stimulate MHC class I-restricted 
CD8+ T cell responses within PBMC, whereas natural processing and presentation 
of epitopes from live pH1N1 virus and inactivated vaccine strain virus by APC could 
stimulate CD4+ and CD8+ T cells within PBMC.  
 
A prevalence of 58 - 75% response to antigens reported in Results section 3.2 is 
lower than the prevalence of 80 - 90% to the same antigens (core antigen peptide 
pool and live virus or inactivated vaccines) that we report in a different subset of 
individuals (n = 33) from the same study cohort (Sridhar et al., 2012). While both 
populations were seronegative for pH1N1-specific antibodies by HAI assay and the 
same fluorescence-immunospot protocol was used, there are some differences that 
may have contributed to the discrepancy in prevalence of pre-existing response to 
core proteins between the two study populations. Firstly, the sample sizes were n = 
76 in this thesis (Results section 3.2) and n = 33 in Sridhar et al. Secondly, different 
thresholds for cut-offs in IFN-γ/IL-2 fluorescence-immunospot were used to define 
responders in the two studies. At the time of publishing our first paper, thresholds for 
cut-offs equating to 2 standard deviations of the mean value of the background 
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response wells in 62 independent PBMC samples were used (Sridhar et al., 2012). 
By completion of experimental work for this thesis, thresholds for cut-offs equating to 
2 standard deviations of the mean value of the background fluorescence-
immunospot response wells in 323 independent PBMC samples were generated 
(Results section 3.1). The thresholds from this significantly larger sample size were 
used consistently in all subsequent IFN-γ/IL-2 fluorescence-immunospot analysis 
and results presented in this thesis (Results section 3.2 – 3.3).  
 
IAVs sH1N1 and sH3N2 have been circulating in the human population prior to the 
emergence of the novel pH1N1 (WHO, 2014a). Hence it would be expected that 
individuals previously exposed to these influenza strains pre-pandemic would exhibit 
T cell responses, and that these T cells cross-react with conserved antigens from the 
novel pH1N1. Indeed, there is 98%, 94% and 90% amino acid sequence similarity 
respectively in PB1 (Berthoud et al., 2011), M1 and NP of pH1N1 compared to pre-
pandemic circulating sH1N1 and 97%, 92% and 90% amino acid sequence similarity 
compared to pre-pandemic circulating sH3N2 (NCBI BLAST sequence analysis 
http://www.ncbi.nlm.nih.gov). Therefore, a high proportion of individuals naïve to 
pH1N1 would be expected to have T cells induced by prior exposure through 
infection with sH1N1 and sH3N2 that could cross-react with the novel pH1N1 (live 
virus). Since all the inactivated vaccines used contain core proteins from A/Puerto 
Rico/8/1934 (Introduction section 1.1.6), it would be expected that similar 
proportions of individuals would have T cells responding to the pH1N1, sH1N1 and 
sH3N2 inactivated vaccine viruses (Results section 3.2). 
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In a landmark paper by Sallusto et al. IFN-γ and IL-2 cytokine-secretion profiles of T 
cells were used to differentiate effector and memory T cells with distinct homing 
marker CCR7 expression (Sallusto et al., 1999). Furthermore, Pantaleo and Harari 
have proposed a paradigm for different viral infection models based on antigen load 
and exposure reflected by distinct T cell cytokine signatures (Pantaleo & Harari, 
2006). According to this paradigm, conditions of acute antigen exposure or 
uncontrolled chronic persistent infections such as HIV-1 are associated with a 
predominantly IFN-γ-secreting T cell signature; acute exposure with cleared antigens 
such as tetanus toxoid or influenza are associated with a predominantly IL-2-
secreting T cell signature, and controlled persistent infections such as latent CMV or 
latent EBV are associated with single-IL-2, single IFN-γ and IL-2/IFN-γ polyfunctional 
cytokine-secreting T cells  (Harari et al., 2004, Harari et al., 2005, Harari et al., 
2004).  
 
Based on this model of influenza as an acute and cleared infection (Pantaleo & 
Harari, 2006), and that circulation of seasonal IAV in the UK had ceased by the end 
of February 2009 (WHO, 2014a), we hypothesised that there would be a 
predominantly IL-2-secreting signature of T cells cross-reactive with pH1N1 in 
individuals. Contrary to this hypothesis, there was a predominance in the frequency 
of IFN-γ+IL-2- T cells specific to pH1N1 measured by fluorescence-immunospot 
(Results section 3.2); a signature that has been associated with acute antigen 
exposure or uncontrolled chronic persistent infections (Pantaleo & Harari, 2006). 
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Interestingly, this predominance of single IFN-γ+ response to live pH1N1 virus was 
not observed by flow cytometry and boolean analysis in CD4+ or CD8+ T cell 
populations (Results section 3.4). Although ex vivo PBMC stimulation conditions 
were similar between the two assays (18 hours stimulation at 37°C, 5% CO2), the 
observed difference could be due to inherent differences in the optimised protocols 
used in each assay to measure responses to live pH1N1 virus. This includes 
different MOI (1 in fluorescence-immunospot, 5 in flow cytometry); use of 0.5 µg/mL 
anti-CD28 co-stimulation in fluorescence-immunospot but no co-stimulation used in 
flow cytometry, and the detection of secreted cytokines in fluorescence-immunospot 
compared to staining of intra-cellular cytokines in flow cytometry. Thus comparability 
of the two assays is limited.  
 
Nevertheless, the predominance of IFN-γ+IL-2- T cells to pH1N1 (core antigens, live 
virus and inactivated vaccine) and sH1N1 inactivated vaccine (and predominance of 
IFN-γ+IL-2- and IFN- +IL-2+ to sH3N2 inactivated vaccine) (Results section 3.2) 
appears real and not an artefact of the fluorescence-immunospot experimental 
system. Regardless of the mode of antigen stimulation, the dominance of IFN-γ+IL-
2- pH1N1 cross-reactive or sH1N1-specific T cells was evident whether PBMC were 
stimulated with live virus to mimic natural processing of antigens, or inactivated virus 
strains to stimulate processing of recombinant antigens for the preferential 
recognition by CD4+ T cells. This finding is also consistent with the only other report 
assessing the polyfunctionality of pH1N1 cross-reactive CD8+ T cells showing 
predominance of single IFN-γ+ pH1N1-specific CD8+ T cells and little 
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polyfunctionality based on IFN- , IL-2 and TNF-  ICS (Scheible et al., 2011). 
Furthermore, the possibility that fluorescence-immunospot biased our results by 
preferentially enumerating IFN-γ rather than IL-2 is unlikely given that a 
predominance of IFN-γ+IL-2+ dual-cytokine secreting T cells to Mycobacterium 
tuberculosis antigens was revealed using this assay in our laboratory (Casey et al., 
2010). 
 
IFN-γ is secreted by antigen-specific T cells in PBMC upon recognition of antigen 
(Morris et al., 1982) and T cell derived IFN-γ is important in the antiviral response to 
influenza with rapid activation (Lalvani et al., 1997). Furthermore, in some animal 
models, IFN-γ has been demonstrated to mediate influenza viral clearance and 
protection against pathology (Seo et al., 2002, Bot et al., 1998, Karupiah et al., 
1998), although there are also conflicting reports (Nguyen et al., 2000). In an IFN-γ 
knock out mouse model of influenza, IFN-γ was dispensible for cytotoxicity 
(mediated by ex-vivo CD4+ T cells in the lungs), but necessary for 
complete protection of challenged mice from weight loss (IFN-γ-/- mice showed 
~70% survival following lethal influenza challenge which was significantly lower 
compared to wild type mice) (Brown et al., 2012). Also, the majority of literature 
reports on T cell-mediated HSI in animal models and human studies have measured 
CD4+ or CD8+ T cell IFN-γ production as an effector mechanism (Introduction 
Table 1.4.1).  
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In contrast to influenza-specific CD8+ T cells, there are a small number of reports on 
the characterisation of influenza-specific CD4+ T cells, and of these the majority are 
described in mouse models with very few human studies. Lee et al. characterised 
M1-specific CD4+ T cell clones from human PBMC that were cross-reactive between 
H5N1 and sH3N2, demonstrating expression of IFN-γ, IL-2 and TNF-  by these cells 
upon peptide stimulation or recognition of target cells infected with recombinant 
vaccinia virus vectors expressing M1 of H5N1 (Lee et al., 2008). Tetramer-guided 
epitope mapping and antigen-specific HLA-II tetramers were used to demonstrate 
H5N1 cross-reactive CD4+ T cells secreting IFN-γ, TNF- , IL-5, and IL-13 (in culture 
supernatants) with a CD45RA- memory phenotype in PBMC from healthy Caucasian 
individuals naïve to H5N1 (Roti et al., 2008). Interestingly, another study found that 
influenza viral lysate -specific CD4+ T cells were positive for IFN-γ, IL-2 and TNF-   
(by ICS) but did not express CD107ab (Kannanganat et al., 2007). Consistent with 
this, we found pH1N1-specific CD4+ T cells positive for IFN-γ, IL-2 and TNF-  and 
low frequencies of CD107ab+ cells within CD4+ cytokine+ T cells (Results section 
3.4). The differences between pH1N1-specific CD4+ and CD8+ T cell responses, 
such as a hierarchy in the CD4+ T cell cytokine response but not in the CD8+ T cell 
cytokine response to pH1N1 (Results section 3.4) may reflect differences in 
development of memory of the two different subsets (Seder & Ahmed, 2003).   
 
We noted differences in the cytokine expression profiles between pH1N1 virus cross-
reactive and CMV lysate-specific CD4+ T cells. Particularly with respect to a 
hierarchy of response and a predominant single TNF- + response among cytokine 
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positive pH1N1 virus cross-reactive CD4+ T cells, but a lack of hierarchy and more 
dual (IFN-γ+TNF- +) in the CMV-specific CD4+ T cell response (Results section 
3.4). This is somewhat consistent with the paradigm proposed by Pantaleo and 
Harari in which distinct T cell cytokine signatures reflect different viral infection 
models based on antigen load and exposure (Harari et al., 2004, Harari et al., 2005, 
Harari et al., 2004). However, we also observe a predominance of single TNF- + 
cells within live pH1N1 virus cross-reactive CD4+ T cells (Results section 3.4). A 
recent study characterising human CD4+ T cells to peptide pools from pH1N1 
(A/California/04/09) demonstrated a higher proportion of IFN-γ-IL-2+TNF-α+ CD4+ T 
cells (termed non-polarized, primed precursor T cells (Thpp)) against non-conserved 
peptides compared to peptide pools containing conserved peptides that induced 
more IFN-γ+TNF-α+ CD4+ T cells (Weaver et al., 2013). Hence it may be that our 
results reflect Thpp-like CD4+ T cells (with or without IL-2) against non-conserved 
antigens in live pH1N1. An alternative explanation is our detection and 
characterisation of different antigen-specific subpopulations within a heterogeneous 
CD4+ T cell population when using whole live virus compared to CMV viral lysate.           
 
Our phenotypic characterisation of cytokine-secreting influenza cross-reactive CD8+ 
T cells by flow cytometry showed that they are predominantly comprised of 
CD45RA+CCR7- Temra and CD45RA-CCR7- Tem (Results section 3.4), 
consistent with some reports (Tu et al., 2010, Greenbaum et al., 2009) but in 
contrast to others reporting a predominance of Tcm cells (Lee et al., 2008). Existing 
literature report circulating, low frequency (< 1% of total CD8+ T cells) influenza-
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peptide (M1 immunodominant HLA-A2 restricted) -specific CD8+ of Tem, Temra or 
Tcm (defined by CD45RA/CCR7 expression) phenotype that are detectable in 
human PBMC (Zimmerli et al., 2005, Hoji & Rinaldo, 2005, Almanzar et al., 2007, 
Touvrey et al., 2009). Cytokine-positive influenza viral lysate -specific (Kannanganat 
et al., 2007) or HA-peptide tetramer-specific (Lucas et al., 2004) CD4+ T cells were 
predominantly Tcm cells. In contrast to this, we found that live pH1N1 virus cross-
reactive CD4+ cytokine positive T cells were predominantly Tem and Temra 
(Results section 3.4). This difference may be due to detection and characterisation 
of different antigen-specific subpopulations within a heterogeneous CD4+ T cell 
population when using influenza viral lysate, peptide-tetramer complexes or whole 
live virus.      
 
M1 epitope-specific tetramer positive CD8+ T cells in influenza asymptomatic or non-
acutely infected individuals were a heterogenous population of cells containing both 
immature (CD27+ CD28+ CD62L+ HLA-DR-) primed memory T cells (CD45RA-), 
and cells expressing moderate levels of the terminal differentiation marker CD94, 
granzyme A/B, perforin, and CCR5 and CXCR3 associated with a more mature, 
effector memory phenotype (Hoji & Rinaldo, 2005, Almanzar et al., 2007) and 
express the degranulation marker CD107 indicating cytotoxic potential (Makedonas 
et al., 2010). Consistently, our analysis revealed that about half of pH1N1-cross-
reactive CD8+ cytokine+ T cells (specifically CD8+IFN-γ+ T cells) were positive for 
CD107ab (Results section 3.4). A lower proportion (medians of 5 – 25%) of pH1N1-
cross-reactive CD4+ cytokine+ T cells were also positive for CD107ab (Results 
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section 3.4), consistent with other recent reports (Wilkinson et al., 2012) and 
suggesting a direct antiviral effect from cytotoxic CD4+ T cells that have been 
reported in chronic viral infections (Appay et al., 2002).  
 
CD57 was used as a marker of replicative senescence, as used by Akondy et al. 
characterising Yellow-Fever virus vaccine-induced CD8+ T cell responses, 
importantly showing that CD45RA+CCR7- Temra cells proliferated to antigen 
stimulation, and lacked CD57 expression, hence CD45RA+CCR7- Temra cells may 
not necessarily be terminally differentiated (Akondy et al., 2009). Notably, low 
proportions (medians < 20%) of pH1N1-cross-reactive cytokine positive CD4+ and 
CD8+ T cells were CD57 positive (Results section 3.4), indicating low replicative 
senescence. This could hint at a mechanism of maintenance of these pH1N1 cross-
reactive T cells in vivo.  
 
In mouse models, the chemokine receptor CCR5 has been shown to be important in 
directing CD8+ T cells to the lungs of mice infected with Sendai virus (Kohlmeier et 
al., 2008). Mice deficient in CCR5 also showed increased mortality following 
influenza infection (Dawson et al., 2000, Fadel et al., 2008). Furthermore, an 
increased allele frequency for the CCR5 32 polymorphism was observed among 
individuals with confirmed severe pH1N1 infection who suffered respiratory failure 
and required admission to intensive care (Keynan et al., 2010). Hence, we assessed 
the expression of CCR5 on pH1N1-specific T cells as a marker of tissue homing to 
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sites of inflammation, and found high inter-individual heterogeneity but a median of 
up to 50% of pH1N1 cross-reactive, cytokine-secreting CD4+ and CD8+ T cells were 
positive for CCR5 (Results section 3.4), indicating homing potential to inflammation 
in lungs upon influenza infection.     
 
CD69, an early activation marker that is up-regulated on activated T cells following 
antigenic stimulation (Marzio et al., 1999) was expressed by our cytokine-positive 
antigen-specific cells. It is interesting that CD69 expression did not correlate 
completely with antigen-specific cytokine positive CD4+ or CD8+ T cells. Among 
CD4+ and CD8+ cytokine positive T cells, IFN-γ+ cells showed highest proportions 
of CD69 expressing cells compared to IL-2+ or TNF-α+ T cells; up to half of live 
pH1N1 virus cross-reactive CD4+IFN-γ+ T cells, and up to 20% median proportions 
of live pH1N1 virus cross-reactive CD8+IFN-γ+ T cells were positive for CD69 
(Results section 3.4). The lack of complete correlation between early activation 
marker CD69-positive and cytokine-positive cells may be due to staining and 
detection of cell surface CD69 expression compared to intracellular cytokine 
accumulation.  
 
We selected a flow cytometric data analysis strategy to gate on markers including 
CD69 within the functionally defined, antigen stimulated cytokine positive CD4+ or 
CD8+ T cells. Our approach is different to some other published flow cytometry 
analysis strategies (Karanikas et al., 2000) that gate on bulk CD4+ or CD8+ T cells 
that are activated (CD69+) followed by gating on cytokine positive cells. Our gating 
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strategy was selected to enable consistency in analysis of antigen-specific data, 
since CMV lysate-specific CD69 expression on bulk CD4+ or CD8+ T cells was not 
consistently detectable in our cohort (Results section 3.4). The reason for this is 
unknown, but due to limited sample availability, we did not perform serological tests 
to detect anti-CMV antibodies for identification of CMV seropositivity in this cohort of 
healthy individuals. Hence CMV seronegativity accounting for low CMV lysate-
specific activation (CD69+) measured by flow cytometry cannot be ruled out. 
However, this seems unlikely given that CMV lysate-specific cytokine positive T cells 
in the same cohort were detectable both by fluorescence-immunospot (Results 
section 3.2) and flow cytometry (Results section 3.4), and a previous study found 
concordant results between CMV seropositivity and CMV-specific CD4+IFN-γ+ T 
cells in a large cohort of individuals (Sester et al., 2003). Furthermore, it is estimated 
that approximately 50 – 60 % of adults in the UK are CMV seropositive (Potter et al., 
2012, Ling et al., 2003). 
 
The circulating pH1N1 cross-reactive T cells we detected in healthy pH1N1 naïve 
individuals display the potential to traffic to the lungs during the inflammatory 
response following influenza infection (CCR5+), display an activated, antigen-
experienced phenotype (Tem and Temra) with low replicative senescence (CD57), 
undergo rapid degranulation (CD107ab+) and secrete cytokines (IFN- +, IL-2+, TNF-
α+) upon encounter with pH1N1-infected host cells. These attributes suggest a pre-
existing, circulating population of CD4+ and CD8+ T cells with a role in local viral 
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containment or clearance and limiting the severity of symptoms following influenza 
infection. 
 
4.3 Cellular correlate of protection against symptomatic influenza 
During an influenza pandemic in which susceptible individuals lack protective 
neutralising antibodies, the most favourable outcome of infection is symptom-free, or 
a reduced severity of illness. The 2009 H1N1 pandemic presented the opportunity to 
prospectively identify a cellular immune correlate of protection against illness caused 
by natural influenza infection with an antigenic shift variant reassortant virus, in a 
population seronegative to pH1N1 by HAI assay.  
 
Using the optimised fluorescence-immunospot assay (Results section 3.1), a 
predominance of IFN-γ+IL-2- pH1N1 cross-reactive T cells were detectable in PBMC 
from healthy, pH1N1 naïve individuals (Results section 3.2). Further flow cytometry 
analyses revealed a phenotype consistent with mediating some level of protection 
upon influenza infection (Results section 3.4). In mouse models, T cell-mediated 
HSI does not prevent infection and thereby does not provide sterilising immunity 
(Yap & Ada, 1978). Consistent with this, pre-existing T cells were not associated with 
risk of subsequent pH1N1 infection in our cohort (Results section 3.3). However, a 
higher frequency of pre-existing pH1N1 CD8 conserved epitope -specific T cells 
were associated with decreased risk of fever, fewer ILI symptoms and reduced 
illness severity score in pH1N1 infected individuals (Results section 3.3). High rates 
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of infection, associated with low prevalence of pH1N1 cross-reactive antibodies, but 
low case-fatality in < 45 year old adults during the 2009 H1N1 pandemic was 
suggestive of protective HSI against severe disease in this age group (Hardelid et 
al., 2010). Our findings of the high prevalence of pH1N1 cross-reactive T cells in 
healthy adults (Results section 3.2), within which the CD8+IFN-γ+IL-2-
CD45RA+CCR7- late effector T cells were correlated with protection against 
community-acquired pH1N1 influenza illness (Results section 3.3), leads to the 
postulation that T cell-mediated HSI may have in part accounted for the mild clinical 
illness observed in young adults during the 2009 pandemic. It is possible that the 
epidemiological observations of the 2009 H1N1 pandemic may have been due to a 
less pathogenic pandemic influenza strain (Arias et al., 2009), lower co-morbidities 
and/or host genetic factors (Keynan et al., 2013). However, evidence of pre-existing 
T cells limiting illness severity from a recent human experimental influenza challenge 
study (Wilkinson et al., 2012) is consistent with the notion of T cell-mediated HSI, 
and we have further demonstrated this during a natural influenza pandemic (Results 
section 3.3). 
 
It is worth pointing out that the data presented in Results section 3.3 has been 
published (Sridhar et al., 2013), but the analysis of IFN-γ/IL-2 fluorescence-
immunospot responses are different as explained previously for Results section 3.2 
(see Discussion section 4.2). Despite the use of thresholds for cut-offs in the re-
analysed data for Results section 3.3 compared to the published report (Sridhar et 
al., 2013), the quantitative CD8+ T cell correlate of protection against symptom score 
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was statistically consistent. Similarly, control CMV antigen responses in the re-
analysed data were not associated with illness severity.  
 
Our data is consistent with challenge studies in many animal models (Introduction 
Table 1.4.1) including mice, but also ferrets and nonhuman primates that more 
closely model human influenza infection physiologically and immunologically. 
However our data contradicts Wilkinson et al. on the subset of T cells associated 
with diminution of clinical symptoms in humans. Wilkinson et al. reported 
homosubtypic (against seasonal circulating sH1N1 and sH3N2) IFN-γ+ CD4+ but not 
CD8+ T cells inversely associated with illness severity in the experimental challenge 
model using direct nasal inoculation of a high-dose, less virulent, serially passaged 
laboratory adapted live virus strain (Wilkinson et al., 2012). We demonstrate an 
association of heterosubtypic CD8+IFN- +IL-2-CD45RA+CCR7- but not CD4+ T 
cells in a community exposure setting of naturally acquired infection with mild to 
moderate illness during a pandemic (Results section 3.3). Hence the protective 
correlate differs in the two markedly different settings – one of natural infection 
following human-to-human transmission, and the other of high-dose artificial 
challenge experiment. This inherent difference in infection setting may be one of the 
reasons for the difference in the subset of T cells associated with asymptomatic 
infection identified by the two studies. We believe that our ability to exploit a setting 
of natural infection has significant advantage over an artificial high-dose challenge 
experiment in identifying a T cell correlate of protection relevant to natural infection.                          
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Experiments in a mouse model of respiratory viral infection (parainfluenza virus) 
have demonstrated the importance of circulating effector memory (CD62L-low) CD8+ 
T cells in recall responses in the lung following secondary infection (Roberts & 
Woodland, 2004). Protection against and control of other intracellular pathogens 
have been associated with effector memory T cells (Hansen et al., 2009, Puissant-
Lubrano et al., 2010). Importantly, in a mouse model of lethal pulmonary influenza 
infection, adoptively transferred influenza-specific IFN-  producing CD8+ effector T 
cell clones promoted lung viral clearance and survival, whereas equal numbers of 
their naïve counterparts could not protect against disease (Cerwenka et al., 1999). 
While there exist contrasting reports on the protective capacity of Tcm versus 
effector and Tem subsets in different pathogen infection mouse models (Wherry et 
al., 2003, Roberts & Woodland, 2004, Bachmann et al., 2005, Olson et al., 2013), 
there have been no reports of the protective capacity of Temra in infectious 
diseases. To our knowledge, we are the first to report a CD8+ Temra subset 
correlating with protection against symptomatic influenza infection in humans 
(Results section 3.3).  
 
The late effector CD8+IFN-γ+IL-2- Temra cell correlate of protection against 
symptomatic influenza that we have identified might in part mitigate the clinical 
severity of anticipated pandemics such as the highly pathogenic H5N1 influenza 
(Gambotto et al., 2008), since a large proportion of healthy, H5N1 naïve individuals 
have detectable T cell responses to H5N1 core proteins (Lee et al., 2008, Roti et al., 
2008, Jameson et al., 1999, Kreijtz et al., 2008). However, the difference in virulence 
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of pandemic strains may also circumvent T cell-mediated protection. The protection-
associated T cells could also provide protection against re-exposure to annually 
circulating seasonal influenza strains. Influenza cross-reactive T cells are more likely 
to recognise influenza drift variants that are estimated to arise every 2 – 3 years 
(Smith et al., 2004). Humoral immunity is evaded by such heterologous drifted 
strains; hence T cell-mediated immunity could limit illness severity and symptoms 
caused by seasonal influenza.  
 
4.4 Durability of influenza-specific memory T cells in natural infection  
We identify durable protection-associated pH1N1-specific CD8+IFN-γ+ late effector 
Temra cells in naturally infected individuals longitudinally followed for up to 1.5 years 
post-infection (Results section 3.5, Fig. 3.5.7A). Importantly, this durability was 
detected in the absence of re-infection in our cohort, implying true maintenance of 
late effector cells. This finding is unexpected given the existing literature on the 
longevity of this subset of T cells in other infection models. Hantavirus-specific 
CD8+tetramer+Temra were detectable ex vivo up to 13 years post-infection, but this 
was documented from 3 individuals and in an endemic area where re-infection was a 
possibility (Manigold et al., 2010). A study on CMV-specific CD4+ T cells showed 
stable maintenance over 1.2 – 2.3 years documented from only 8 individuals, and in 
a subset of these individuals, the CMV-specific CD4+ T cells were shown to have a 
Temra phenotype (Sester et al., 2002). Similarly, EBV-specific CD8+ T cells with 
Temra phenotype were maintained to at least 1 yr after infectious mononucleosis 
across 12 individuals (Dunne et al., 2002).  
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Taken together, these studies give plausibility to the maintenance of Temra in the 
case of chronic or latent infection (CMV and EBV) or re-exposure to an acute 
infection in an endemic setting (Hantavirus). It is important to note that in these 
reports (Manigold et al., 2010, Sester et al., 2002, Dunne et al., 2002) there are no 
pre-infection time-points for comparison and the apparent durability is demonstrated 
in cross-sectional times across different individuals. Hence the careful study of the 
kinetics of the response from pre-infection through longitudinal follow-up is unique to 
our study. Although re-exposure to pH1N1 in a community setting cannot be 
chategorically ruled out, none of the infected individuals had evidence of re-infection 
by paired serology during the influenza seasons in the study period. Hence our 
finding of the maintenance of pH1N1-specific CD8+ Temra following pH1N1 infection 
(Results section 3.5) is notable.     
 
Pre-existing, durable protective T cells may partly explain evidence of HSI and the 
durability of protection against symptomatic influenza during influenza pandemics 
inferred from epidemiological studies (Slepushkin, 1959, Epstein, 2006, Sonoguchi 
et al., 1985, Cowling et al., 2010). In the Cleveland family study, adults infected with 
seasonal H1N1 in the period 1950 – 1957 were less likely to be symptomatically 
infected 4 – 6 years later with H2N2 in the 1957 pandemic (OR: 0.294, 95% CI: 0.01 
– 3.07), although the non-significant effect was attributed to a small sample size (n = 
18) (Epstein, 2006). During the same pandemic, another study showed that Russian 
factory workers reporting symptomatic ILI during seasonal H1N1 in the spring of 
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1957 were less likely to be symptomatic 2 – 3 months later in the summer 1957 
H2N2 pandemic (OR: 0.418, 95% CI: 0.304 – 0.575) (Slepushkin, 1959). This 
protection to H2N2 was maintained (albeit at a reduced level compared to the spring 
outbreak) by 6 – 7 months later in the autumn of 1957 (OR: 0.625, 95% CI: 0.530 – 
0.737) (Slepushkin, 1959). In another study, Japanese schoolchildren infected with 
H3N2 were less likely to be infected days to weeks (from 23 days – 18 weeks) later 
with H1N1 re-emergence in 1977 – 1978, with differences in risk between high 
school children (OR: 0.059, 95% CI: 0.019 – 0.131) and primary school children (OR: 
0.154, 95% CI: 0.076 – 0.309) attributed to increasing prior exposure to seasonal 
influenza strains with age (Sonoguchi et al., 1985). Finally, during the recent 2009 
H1N1 pandemic, children infected with seasonal influenza 6 – 11 months prior were 
less likely to have laboratory-confirmed pH1N1 in the following season (OR: 0.35, 
95% CI: 0.14-0.87) (Cowling et al., 2010).  
 
It is interesting that there is an increase in OR for symptomatic infection during a 
pandemic with increasing time since exposure or infection with a pre-pandemic 
seasonal influenza strain (compare ORs in Sonoguchi et al., 1985 to Slepushkin et 
al., 1959, Cowling et al., 2010 and Epstein, 2006). There are obvious limitations in 
the direct comparison across these studies including differences in age groups, 
different geographical locations and ethnicities and differences in viral pandemic 
strains. Nevertheless the data is suggestive of increasing risk of symptomatic 
infection with time since previous documented infection as has been noted by others 
(Couch & Kasel, 1983, Mathews et al., 2010), implying that components of HSI to 
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influenza can wane over the time-scales reported across these studies. Our data 
shows that the frequency of protection-associated CD8+ T cells to influenza are 
maintained from 6 months to up to 1.5 years post-infection in pH1N1 naturally 
infected individuals (Results section 3.5). In 21 of these individuals, the exact date 
of infection could be ascertained and this showed that there was a median of 96 
days (range 55 – 155 days) between infection and the first time-point measure post-
infection. The second and third time-points post-infection were medians of 316.5 
days and 483.5 days post-infection respectively, ascertained from 8 individuals. If we 
postulate that the decline in strength of protection over time observed in the previous 
epidemiological studies is due to a decline in influenza-specific CD8+ T cells 
mediating symptomatic protection, then the highest protection (lowest risk of 
symptomatic infection) is evident early post-infection (range of 23 - 126 days in 
Sonoguchi et al., 1985). Protection declines later post-infection (by 2 – 3 months in 
Slepushkin et al., 1959) and is followed by maintenance (at 6 – 7 months in 
Slepushkin et al., 1959, 4 – 6 years in Epstein, 2006 and 6 – 11 months in Cowling 
et al., 2010). Hence our data on the kinetics of the influenza-specific T cell response 
post natural influenza infection is consistent with the later maintenance in the 
strength of protection over the time-scales observed in epidemiological studies of 
HSI.   
 
Other studies in humans have reported induction of influenza-specific CD8+ T cells 
post-infection (Hillaire et al., 2011b, McMichael et al., 1983a), although to date there 
has been only 1 report of durability of pH1N1-specific CD4+ and CD8+ T cell 
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responses in a single naturally infected individual followed longitudinally (Wagar et 
al., 2011). These studies have suggested an overall decline in influenza-specific T 
cell responses over the time periods of 2 – 43 days (Hillaire et al., 2011b) or up to 
700 days (Wagar et al., 2011) post symptom onset. The decline in HLA -restricted 
CTL responses to influenza during the 6-year study period in McMichael et al. was 
attributed to a reduced influenza activity in the study region time period (McMichael 
et al., 1983a). Our data (Results section 3.5) is the first to show durability of a 
protection-associated CD8+ T cell subset in a larger cohort of up to 45 naturally 
infected individuals longitudinally followed from pre-infection for up to 1.5 years.  
 
Importantly, we did not detect significant alterations in any other cytokine-secreting 
CD4+ or CD8+ T cell subsets, except a decrease in frequency of total IL-2+ and 
single IL-2+ antigen-specific CD4+ and CD8+ T cells post pH1N1 infection (Results 
section 3.5). While this was unexpected, the effect was apparent for both pH1N1-
specific and CMV lysate-specific T cells. To our knowledge, this decrease in antigen-
specific T cell IL-2 responses was not due to technical aspects of the flow cytometry 
assay since longitudinal samples from individuals were processed in batch and the 
same flow cytometer settings were used across all experiments to minimise intra-
assay variability in longitudinal results on an individual basis. Furthermore, we did 
not use co-stimulation in our stimulation protocol although it is frequently used in flow 
cytometry and ICS for increasing sensitivity of the assay to detect low frequency ex 
vivo responses (Lamoreaux et al., 2006). In fluorescence-immunospot we did detect 
a weaker correlation of antigen-specific total IL-2+ PBMC responses in 
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cryopreserved-thawed PBMC compared to fresh PBMC which was not the same in 
the case of antigen-specific total IFN-γ+ PBMC responses (Results section 3.1). 
Therefore the decrease in frequency of total IL-2+ and single IL-2+ antigen-specific 
CD4+ and CD8+ T cells detected by flow cytometry from cryopreserved-thawed 
PBMC (Results section 3.5) may reflect the selective negative effect of 
cryopreservation (independent of time of cryopreservation) on IL-2 responses.     
 
Since pH1N1-specific CD4+IFN- + and CD8+IFN- + T cell responses were 
significantly increased post natural pH1N1 infection (Results section 3.5), we 
explored the relationship between the increase in total- or single- IFN- + CD4+ and 
CD8+ T cell responses post-infection with pre-infection frequencies. We found 
inverse correlations between post-infection rise in IFN- + and pre-infection IFN- + in 
both CD4+ and CD8+ T cells specific to pH1N1 (Results section 3.5). The post-
infection rise in CD4+IFN- + T cells was also inversely correlated with pre-infection 
CD4+ TNF- + T cells. Consistently, inverse correlations of pre-vaccination 
CD4+IFN- + and CD8+IFN- + T cells with post-vaccination CD4+IFN- + and 
CD8+IFN- + respectively been reported following influenza vaccination with TIV and 
LAIV (He et al., 2006, Co et al., 2008, He et al., 2008, Chirkova et al., 2011). 
Together, these data suggest that frequencies of influenza-specific CD4+ and CD8+ 
T cells existing prior to infection or vaccination affects the ability of infection or 
vaccination to significantly increase responses post- infection or vaccination 
respectively. This inverse relationship may be as a result of pre-exposure influenza-
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specific T cells rapidly eliminating influenza-containing APCs, thereby limiting T cell 
expansion post-exposure (Co et al., 2008).  
 
4.5 Implications of our findings for influenza vaccination 
In a small subset of individuals from our cohort that were vaccinated with the pH1N1 
vaccine during the study period, vaccination with or without seroconversion did not 
significantly alter the frequency of pH1N1-specific CD4+ or CD8+ cytokine-secreting 
T cells (Results section 3.5). Notably, seasonal influenza vaccination received > 6 
months prior did not affect the frequency or cytokine-secreting profile of pre-existing 
pH1N1 cross-reactive T cells (Results section 3.2 and Sridhar et al., 2012). 
Previous studies report increases in the frequency of core antigen epitope-specific 
CD8+ T cells detectable 1 month after seasonal influenza vaccination in humans (Tu 
et al., 2010, Terajima et al., 2008). However, reports in animal models suggest that 
inactivated seasonal influenza vaccination may hamper the development of HSI 
(Bodewes et al., 2011b, Bodewes et al., 2010). This effect is also reported in children 
aged 2 – 9 years old where influenza-specific CD8+ T cell responses were 
detectable in unvaccinated children, but the age-dependent increase in influenza-
specific CD8+ T cells was not detected in children vaccinated every year with 
seasonal influenza vaccines from age 4 onwards (Bodewes et al., 2011c).  
 
In conjunction with the existing literature, our data (Results sections 3.2 and 3.5) 
suggest that influenza infection is able to maintain influenza cross-reactive T cell 
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responses, in contrast to vaccination with inactivated seasonal influenza. 
Additionally, the durable maintenance of a protection-associated CD8+ T cell subset 
in naturally infected individuals suggests that successful T cell-based influenza 
vaccines may need to boost and maintain responses similar to natural infection to 
afford protection against illness severity with influenza. However, a larger sample 
size would be required to confirm this difference between infection and vaccination 
maintaining frequencies of pH1N1-specific T cells. 
 
The strongest association with limiting illness severity was with summed T cell 
responses to conserved CD8 T cell epitopes from core proteins PB1, M1 and NP 
(Results section 3.3). Hence in the absence of detectable cross-reactive 
neutralising antibodies, CD8+ HLA class I- restricted T cells specific for epitopes 
conserved across IAV subtypes may confer broad protection against illness severity 
following infection with IAVs. Our findings provide an immunological surrogate of 
protection (that is durable CD8+IFN- +IL-2- T cell responses), and target antigen 
epitopes (based on the 91 highly conserved CD8 T cell epitopes from PB1, M1 and 
NP) for the development and evaluation of broadly protective universal influenza 
vaccines conferring protection against illness caused by viruses evading humoral 
immunity. Furthermore, the frequency of CD8+IFN- +IL-2- T cells could be used as a 
biomarker for risk stratification of individuals most likely to become symptomatic in 
the event of pandemics, and thus would inform vaccination strategies to prioritise 
populations most at-risk of increased illness severity with influenza.   
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4.6 Study limitations 
Our longitudinal cohort study conducted during a rapidly evolving pandemic in real 
time has limitations inherent to such research settings. Research ethics approval 
was obtained after the first wave of pH1N1 in the UK (April – August 2009) had 
occurred hence recruitment of individuals was commenced prior to the second wave 
(September – November 2009), and individuals were followed through the second 
(September 2009 - April 2010) and third waves of the pandemic (August 2010 – April 
2011). Serum and PBMC isolated from whole blood collected at each study time-
point were bio-banked, hence cryopreserved PBMC were used in all immunological 
assays. While at least 30 x 106 PBMC were stored for each individual, variable loss 
of viable cell quantity through cryopreservation and thawing limited the number of 
assays that could be used to characterise immunological responses. Further epitope 
mapping of T cell responses identified to conserved peptides from core antigens 
PB1, M1, NP could not be performed due to this limitation of sample availability.          
 
We excluded individuals reporting multiple ILI episodes (analysis in Results section 
3.3); hence the use of stringent criteria to reliably identify distinct clinical outcomes in 
the community-based study setting reduced the sample size for individuals with 
incident influenza infection. Furthermore, not all individuals recruited remained to 
follow-up time-points 1, 2 and 3, therefore further diminishing sample sizes available 
for longitudinal analysis. The community-based nature of the study resulted in a 
cohort in which the majority of infected individuals had mild to moderate illness, 
representing only part of the full clinical spectrum of influenza disease severity. 
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Hence the use of our identified CD8+IFN- +IL-2- late effector T cells as a surrogate 
of protection in clinical trials of new universal influenza vaccines will need to be in 
combination with robust clinical endpoints including protection from severe illness. 
 
Although the findings in this healthy adult cohort of staff and students at Imperial 
College London may be generalisable to other healthy adult populations with similar 
demography, the results cannot be directly extrapolated to individuals at high risk of 
severe illness caused by pandemic H1N1. Hence future studies could assess the 
protection-associated T cell subset in other populations including young children, 
pregnant women, the elderly and HIV-1 infected patients and other 
immunocompromised individuals. The protective correlate against severe illness and 
fatal disease may be different in high-risk individuals, although some level of 
protective effect of T cells might be expected in such cases. 
 
Our study was designed to specifically address the role of CD8+ T cells in HSI using 
conserved CD8 T cell epitopes stimulating CD8+ T cell responses by fluorescence-
immunospot. Longer peptides optimal for processing and presentation of CD4 
epitopes were not used; hence we cannot exclude the possibility of correlation of 
CD4+ T cells with illness severity. HAI and microneutralisation assays were used to 
select individuals lacking cross-reactive neutralising antibodies to the HA1 head 
region and HA2 stem regions of pH1N1 virus HA respectively, thereby excluding the 
contribution of these demonstrated in other studies to limit disease (Wrammert et al., 
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2011). Antibodies directed to other viral proteins including NA (Couch et al., 1974) 
and M2 ectodomain (Grandea et al., 2010) have been shown to have a protective 
effect. An age-dependent increasing prevalence of non-neutralising serum 
antibodies inducing antibody-dependent cellular cytotoxicity toward pH1N1 virus has 
also been reported (Jegaskanda et al., 2013a), with protective HSI demonstrated in 
macaques (Jegaskanda et al., 2013b). These antibodies are not detected by the 
standard assays used in our study, and it is conceivable that such antibodies in 
conjunction with cellular immunity may have a role in limiting illness severity 
following influenza infection. Similarly, mucosal responses in human experimental 
challenge (Hayden et al., 1998), or systemic innate immune responses in human 
infection (Everitt et al., 2012) studies, that have been shown to protect against 
severe disease were not measured in our study.              
 
4.7 Future work 
Future work could address some of the limitations outlined above, but the challenge 
in studying HSI to natural influenza infection in humans is the requirement for 
occurrence of a influenza pandemic in which a novel antigenically shifted virus is 
introduced. Fluorescence-immunospot was selected due to the high sensitivity of this 
assay to detect low frequency, cytokine-secreting antigen-specific responses that 
would be expected for pH1N1 cross-reactive T cells in healthy individuals naïve to 
pH1N1. To minimise the effect of inter-assay variation, cryopreserved PBMC 
samples from different study time-points available for each individual were 
processed in batch in both fluorescence-immunospot and flow cytometry. Inter-assay 
 223 
CV determined for fluorescenece-immunospot was low (Results section 3.1), hence 
future cohort studies of a similar design could consider processing of PBMC in real 
time to optimise sample availability and minimise the effects of cryopreservation on 
assay results (Results section 3.1).         
 
The size of our recruited cohort was based on a power calculation to detect 
differences between symptomatic and asymptomatic infected individuals to address 
the role of pre-existing cross-reactive CD8+ T cells (Material and methods section 
2.2). Hence we were only able to assess the effect of influenza vaccination due to 
incidental vaccination in a small subset of our cohort. Future longitudinal studies 
following individuals post-vaccination and comparing cross-reactive T cell responses 
pre- and post- vaccination would enable comprehensive assessment of the effect of 
vaccination on heterosubtypic immune mediators. More immediate future work 
planned in our laboratory involves determining whether the vaccination programme 
with LAIV which is being rolled out nationally, starting in autumn 2014 in the UK, can 
induce HSI against new influenza strains, and if so, whether and to what extent our 
identified T cell correlate mediates this immunity. 
 
Our study cohort captured mild to moderate illness in a community-acquired infection 
setting among young adults only. An increasing cumulative life-time exposure to 
influenza is expected with increasing age, hence it will be interesting to test the 
hypothesis that the frequency of heterosubtypic T cells increases with age in a study 
population including young children, young adult and older adult age groups. It will 
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also be important to test whether the protective T cell correlate against mild to 
moderate illness is also associated with protection against severe illness. We have 
demonstrated a cellular correlate of protection against symptomatic influenza illness 
in the accessible peripheral blood compartment. However, the primary mediator of 
protection against influenza illness severity may be local rather than systemic, and 
could be a different cell population, as suggested by murine work (Wu et al., 2014). 
Furthermore, another study has reported high frequencies of circulating NP- and M1- 
specific CD4+IFN- + T cells in pH1N1 infected hospitalised patients within 48 hours 
of symptom onset correlating with severe disease outcomes (Zhao et al., 2012). 
Hence it will be important to assess the temporal and anatomical relationship 
between our identified cellular correlate of protection to that observed at the sites of 
infection in the respiratory tract (URT and/or LRT); the relationship and relative 
contributions of systemic versus local cellular mediators of protection, and how these 
develop longitudinally following antigen exposure in humans. 
        
4.8 Summary 
In conclusion, using an optimised fluorescence-immunospot assay (Results section 
3.1), our data identify cross-reactive T cells pre-existing in naïve individuals that 
recognise and respond to novel pH1N1 virus ex vivo (Results section 3.2 and 
Sridhar et al., 2012). Through detailed phenotypic characterisation (Results section 
3.4), we demonstrate that pre-existing CD8+IFN- +IL-2- Temra (CD45RA+CCR7-) 
cells limit disease severity following incident pH1N1 infection in the absence of 
protective strain-specific antibodies (Results section 3.3 and Sridhar et al., 2013).  
 225 
Furthermore, we show that this protection-associated T cell subset is durably 
maintained in the absence of re-infection up to 1.5 years post infection, and that pre-
exposure frequencies of pH1N1-specific T cells may impact the post-infection 
pH1N1-specific T cell frequencies (Results section 3.5). These findings may have 
important implications in the development and evaluation of new influenza vaccines.   
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6 APPENDIX 
Table 6.1 Expected conserved HLA-I CD8 9-mer 
epitopes of influenza A virus proteins Polymerase 
Basic Protein 1 (PB1), Matrix 1 (M1) and 
Nucleoprotein (NP)  and predicted HLA restriction. 
 
Protein Peptide ID 
Amino Acid position and 
Sequence 
HLA restriction 
PB1 PB1/1 4-NPTLLFLKV-12 
HLA-A2 
PB1 PB1/2 16-NAISTTFPY-24 
HLA-A2 
PB1 PB1/3 22-FPYTGDPPY-30 
ND 
PB1 PB1/4 30-YSHGTGTGY-38 
HLA-A1, A26, A30, 
A29 
PB1 PB1/5 77-NEPSGYAQT-85 
HLA-A1 
PB1 PB1/6 81-GYAQTDCVL-89 
ND 
PB1 PB1/7 83-AQTDCVLEA-91 
ND 
PB1 PB1/8 123-TQGRQTYDW-131 
ND 
PB1 PB1/9 127-QTYDWTLNR-135 
ND 
PB1 PB1/10 221-ALTLNTMTK-229 
ND 
PB1 PB1/11 228-TKDAERGKL-236 
ND 
PB1 PB1/12 230-DAERGKLKR-238 
ND 
PB1 PB1/13 233-RGKLKRRAI-241 
ND 
PB1 PB1/14 235-KLKRRAIAT-243 
HLA-B27 
PB1 PB1/15 238-RRAIATPGM-246 
HLA-B27 
PB1 PB1/16 240-AIATPGMQI-248 
HLA-B27 
PB1 PB1/17 243-TPGMQIRGF-251 
ND 
PB1 PB1/18 271-LPVGGNEKK-279 
ND 
PB1 PB1/19 274-GGNEKKAKL-282 
ND 
PB1 PB1/20 275-GNEKKAKLA-283 
ND 
PB1 PB1/21 277-EKKAKLANV-285 
ND 
PB1 PB1/22 280-AKLANVVRK-288 
ND 
PB1 PB1/23 281-KLANVVRKM-289 
ND 
PB1 PB1/24 340-APIMFSNKM-348 
ND 
PB1 PB1/25 342-IMFSNKMAR-350 
ND 
PB1 PB1/26 343-MFSNKMARL-351 
ND 
PB1 PB1/27 347-KMARLGKGY-355 
HLA-B62 
PB1 PB1/28 349-ARLGKGYMF-357 
HLA-B27 
PB1 PB1/29 403-LSPGMMMGM-411 
HLA-A2 
PB1 PB1/30 404-SPGMMMGMF-412 
HLA-A2 
PB1 PB1/31 407-MMMGMFNML-415 
HLA-A2 
PB1 PB1/32 410-GMFNMLSTV-418 
HLA-A2 
PB1 PB1/33 411-MFNMLSTVL-419 
HLA-A2 
PB1 PB1/34 413-NMLSTVLGV-421 
HLA-A2 
PB1 PB1/35 439-DGLQSSDDF-447 
ND 
PB1 PB1/36 441-LQSSDDFAL-449 
ND 
PB1 PB1/37 443-SSDDFALIV-451 
ND 
PB1 PB1/38 475-INMSKKKSY-483 
HLA-A3, A11, A31, 
A68 
PB1 PB1/39 487-TGTFEFTSF-495 
HLA-A03, A11, A31, 
A68 
PB1 PB1/40 489-TFEFTSFFY-497 
HLA-A1 
PB1 PB1/41 491-EFTSFFYRY-499 
 
PB1 PB1/42 497-YRYGFVANF-505 
HLA-A24 
PB1 PB1/43 501-FVANFSMEL-509 
HLA-A2 
PB1 PB1/44 504-NFSMELPSF-512 
HLA-A2 
PB1 PB1/45 598-LYNIRNLHI-606 
ND 
PB1 PB1/46 658-DAVATTHSW-666 
ND 
PB1 PB1/47 669-KRNRSILNT-677 
ND 
PB1 PB1/48 697-EKFFPSSSY-705 
ND 
PB1 PB1/49 698-KFFPSSSYR-706 
ND 
PB1 PB1/50 699-FFPSSSYRR-707 
ND 
PB1 PB1/51 716-EAMVSRARI-724 
ND 
M1 M1/1 29-EDVFAGKNT-37 
HLA-A3 
M1 M1/2 31-VFAGKNTDL-39 
HLA-A2 
M1 M1/3 37-TDLEALMEW-45 
ND 
M1 M1/4 49-RPILSPLTK-57 
HLA-A3 
M1 M1/5 51-ILSPLTKGI-59 
HLA-A2 
M1 M1/6 56-TKGILGFVF-64 
HLA-A2 
M1 M1/7 58-GILGFVFTL-66 
HLA-A2 
M1 M1/8 60-LGFVFTLTV-68 
HLA-A2 
M1 M1/9 66-LTVPSERGL-74 
HLA-A2 
M1 M1/10 68-VPSERGLQR-76 
HLA-A2 
M1 M1/11 71-ERGLQRRRF-79 
HLA-A2 
M1 M1/12 75-QRRRFVQNA-83 
HLA-A2 
M1 M1/13 76-RRRFVQNAL-84 
HLA-A2 
M1 M1/14 122-GALASCMGL-130 
HLA-B35 
M1 M1/15 123-ALASCMGLI-131 
HLA-B35 
M1 M1/16 124-LASCMGLIY-132 
HLA-B35 
M1 M1/17 126-SCMGLIYNR-134 
HLA-A3, A11, A31, 
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A33, A68, B27, B35 
M1 M1/18 177-NRMVLASTT-185 
HLA-A3, A11 
M1 M1/19 179-MVLASTTAK-187 
HLA-A3, A11 
M1 M1/20 180-VLASTTAKA-188 
HLA-A3, A11 
M1 M1/21 181-LASTTAKAM-189 
HLA-A3, A11 
NP NP/1 88-DPKKTGGPI-96 
HLA-A68 
NP NP/2 89-PKKTGGPIY-97 
HLA-A68 
NP NP/3 147-TYQRTRALV-155 
HLA-B15 
NP NP/4 149-QRTRALVRT-157 
HLA-A68 
NP NP/5 158-GMDPRMCSL-166 
HLA-2 
NP NP/6 164-CSLMQGSTL-172 
HLA-B15 
NP NP/7 166-LMQGSTLPR-174 
HLA-B15 
NP NP/8 218-AYERMCNIL-226 
HLA-B18 
NP NP/9 225-ILKGKFQTA-233 
HLA-B8 
NP NP/10 226-LKGKFQTAA-234 
HLA-B15 
NP NP/11 245-SRNPGNAEI-253 
HLA-B15 
NP NP/12 250-NAEIEDLIF-258 
HLA-B40 
NP NP/13 256-LIFLARSAL-264 
HLA-A2 
NP NP/14 257-IFLARSALI-265 
HLA-A2 
NP NP/15 258-FLARSALIL-266 
HLA-A3 
NP NP/16 296-YSLVGIDPF-304 
HLA-B15 
NP NP/17 462-GVFELSDEK-470 
HLA-B15 
NP NP/18 463-VFELSDEKA-471 
HLA-B15 
NP NP/19 464-FELSDEKAT-472 
HLA-B15 
   
 
 
Table 6.2 15-mer overlapping peptides from M1 
antigen of influenza A/California/07/09   
Protein Peptide id Peptide sequence 
M1 M1 1 MSLLTEVETYVLSII 
M1 M1 2 EVETYVLSIIPSGPL 
M1 M1 3 VLSIIPSGPLKAEIA 
M1 M1 4 PSGPLKAEIAQRLES 
M1 M1 5 KAEIAQRLESVFAGK 
M1 M1 6 QRLESVFAGKNTDLE 
M1 M1 7 VFAGKNTDLEALMEW  
M1 M1 8 NTDLEALMEWLKTRP 
M1 M1 9 ALMEWLKTRPILSPL 
M1 M1 10 LKTRPILSPLTKGIL 
M1 M1 11 ILSPLTKGILGFVFT 
M1 M1 12 TKGILGFVFTLTVPS 
M1 M1 13 GFVFTLTVPSERGLQ 
M1 M1 14 LTVPSERGLQRRRFV 
M1 M1 15 ERGLQRRRFVQNALN 
M1 M1 16 RRRFVQNALNGNGDP 
M1 M1 17 QNALNGNGDPNNMDR 
M1 M1 18 GNGDPNNMDRAVKLY 
M1 M1 19 NNMDRAVKLYKKLKR 
M1 M1 20 AVKLYKKLKREITFH 
M1 M1 21 KKLKREITFHGAKEV 
M1 M1 22 EITFHGAKEVSLSYS 
M1 M1 23 GAKEVSLSYSTGALA 
M1 M1 24 SLSYSTGALASCMGL 
M1 M1 25 TGALASCMGLIYNRM 
M1 M1 26 SCMGLIYNRMGTVTT 
M1 M1 27 IYNRMGTVTTEAAFG 
M1 M1 28 GTVTTEAAFGLVCAT 
M1 M1 29 EAAFGLVCATCEQIA 
M1 M1 30 LVCATCEQIADSQHR 
M1 M1 31 CEQIADSQHRSHRQM 
M1 M1 32 DSQHRSHRQMATTTN 
M1 M1 33 SHRQMATTTNPLIRH 
M1 M1 34 ATTTNPLIRHENRMV 
M1 M1 35 PLIRHENRMVLASTT 
M1 M1 36 ENRMVLASTTAKAME 
M1 M1 37 LASTTAKAMEQMAGS 
M1 M1 38 AKAMEQMAGSSEQAA 
M1 M1 39 QMAGSSEQAAEAMEV 
M1 M1 40 SEQAAEAMEVANQTR 
M1 M1 41 EAMEVANQTRQMVHA 
M1 M1 42 ANQTRQMVHAMRTIG 
M1 M1 43 QMVHAMRTIGTHPSS 
M1 M1 44 MRTIGTHPSSSAGLK 
M1 M1 45 THPSSSAGLKDDLLE 
M1 M1 46 SAGLKDDLLENLQAY 
M1 M1 47 DDLLENLQAYQKRMG 
M1 M1 48 NLQAYQKRMGVQMQR 
M1 M1 49 QKRMGVQMQRFK 
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Table 6.3 15-mer overlapping peptides from NP 
antigen of influenza A/California/07/09   
Protein Peptide id Peptide sequence 
NP NP 1 MASQGTKRSYEQMET 
NP NP 2 TKRSYEQMETGGERQ 
NP NP 3 EQMETGGERQDATEI 
NP NP 4 GGERQDATEIRASVG 
NP NP 5 DATEIRASVGRMIGG 
NP NP 6 RASVGRMIGGIGRFY 
NP NP 7 RMIGGIGRFYIQMCT 
NP NP 8 IGRFYIQMCTELKLS 
NP NP 9 IQMCTELKLSDYDGR 
NP NP 10 ELKLSDYDGRLIQNS 
NP NP 11 DYDGRLIQNSITIER 
NP NP 12 LIQNSITIERMVLSA 
NP NP 13 ITIERMVLSAFDERR 
NP NP 14 MVLSAFDERRNKYLE 
NP NP 15 FDERRNKYLEEHPSA 
NP NP 16 NKYLEEHPSAGKDPK 
NP NP 17 EHPSAGKDPKKTGGP 
NP NP 18 GKDPKKTGGPIYRRV 
NP NP 19 KTGGPIYRRVDGKWM 
NP NP 20 IYRRVDGKWMRELIL 
NP NP 21 DGKWMRELILYDKEE 
NP NP 22 RELILYDKEEIRRVW 
NP NP 23 YDKEEIRRVWRQANN 
NP NP 24 IRRVWRQANNGEDAT 
NP NP 25 RQANNGEDATAGLTH 
NP NP 26 GEDATAGLTHIMIWH 
NP NP 27 AGLTHIMIWHSNLND 
NP NP 28 IMIWHSNLNDATYQR 
NP NP 29 SNLNDATYQRTRALV 
NP NP 30 ATYQRTRALVRTGMD 
NP NP 31 TRALVRTGMDPRMCS 
NP NP 32 RTGMDPRMCSLMQGS 
NP NP 33 PRMCSLMQGSTLPRR 
NP NP 34 LMQGSTLPRRSGAAG 
NP NP 35 TLPRRSGAAGAAVKG 
NP NP 36 SGAAGAAVKGVGTIA 
NP NP 37 AAVKGVGTIAMELIR 
NP NP 38 VGTIAMELIRMIKRG 
NP NP 39 MELIRMIKRGINDRN 
NP NP 40 MIKRGINDRNFWRGE 
NP NP 41 INDRNFWRGENGRRT 
NP NP 42 FWRGENGRRTRVAYE 
NP NP 43 NGRRTRVAYERMCNI 
NP NP 44 RVAYERMCNILKGKF 
NP NP 45 RMCNILKGKFQTAAQ 
NP NP 46 LKGKFQTAAQRAMMD 
NP NP 47 QTAAQRAMMDQVRES 
NP NP 48 RAMMDQVRESRNPGN 
NP NP 49 QVRESRNPGNAEIED 
NP NP 50 RNPGNAEIEDLIFLA 
NP NP 51 AEIEDLIFLARSALI 
NP NP 52 LIFLARSALILRGSV 
NP NP 53 RSALILRGSVAHKSC 
NP NP 54 LRGSVAHKSCLPACV 
NP NP 55 AHKSCLPACVYGLAV 
NP NP 56 LPACVYGLAVASGHD 
NP NP 57 YGLAVASGHDFEREG 
NP NP 58 ASGHDFEREGYSLVG 
NP NP 59 FEREGYSLVGIDPFK 
NP NP 60 YSLVGIDPFKLLQNS 
NP NP 61 IDPFKLLQNSQVVSL 
NP NP 62 LLQNSQVVSLMRPNE 
NP NP 63 QVVSLMRPNENPAHK 
NP NP 64 MRPNENPAHKSQLVW 
NP NP 65 NPAHKSQLVWMACHS 
NP NP 66 SQLVWMACHSAAFED 
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NP NP 67 MACHSAAFEDLRVSS 
NP NP 68 AAFEDLRVSSFIRGK 
NP NP 69 LRVSSFIRGKKVIPR 
NP NP 70 FIRGKKVIPRGKLST 
NP NP 71 KVIPRGKLSTRGVQI 
NP NP 72 GKLSTRGVQIASNEN 
NP NP 73 RGVQIASNENVETMD 
NP NP 74 ASNENVETMDSNTLE 
NP NP 75 VETMDSNTLELRSRY 
NP NP 76 SNTLELRSRYWAIRT 
NP NP 77 LRSRYWAIRTRSGGN 
NP NP 78 WAIRTRSGGNTNQQK 
NP NP 79 RSGGNTNQQKASAGQ 
NP NP 80 TNQQKASAGQISVQP 
NP NP 81 ASAGQISVQPTFSVQ 
NP NP 82 ISVQPTFSVQRNLPF 
NP NP 83 TFSVQRNLPFERATV 
NP NP 84 RNLPFERATVMAAFS 
NP NP 85 ERATVMAAFSGNNEG 
NP NP 86 MAAFSGNNEGRTSDM 
NP NP 87 GNNEGRTSDMRTEVI 
NP NP 88 RTSDMRTEVIRMMES 
NP NP 89 RTEVIRMMESAKPED 
NP NP 90 RMMESAKPEDLSFQG 
NP NP 91 AKPEDLSFQGRGVFE 
NP NP 92 LSFQGRGVFELSDEK 
NP NP 93 RGVFELSDEKATNPI 
NP NP 94 LSDEKATNPIVPSFD 
NP NP 95 ATNPIVPSFDMSNEG 
NP NP 96 VPSFDMSNEGSYFFG 
NP NP 97 MSNEGSYFFGDNAEE 
NP NP 98 SYFFGDNAEEYDS 
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Table 6.4 15-mer overlapping peptides from PB1 
antigen of influenza A/California/07/09   
Protein Peptide id Peptide sequence 
PB1 PB1 1 MDVNPTLLFLKIPAQ 
PB2 PB1 2 TLLFLKIPAQNAIST 
PB3 PB1 3 KIPAQNAISTTFPYT 
PB4 PB1 4 NAISTTFPYTGDPPY 
PB5 PB1 5  TFPYTGDPPYSHGTG 
PB6 PB1 6 GDPPYSHGTGTGYTM 
PB7 PB1 7 SHGTGTGYTMDTVNR 
PB8 PB1 8 TGYTMDTVNRTHQYS 
PB9 PB1 9 DTVNRTHQYSEKGKW 
PB10 PB1 10 THQYSEKGKWTTNTE 
PB11 PB1 11 EKGKWTTNTETGAPQ 
PB12 PB1 12 TTNTETGAPQLNPID 
PB13 PB1 13  TGAPQLNPIDGPLPE 
PB14 PB1 14 LNPIDGPLPEDNEPS 
PB15 PB1 15 GPLPEDNEPSGYAQT 
PB16 PB1 16 DNEPSGYAQTDCVLE 
PB17 PB1 17 GYAQTDCVLEAMAFL 
PB18 PB1 18 DCVLEAMAFLEESHP 
PB19 PB1 19 AMAFLEESHPGIFEN 
PB20 PB1 20 EESHPGIFENSCLET 
PB21 PB1 21 GIFENSCLETMEVVQ 
PB22 PB1 22 SCLETMEVVQQTRVD 
PB23 PB1 23 MEVVQQTRVDKLTQG 
PB24 PB1 24  QTRVDKLTQGRQTYD 
PB25 PB1 25 KLTQGRQTYDWTLNR 
PB26 PB1 26  RQTYDWTLNRNQPAA 
PB27 PB1 27 WTLNRNQPAATALAN 
PB28 PB1 28 NQPAATALANTIEVF 
PB29 PB1 29 TALANTIEVFRSNGL 
PB30 PB1 30 TIEVFRSNGLTANES 
PB31 PB1 31 RSNGLTANESGRLID 
PB32 PB1 32 TANESGRLIDFLKDV 
PB33 PB1 33 GRLIDFLKDVMESMN 
PB34 PB1 34 FLKDVMESMNKEEIE 
PB35 PB1 35 MESMNKEEIEITTHF 
PB36 PB1 36 KEEIEITTHFQRKRR 
PB37 PB1 37 ITTHFQRKRRVRDNM 
PB38 PB1 38 QRKRRVRDNMTKKMV 
PB39 PB1 39  VRDNMTKKMVTQRTI 
PB40 PB1 40 TKKMVTQRTIGKKKQ 
PB41 PB1 41 TQRTIGKKKQRLNKR 
PB42 PB1 42 GKKKQRLNKRGYLIR 
PB43 PB1 43 RLNKRGYLIRALTLN 
PB44 PB1 44 GYLIRALTLNTMTKD 
PB45 PB1 45 ALTLNTMTKDAERGK 
PB46 PB1 46 TMTKDAERGKLKRRA  
PB47 PB1 47 AERGKLKRRAIATPG 
PB48 PB1 48 LKRRAIATPGMQIRG 
PB49 PB1 49 IATPGMQIRGFVYFV 
PB50 PB1 50 MQIRGFVYFVETLAR 
PB51 PB1 51 FVYFVETLARSICEK 
PB52 PB1 52 ETLARSICEKLEQSG 
PB53 PB1 53 SICEKLEQSGLPVGG 
PB54 PB1 54 LEQSGLPVGGNEKKA 
PB55 PB1 55 LPVGGNEKKAKLANV 
PB56 PB1 56 NEKKAKLANVVRKMM 
PB57 PB1 57 KLANVVRKMMTNSQD 
PB58 PB1 58 VRKMMTNSQDTEISF 
PB59 PB1 59 TNSQDTEISFTITGD 
PB60 PB1 60 TEISFTITGDNTKWN 
PB61 PB1 61 TITGDNTKWNENQNP 
PB62 PB1 62 NTKWNENQNPRMFLA 
PB63 PB1 63 ENQNPRMFLAMITYI 
PB64 PB1 64 RMFLAMITYITRNQP 
PB65 PB1 65 MITYITRNQPEWFRN 
PB66 PB1 66 TRNQPEWFRNILSMA 
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PB67 PB1 67 EWFRNILSMAPIMFS 
PB68 PB1 68 ILSMAPIMFSNKMAR 
PB69 PB1 69 PIMFSNKMARLGKGY 
PB70 PB1 70 NKMARLGKGYMFESK 
PB71 PB1 71 LGKGYMFESKRMKIR 
PB72 PB1 72 MFESKRMKIRTQIPA 
PB73 PB1 73 RMKIRTQIPAEMLAS 
PB74 PB1 74 TQIPAEMLASIDLKY 
PB75 PB1 75 EMLASIDLKYFNEST 
PB76 PB1 76 IDLKYFNESTKKKIE 
PB77 PB1 77 FNESTKKKIEKIRPL 
PB78 PB1 78 KKKIEKIRPLLIDGT  
PB79 PB1 79 KIRPLLIDGTASLSP 
PB80 PB1 80 LIDGTASLSPGMMMG 
PB81 PB1 81 ASLSPGMMMGMFNML 
PB82 PB1 82 GMMMGMFNMLSTVLG 
PB83 PB1 83 MFNMLSTVLGVSILN 
PB84 PB1 84 STVLGVSILNLGQKK 
PB85 PB1 85 VSILNLGQKKYTKTI 
PB86 PB1 86 LGQKKYTKTIYWWDG 
PB87 PB1 87 YTKTIYWWDGLQSSD 
PB88 PB1 88 YWWDGLQSSDDFALI 
PB89 PB1 89 LQSSDDFALIVNAPN 
PB90 PB1 90 DFALIVNAPNHEGIQ 
PB91 PB1 91 VNAPNHEGIQAGVDR 
PB92 PB1 92 HEGIQAGVDRFYRTC 
PB93 PB1 93 AGVDRFYRTCKLVGI 
PB94 PB1 94 FYRTCKLVGINMSKK 
PB95 PB1 95 KLVGINMSKKKSYIN 
PB96 PB1 96 NMSKKKSYINKTGTF 
PB97 PB1 97 KSYINKTGTFEFTSF 
PB98 PB1 98 KTGTFEFTSFFYRYG 
PB99 PB1 99 EFTSFFYRYGFVANF 
PB100 PB1 100 FYRYGFVANFSMELP 
PB101 PB1 101 FVANFSMELPSFGVS 
PB102 PB1 102 SMELPSFGVSGVNES 
PB103 PB1 103 SFGVSGVNESADMSI 
PB104 PB1 104 GVNESADMSIGVTVI 
PB105 PB1 105 ADMSIGVTVIKNNMI 
PB106 PB1 106 GVTVIKNNMINNDLG 
PB107 PB1 107 KNNMINNDLGPATAQ 
PB108 PB1 108 NNDLGPATAQMALQL 
PB109 PB1 109 PATAQMALQLFIKDY 
PB110 PB1 110 MALQLFIKDYRYTYR 
PB111 PB1 111 FIKDYRYTYRCHRGD 
PB112 PB1 112 RYTYRCHRGDTQIQT 
PB113 PB1 113 CHRGDTQIQTRRSFE 
PB114 PB1 114 QIQTRRSFELKKLW 
PB115 PB1 115 RRSFELKKLWDQTQS 
PB116 PB1 116 LKKLWDQTQSKVGLL 
PB117 PB1 117 DQTQSKVGLLVSDGG 
PB118 PB1 118 KVGLLVSDGGPNLYN 
PB119 PB1 119 VSDGGPNLYNIRNLH 
PB120 PB1 120 PNLYNIRNLHIPEVC 
PB121 PB1 121 IRNLHIPEVCLKWEL 
PB122 PB1 122 IPEVCLKWELMDDDY 
PB123 PB1 123 LKWELMDDDYRGRLC 
PB124 PB1 124 MDDDYRGRLCNPLNP 
PB125 PB1 125 RGRLCNPLNPFVSHK 
PB126 PB1 126 NPLNPFVSHKEIDSV 
PB127 PB1 127 FVSHKEIDSVNNAVV 
PB128 PB1 128 EIDSVNNAVVMPAHG 
PB129 PB1 129 NNAVVMPAHGPAKSM 
PB130 PB1 130 MPAHGPAKSMEYDAV 
PB131 PB1 131 PAKSMEYDAVATTHS 
PB132 PB1 132 EYDAVATTHSWIPKR 
PB133 PB1 133 ATTHSWIPKRNRSIL 
PB134 PB1 134 WIPKRNRSILNTSQR 
PB135 PB1 135 NRSILNTSQRGILED 
PB136 PB1 136 NTSQRGILEDEQMYQ 
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PB137 PB1 137 GILEDEQMYQKCCNL 
PB138 PB1 138 EQMYQKCCNLFEKFF 
PB139 PB1 139 KCCNLFEKFFPSSSY 
PB140 PB1 140 FEKFFPSSSYRRPVG 
PB141 PB1 141 PSSSYRRPVGISSMV 
PB142 PB1 142 RRPVGISSMVEAMVS 
PB143 PB1 143 ISSMVEAMVSRARID 
PB144 PB1 144 EAMVSRARIDARVDF 
PB145 PB1 145 RARIDARVDFESGRI 
PB146 PB1 146 ARVDFESGRIKKEEF 
PB147 PB1 147 ESGRIKKEEFSEIMK 
PB148 PB1 148 KKEEFSEIMKICSTI 
PB149 PB1 149 SEIMKICSTIEELRR 
PB150 PB1 150 ICSTIEELRRQK 
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Table 6.5 Camera and 
count settings for 
fluorescence-
immunospot 
optimisation work.  
 
Fluorescence-
immunospot Optical 
filter 1 (Cy3)  
Fluorescence-
immunospot 
Optical filter 2 
(FITC) 
CAMERA SETTINGS   
Brightness 36 36 
Hue 51 51 
Saturation 291 321 
Sharpness 1 1 
Gamma 0 0 
White Balance -R 103 83 
White Balance -B 53 53 
Gain 32 96 
Exposure/Shutter 1100 2409 
COUNT SETTINGS   
Algorithm v.3.2.x v.3.2.x 
Intensity Minimum 5 15 
Gradient Minimum 2 1 
Size Minimum 50 50 
Emphasis Tiny Tiny 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.6 Camera and 
count settings for 
fluorescence-
immunospot on 
Immunoflu samples.  
 
Fluorescence-
immunospot Optical 
filter 1 (Cy3)  
Fluorescence-
immunospot 
Optical filter 2 
(FITC) 
CAMERA SETTINGS   
Brightness 0 0 
Hue 40 40 
Saturation 214 256 
Sharpness 0 0 
Gamma 0 0 
White Balance -R 85 84 
White Balance -B 51 44 
Gain 32 96 
Exposure/Shutter 1783 2795 
COUNT SETTINGS   
Algorithm v.3.2.x v.3.2.x 
Intensity Minimum 5 22 
Gradient Minimum 2 1 
Size Minimum 50 50 
Emphasis Tiny Tiny 
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Figure 6.1 Titrating antibody-fluorochrome conjugates for multi-parameter flow cytometry panel. Numbers next to 
plots are dilution factors (by volume) of antibody-fluorochrome conjugates (A – M). 
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Table 6.7 Live/Dead Blue on fresh and frozen PBMC 
Staining antibody 
dilution (by volume) 
Live/Dead 
Blue-
positive (% 
of total) 
Live/Dead 
Blue-
positive 
(Geom. 
Mean) 
Live/Dead 
Blue-
positive 
(SD) 
Live/Dead 
Blue-
negative (% 
of total) 
Live/Dead 
Blue-
negative 
(Geom. 
Mean) 
Live/Dead 
Blue-
negative 
(SD) 
STAIN 
INDEX 
 Fresh_Unstained.fcs 0.04 6477.00 25185.00 55.50 140.00 168.00 37.72 
 Fresh_1 in 250.fcs 52.00 40257.00 103000.00 26.80 1284.00 399.00 97.68 
 Fresh_1 in 500.fcs 43.40 38197.00 83925.00 36.90 860.00 517.00 72.22 
 Fresh_1 in 1000.fcs 42.50 21401.00 57392.00 38.00 594.00 448.00 46.44 
 Fresh_1 in 2000.fcs 38.60 11455.00 34161.00 34.10 360.00 311.00 35.68 
 Fresh_1 in 4000.fcs 17.70 14809.00 16800.00 38.10 186.00 188.00 77.78 
 Frozen_Unstained.fcs 0.71 10495.00 40128.00 74.90 151.00 189.00 54.73 
 Frozen_1 in 250.fcs 58.50 78214.00 104000.00 33.20 1090.00 464.00 166.22 
 Frozen_1 in 500.fcs 53.00 60407.00 79130.00 38.40 723.00 488.00 122.30 
 Frozen_1 in 1000.fcs 51.20 37688.00 58212.00 38.90 491.00 402.00 92.53 
 Frozen_1 in 2000.fcs 52.00 36494.00 54860.00 37.70 402.00 388.00 93.02 
 Frozen_1 in 4000.fcs 44.90 25982.00 36938.00 38.40 286.00 294.00 87.40 
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Table 6.8 Streptavidin-PE-CY5 
Staining antibody 
dilution (by volume) 
CD14/CD19/CD56-
SA-PE-CY5-
positive (% of 
PBMC singlets) 
CD14/CD19/CD56-
SA-PE-CY5-
positive (Geom. 
Mean) 
CD14/CD19/CD56-
SA-PE-CY5-
positive (SD) 
CD14/CD19/CD56-
SA-PE-CY5-
negative (% of 
PBMC singlets) 
CD14/CD19/CD56-
SA-PE-CY5-
negative (Geom. 
Mean) 
CD14/CD19/CD56-
SA-PE-CY5-
negative (SD) 
STAIN 
INDEX 
1 in 10 18.00 14120.00 14934.00 66.50 235.00 454.00 30.58 
1 in 20 18.50 5496.00 5977.00 68.50 123.00 215.00 24.99 
1 in 40 15.40 2750.00 2532.00 67.80 116.00 197.00 13.37 
1 in 80 14.80 1498.00 1566.00 71.10 81.60 144.00 9.84 
1 in 160 14.80 857.00 695.00 76.40 54.30 107.00 7.50 
1 in 320 0.30 16491.00 18637.00 75.80 329.00 535.00 30.21 
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Table 6.9 CD3-PE-CF594 
Staining 
antibody 
dilution (by 
volume) 
CD3-PE-CF594-
positive (% of 
PBMC singlets) 
CD3-PE-CF594-
positive (Geom. 
Mean) 
CD3-PE-CF594-
positive (SD) 
CD3-PE-
CF594-
negative (% 
of PBMC 
singlets) 
CD3-PE-
CF594-
negative 
(Geom. Mean) 
CD3-PE-
CF594-
negative (SD) STAIN INDEX 
Unstained 0 0 0 98 8.1 29.2 -0.28 
1 in 5 74.9 56352 24566 22.3 319 630 88.94 
1 in 10 75.3 40981 20604 22.2 237 453 89.94 
1 in 20 74 20278 17577 22.3 160 254 79.20 
1 in 40 72.2 13918 10729 20.5 101 124 111.43 
1 in 80 74.6 5174 6844 21.8 68.9 78.7 64.87 
1 in 160 70.3 3106 3161 25.3 57.6 69.9 43.61 
1 in 320 63.3 2471 1796 24.4 33.1 51.2 47.62 
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Table 6.10 CD4-QDOT605 
Staining 
antibody 
dilution 
(by 
volume) 
CD4-
QDOT605-
positive (% 
of PBMC 
singlets) 
CD4-QDOT605-
positive 
(Geom. Mean) 
CD4-QDOT605-
positive (SD) 
CD4-
QDOT605-
negative (% 
of PBMC 
singlets) 
CD4-
QDOT605-
negative 
(Geom. Mean) 
CD4-QDOT605-
negative (SD) STAIN INDEX 
1 in 5 45.10 112000.00 41274.00 53.20 2749.00 1965.00 55.60 
1 in 10 44.60 130000.00 43494.00 54.30 2881.00 1877.00 67.72 
1 in 20 43.90 130000.00 43784.00 55.20 1935.00 1281.00 99.97 
1 in 40 44.20 124000.00 47635.00 49.40 777.00 821.00 150.09 
1 in 80 42.20 130000.00 47571.00 52.60 747.00 615.00 210.17 
1 in 160 44.20 126000.00 53919.00 49.40 736.00 616.00 203.35 
1 in 320 44.50 119000.00 53586.00 49.00 605.00 439.00 269.69 
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Table 6.11 CD8-AF700 
Staining antibody dilution 
(by volume) 
CD8-AF700-
positive (% of 
PBMC singlets) 
CD8-AF700-
positive (Geom. 
Mean) 
CD8-AF700-
positive (SD) 
CD8-AF700-
negative (% 
of PBMC 
singlets) 
CD8-AF700-
negative 
(Geom. 
Mean) 
CD8-AF700-
negative (SD) 
STAIN 
INDEX 
1 in 5 17.50 286.00 147.00 79.30 12.30 30.80 8.89 
1 in 10 13.10 241.00 120.00 82.50 13.00 31.80 7.17 
1 in 20 6.85 211.00 87.50 89.10 13.50 32.60 6.06 
1 in 40 6.07 205.00 73.30 90.10 13.00 32.40 5.93 
1 in 80 3.94 195.00 77.60 92.60 13.40 32.40 5.60 
1 in 160 1.27 183.00 90.70 96.00 12.30 30.10 5.67 
1 in 320 0.55 178.00 142.00 97.30 11.40 28.60 5.83 
1 in 640 0.13 184.00 182.00 98.10 9.10 25.20 6.94 
Unstained 0.08 303.00 183.00 98.40 3.45 28.40 10.55 
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Table 6.12 CD45RA-QDOT655 
Staining antibody 
dilution (by 
volume) 
CD45RA-
QDOT655-
positive (% of 
PBMC singlets) 
CD45RA-
QDOT655-
positive (Geom. 
Mean) 
CD45RA-
QDOT655-positive 
(SD) 
CD45RA-
QDOT655-
negative (% of 
PBMC singlets) 
CD45RA-
QDOT655-
negative 
(Geom. Mean) 
CD45RA-
QDOT655-
negative (SD) 
STAIN 
INDEX 
1 in 5 51.60 112000.00 80001.00 46.80 4416.00 5020.00 21.43 
1 in 10 50.00 110000.00 82754.00 49.70 4687.00 4790.00 21.99 
1 in 20 44.30 108000.00 84784.00 55.00 3486.00 4853.00 21.54 
1 in 40 42.30 91476.00 80157.00 56.90 2544.00 4751.00 18.72 
1 in 80 42.00 59432.00 76428.00 55.70 1487.00 2868.00 20.20 
1 in 160 40.00 45119.00 70422.00 57.10 1309.00 2567.00 17.07 
1 in 320 44.70 21954.00 49290.00 52.90 785.00 1188.00 17.82 
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Table 6.13 CCR7-PE-CY7 
Staining 
antibody 
dilution 
(by 
volume) 
CCR7-
PE-
CY7-
positive 
(% of 
PBMC 
singlets
) 
CCR7-PE-CY7-
positive (Geom. 
Mean) 
CCR7-PE-CY7-positive 
(SD) 
CCR7-PE-CY7-
negative (% of 
PBMC singlets) 
CCR7-PE-CY7-
negative 
(Geom. Mean) 
CCR7-PE-CY7-
negative (SD) STAIN INDEX 
1 in 5 39.6 5315 3000 47.8 752 620 7.36 
1 in 10 28.8 4557 2333 53.9 440 584 7.05 
1 in 20 38.2 2235 1667 43.5 170 188 10.98 
1 in 40 38.8 1558 1306 40.7 143 140 10.11 
1 in 80 34.4 592 612 40.8 88 77.7 6.49 
1 in 160 0.05 5930 4332 70.6 130 189 30.69 
1 in 320 0.05 8508 8669 67.9 109 147 57.14 
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Table 6.14 CD69-PERCP-CY5.5 
Staining antibody 
dilution (by volume) 
CD69-PERCP-
CY5.5-positive 
(% of PBMC 
singlets) 
CD69-PERCP-
CY5.5-positive 
(Geom. Mean) 
CD69-PERCP-
CY5.5-positive 
(SD) 
CD69-PERCP-
CY5.5-
negative (% 
of PBMC 
singlets) 
CD69-PERCP-
CY5.5-
negative 
(Geom. Mean) 
CD69-PERCP-
CY5.5-
negative (SD) 
STAIN 
INDEX 
Unstained 
(Unstimulated) 0.00 931.00 72.70 100.00 26.70 40.00 22.61 
Unstained (PMA/I) 0.01 988.00 70.20 100.00 35.30 42.80 22.26 
1 in 5 17.20 1588.00 1645.00 82.80 148.00 200.00 7.20 
1 in 10 83.80 3437.00 2886.00 16.20 296.00 232.00 13.54 
1 in 20 75.10 2824.00 2468.00 24.90 282.00 220.00 11.55 
1 in 40 65.90 2267.00 2161.00 34.10 249.00 218.00 9.26 
1 in 80 67.60 1229.00 1559.00 31.70 140.00 104.00 10.47 
1 in 160 32.40 1335.00 989.00 66.50 193.00 166.00 6.88 
1 in 320 21.60 1029.00 614.00 77.50 154.00 136.00 6.43 
1 in 640 14.20 641.00 1187.00 85.10 109.00 91.80 5.80 
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Table 6.15 CCR5-APC-CY7 
Staining 
antibody 
dilution (by 
volume) 
CCR5-APC-
CY7-positive 
(% of PBMC 
singlets) 
CCR5-APC-CY7-
positive (Geom. 
Mean) 
CCR5-APC-CY7-
positive (SD) 
CCR5-APC-
CY7-negative 
(% of PBMC 
singlets) 
CCR5-APC-
CY7-negative 
(Geom. Mean) 
CCR5-APC-
CY7-negative 
(SD) 
STAIN 
INDEX 
1 in 5 10.50 433.00 3166.00 89.50 65.80 53.90 6.81 
1 in 10 6.53 420.00 2089.00 93.50 47.80 47.80 7.79 
1 in 20 4.20 427.00 2510.00 95.80 41.60 46.80 8.24 
1 in 40 2.74 521.00 3693.00 97.30 31.70 41.90 11.68 
1 in 80 1.31 623.00 1801.00 98.70 20.60 34.30 17.56 
1 in 160 0.85 807.00 1144.00 99.10 14.10 28.60 27.72 
1 in 320 0.70 1035.00 22260.00 99.30 11.60 25.60 39.98 
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Table 6.16 CD57-BV570 
Staining 
antibody 
dilution (by 
volume) 
CD57-BV570-
positive (% of 
PBMC singlets) 
CD57-BV570-
positive (Geom. 
Mean) 
CD57-BV570-
positive (SD) 
CD57-BV570-
negative (% of 
PBMC singlets) 
CD57-BV570-
negative 
(Geom. Mean) 
CD57-BV570-
negative (SD) 
STAIN 
INDEX 
1: CD57-
BV570_Unstim 
1,3a,10.fcs 6.20 13198.00 22647.00 85.80 173.00 228.00 75.79 
1 in 10 19.80 8831.00 24000.00 77.20 332.00 335.00 26.37 
1 in 20 21.30 8853.00 20656.00 75.60 258.00 271.00 34.02 
1 in 40 19.10 9525.00 15583.00 77.10 251.00 320.00 37.64 
1 in 80 19.90 7296.00 16277.00 77.10 222.00 242.00 32.52 
1 in 160 20.20 6510.00 9835.00 75.80 217.00 233.00 29.65 
1 in 320 17.70 4738.00 5318.00 78.20 216.00 235.00 21.57 
1 in 640 18.00 3276.00 3348.00 79.60 209.00 202.00 15.29 
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Table 6.17 IFN- -V450 
Staining antibody 
dilution (by volume) 
IFN- -V450-
positive (% 
of PBMC 
singlets) 
IFN- -V450-positive 
(Geom. Mean) 
IFN- -V450-
positive (SD) 
IFN- -V450-
negative (% of 
PBMC singlets) 
IFN- -V450-
negative (Geom. 
Mean) 
IFN- -V450-
negative 
(SD) 
STAIN 
INDEX 
1 in 5 48.30 6112.00 14887.00 52.10 237.00 96.90 60.63 
1 in 10 48.20 6797.00 15782.00 52.10 234.00 92.50 70.95 
1 in 20 47.10 7006.00 18940.00 53.20 219.00 90.90 74.66 
1 in 40 46.10 6213.00 15516.00 54.00 197.00 91.20 65.96 
1 in 80 42.70 5153.00 12040.00 57.60 170.00 94.30 52.84 
1 in 160 39.90 4066.00 8966.00 60.30 162.00 92.60 42.16 
1 in 320 37.40 2862.00 4933.00 62.90 155.00 98.80 27.40 
Unstimulated (1 in 
5) 0.14 836.00 186.00 99.90 175.00 71.70 9.22 
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Table 6.18 CD107ab-FITC 
Staining antibody dilution (by 
volume) 
CD107AB-
FITC-
positive (% 
of PBMC 
singlets) 
CD107AB-
FITC-positive 
(Geom. Mean) 
CD107AB-
FITC-
positive 
(SD) 
CD107AB-
FITC-
negative (% 
of PBMC 
singlets) 
CD107AB-
FITC-
negative 
(Geom. 
Mean) 
CD107AB-
FITC-
negative 
(SD) 
STAIN 
INDEX 
UNSTAINED 0.01 318.00 99.60 100.00 49.20 24.10 11.15 
UNSTIM 1 in 100 7.71 472.00 450.00 91.70 73.60 34.80 11.45 
UNSTIM 1 in 50 10.30 476.00 776.00 88.60 85.30 37.70 10.36 
UNSTIM 1 in 25 12.90 439.00 594.00 85.40 93.90 40.10 8.61 
PMA/I 1 in 100 17.60 487.00 525.00 80.90 80.40 42.60 9.54 
PMA/I 1 in 50 36.00 631.00 1119.00 62.00 91.90 42.70 12.63 
PMA/I 1 in 25 41.00 608.00 1037.00 56.80 98.40 42.60 11.96 
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